Novarti
s Research  and Development  
LOU064/remibrutinib 
Clinical 
Trial Protocol CLOU064A2302 / [STUDY_ID_REMOVED]
A multicenter, randomized, double-b lind, 
placebo-controlled Phase 3 study of remibrutinib (LOU064) 
to investigate the efficacy, safety and tolerability for 52 
weeks in adult chronic spontaneous urticaria patients 
inadequatel y controlled b y H1-antihistamines 
Document  type:  Global  Amended Clinical Trial Protocol  
EUDRACT  number:  2021- 000424- 35 
Version  number:  01 (Clean)  
Clinical Trial Phase:  III 
Release  date:  23-May-2022 (content  final)
Property  of [COMPANY_001] 
Confidential  
May not be used,  divulged,  published,  or otherwise disclosed 
without the consent of [COMPANY_001]  
Clinical Trial Protocol  Template Version 4.0 dated 15-Feb- 2021 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400425] of abbreviations  ............................................................................................................. 7 
Glossary  of terms  ............................................................................................................... 11 
Protocol summary  .............................................................................................................. 17 
1 Introduction  ........................................................................................................................ 23 
1.1 Background  ............................................................................................................ 23 
1.2 Purpose  ................................................................................................................... 24 
2 Objectives,  endpoints and estimands  ................................................................................. 24 
2.1 Primary  estimands  .................................................................................................. 29 
2.2 Secondary estimands  .............................................................................................. 30 
3 Study design  ....................................................................................................................... 31 
4 Rationale  ............................................................................................................................ 32 
4.1 Rationale for study design ...................................................................................... 32 
4.1.1 Rationale for choice of background therapy  .......................................... 34 
4.2 Rationale for dose/regimen  and duration of treatment  ........................................... 34 
4.3 Rationale for choice  of control drugs (comparator/placebo) or combination  
drugs  ....................................................................................................................... 37 
4.4 Purpose and timing  of interim analyses/design  adaptations  ................................... 38 
4.5 Ri
sks and benefits  .................................................................................................. 38 
4.6 Rational e for Public Health Emergency  mitigation procedures  ............................. 43 
5 Study Population  ................................................................................................................ 43 
5.1 Inclusion criteria  ..................................................................................................... 43 
5.2 Exclusion criteria  ................................................................................................... 44 
6 Treatment  ........................................................................................................................... 46 
6.1 Study treatment ...................................................................................................... 46 
6.1.1 Investigational and control drugs  ........................................................... 48 
6.1.2 Additional study treatments  ................................................................... 48 
6.1.3 Treatment  arms/group  ............................................................................ 48 
6.1.4 Treatment duration  ................................................................................ 48 
6.2 Other  treatment(s) .................................................................................................. 48 
6.2.1 Concomitant therapy.............................................................................. 48 
6.2.2 Permitted  concomitant therapy  requiring  caution and/or action  ............ 49 
6.2.3 Prohibited medication  ............................................................................ 49 
6.2.4 Rescue medication  ................................................................................. 52 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  3 of 133 
Protocol  No. CLOU064A2302   
6.3 Preparation and dispensation .................................................................................. 53 
6.3.1 Handling of study treatment and other treatment .................................. 53 
6.3.2 Instruction  for prescribing  and taking  study treatment  .......................... 54 
6.4 Participant numbering, treatment assignment, randomization  ............................... 54 
6.4.1 Participant numbering  ........................................................................... 54 
6.4.2 Treatment assignment, randomization  ................................................... 55 
6.5 Treatment blinding  ................................................................................................. 55 
6.6 Dose escalation and dose modification  .................................................................. 56 
6.6.1 Follow-up for toxicities  ......................................................................... 56 
6.7 Additional treatment  guidance  ............................................................................... 56 
6.7.1 Treatment  compliance  ........................................................................... 56 
6.7.2 Emergency  breaking of assigned treatment code .................................. 57 
6.7.3 Treatment  of overdose  ........................................................................... 57 
7 Informed  consent  procedures  ............................................................................................. 58 
8 Visit schedule and assessments .......................................................................................... 59 
8.1 Screening  ................................................................................................................ 66 
8.1.1 Information  to be collected  on screening  failures  .................................. 66 
8.2 Participant  demographics/other baseline characteristics ........................................ 66 
8.3 Efficacy  .................................................................................................................. 67 
8.3.1 eDiary  assessments  ................................................................................ 67 
8.3.2 Other  Patient  Reported Outcomes (PRO)  assessments ......................... 70 
8.3.3 A
ppropriateness of efficacy  assessments ............................................... 72 
8.3.4 Other  assessments:  evidence of urticaria  ............................................... 72 
  73 
8.4 Safety  ..................................................................................................................... 73 
8.4.1 Laboratory  evaluations  .......................................................................... 75 
8.4.2 Electrocardiogram  (ECG) ...................................................................... 76 
8.4.3 Pregnancy and assessments of fertility  .................................................. 77 
8.4.4 Appropriateness of safety measurements .............................................. 78 
8.5 Additional assessments  .......................................................................................... 78 
8.5.1 Clinical Outcome Assessments  (COAs)  ................................................ 78 
  78 
  79 
9 Discontinuation and completion  ........................................................................................ 80 
9.1 Discontinuation from study  treatment and from study  .......................................... 80 
9.1.1 Discontinuation from study  treatment ................................................... 80 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400426] to follow -up ................................................................................... 82 
9.2 Withdrawal of informed consent/Opposition to use data/biological samples ....... [ADDRESS_400427]-study treatment ........................................................... 83 
9.4 Early  study termination  by [CONTACT_456]  .................................................................. 83 
10 Safety  monitoring, reporting and committees  .................................................................... 84 
10.1 Definition of adverse events and reporting requirements  ...................................... 84 
10.1.1 Adverse events  ....................................................................................... 84 
10.1.2 Serious adverse events  ........................................................................... 85 
10.1.3 SAE reporting  ........................................................................................ 86 
10.1.4 Pregnancy reporting  ............................................................................... 87 
10.1.5 Reporting of study treatment errors  including misuse/abuse  ................. 88 
10.2 Additional Safety  Monitoring  ................................................................................ 88 
10.2.1 Liver safety  monitoring  ......................................................................... 88 
10.2.2 Renal  safety  monitoring ......................................................................... 89 
10.3 Committees  ............................................................................................................ 89 
10.3.1 Data  Monitoring Committee  .................................................................. 89 
10.3.2 Steering  Committee  ............................................................................... 90 
11 Data  Collection  and Database  manag ement  ....................................................................... 90 
11.1 Data collection  ....................................................................................................... 90 
11.2 D
atabase management and quality  control  ............................................................ 90 
11.3 Site monitoring  ....................................................................................................... 91 
12 Data  analysis and statistical methods  ................................................................................. 92 
12.1 Analysis sets ........................................................................................................... 92 
12.2 Participant  demographics and other baseline characteristics ................................. 92 
12.3 Treatments  .............................................................................................................. 92 
12.4 Analysis supporting primary  objectives  ................................................................. 93 
12.4.1 Definition of primary  endpoint(s)  .......................................................... 93 
12.4.2 Statistical model, hypothesis, and method of analysis  .......................... 93 
12.4.3 Handling of intercurrent events of pri mary  estimand  ............................ 94 
12.4.4 Handling of missing  values  not related  to intercurrent event  ................ 95 
12.4.5 Sensitivity  analyses  ............................................................................... 96 
12.4.6 Supplementary analysis ......................................................................... 96 
12.5 Analysis supporting secondary objectives  ............................................................. 97 
12.5.1 Efficacy  and/or Pharmacodynamic endpoint(s)  ..................................... 97 
12.5.2 Safety  endpoints  .................................................................................. 101 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  5 of 133 
Protocol  No. CLOU064A2302   
  103 
  103 
  103 
  103 
  103 
  104 
12.7
 Interim analyses  ................................................................................................... 105 
12.8 Sample size calculation  ........................................................................................ 105 
12.8.1 Primary  endpoint(s)  ............................................................................. 105 
12.8.2 Secondary endpoint(s)  ......................................................................... 106 
13 Ethical considerations and administrative  procedures  ..................................................... 107 
13.1 Regulatory and ethical compliance  ...................................................................... 107 
13.2 Responsibilities of the investigator  and IRB/IEC  ................................................ 107 
13.3 Publication of study protocol and results  ............................................................. 107 
13.4 Quality  Control and Quality  Assurance ............................................................... 108 
13.5 Participant  Engagement  ........................................................................................ 108 
14 Protocol adherence  ........................................................................................................... 108 
14.1 Protocol amendments  ........................................................................................... 108 
15 References  ........................................................................................................................ 110 
16 Appendices  ....................................................................................................................... 114 
16.1 Appendix 1: Clinically notable laboratory values and vital signs  ....................... 114 
16.2 Appendix 2: Liver event and laboratory trigger definitions & follow-up 
requirements  ......................................................................................................... 115 
16.3 A
ppendix 3: Specific Renal  Alert  Criteria  and Actions and Event Follow- up .... 119 
16.4 Appendix 4: PRO Tools  ...................................................................................... [ADDRESS_400428] of tables  
Table  2-1 Objectives and related  endpoints – Scenario  with UAS7  as the 
primary  efficacy  endpoint  ...................................................................... 25 
Table  2-2 Objectives a nd related endpoints - Scenario with ISS7 and HSS7 as 
the co-primary  efficacy  endpoints  ......................................................... 27 
Table  6-1 Investigational and control drug ............................................................ 48 
Table  6-2 Permitted  concomitant therapy  requiring  caution and/or action  ............ 49 
Table  6-3 Prohibited medication  ............................................................................ 49 
Table  8-1 Assessment  Schedule ............................................................................. 61 
Table  8-2 UPDD .................................................................................................... 67 
Table  8-3 Hives  Severity  Score  ............................................................................. 68 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400429]  on patient's  life ...................................... 70 
Table  8-8 Physical  assessments  ............................................................................. 74 
Table  8-9 Laboratory  assessments  ......................................................................... 75 
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse .......................................................................................... [ADDRESS_400430]  repeated  measurement  analysis,  by [CONTACT_2948] 
(FAS)  ..................................................................................................... 35 
Figure 4-2 UAS 7 = 0 and UAS7 <= 6 response rate over time by [CONTACT_56842] (as observed) (FAS)  .................................................................... 36 
 73
 
Figure 12-1 Testing  strategy  with UAS7 as  the primary  endpoint  ............................ 99 
Figure 12-2 Testing  strategy  with ISS7/HSS7  as the co-primary endpoints  ........... 101 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400431] Aspartate  Aminotransferase  
ATC Anatomical  Therapeutic  Chemical  
b.i.d.  bis in die/twice  a day 
BCR B cell receptor  
BCRP  Breast  Cancer  Resistance  Protein  
BP Blood  Pressure  
BTK Bruton's  Tyrosine  Kinase  
BTKi Bruton's  Tyrosine  Kinase  inhibitor  
BUN Blood  Urea  Nitrogen  
CINDU  Chronic  Inducible  Urticaria  
CIU Chronic  Idiopathic  Urticaria  
CK Creatine  Kinase  
CMO&PS  Chief  Medical  Office  and Patient  Safety  
CO Country  Organization  
COA  Clinical  Outcome  Assessment  
COVID -19 Coronavirus  disease  2019  
CRA Clinical  Research  Associate  
CRF Case  Report/Record  Form  (paper  or electronic  (eCRF))  
CRO  Contract  Research  Organization  
CSR Clinical  Study  Report  
CSU Chronic  Spontaneous  Urticaria  
CU Chronic  Urticaria  
CV Coefficient  of Variation  
CYP Cytochrome  P 
DBP Diastolic  Blood  Pressure  
DIN Drug  Inducted  Nephrotoxicity  
DLQI  Dermatology  Life Quality  Index  
DMC  Data  Monitoring  Committee  
DNA Deoxyribonucleic  Acid 
ECG  Electrocardiogram  
EDC Electronic  Data  Capture  
eGFR  Estimated  Glomerular  Filtration  Rate 
  
eSAE  Electronic  Serious  Adverse  Event  
eSource  Electronic  Source  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400432]  hepatitis  B core antigen  (anti-HBcAg  antibodies)  
HBsAb  Antibodies  against  hepatitis  B surface  antigen  (anti-HBsAg  antibodies)  
HBsAg  Hepatitis  B virus  surface  antigen  
HBV Hepatitis  B Virus  
HCP Healthcare  Professional  
HCV Hepatitis  C Virus  
HCVAb  Hepatitis  C Virus  Antibody  
HDL High-Density  Lipoprotein  
hERG  Human  ether -a-go-go related  gene  
HIV Human  Immunodeficiency  Virus  
HRQoL  Health -Related  Quality  of Life 
HSS Hives  Severity  Score  
HSS7  Weekly  Hives  Severity  Score  
i.v. Intravenous  
IA Intra-articular  
IB Investigator’s  Brochure  
ICF Informed  Consent  Form  
ICH International  Council  for Harmonization  of Technical  Requirements  for 
Pharmaceuticals for Human Use  
IEC Independent  Ethics  Committee  
Ig Immunoglobulin  
IMP Investigational  Medicinal  Product  
IN Investigator  Notification  
INR International  Normalized  Ratio  
IRB Institutional  Review  Board  
IRT Interactive  Response  Technology  
ISS Itch Severity  Score  
ISS7 Weekly  Itch Severity  Score  
  
  
J2R Jump  to Reference  
KDIGO  Kidney  Disease  Improving  Global  Outcome  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  9 of 133 
Protocol  No. CLOU064A2302   
 
LC- 
MS/MS  Liquid Chromatography -Mass  Spectrometry  
LDH Lactate  Dehydrogenase  
LDL Low-Density  Lipoprotein  
LFT Liver  Function  Test 
LLOQ  Lower  Limit  of Quantification  
LTRA  Leukotriene  Receptor  Antagonists  
MAR  Missing  At Random  
MCH  Mean  Corpuscular  Hemoglobin  
MCHC  Mean  Corpuscular  Hemoglobin  Concentration  
MCV  Mean  Corpuscular  Volume  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
mg Milligram(s)  
MI Multiple  Imputation  
ml Milliliter(s)  
MMRM  Mixed  effect  Model  for Repeated  Measures  
NOAC  Novel  Oral Anti Coagulant  
NSAID  Nonsteroidal  Anti-Inflammatory  Drug 
PA Primary  analysis  
Pbo Placebo  
PCR Protein -creatinine  ratio 
PD Pharmacodynamic(s)  
PE Primary  endpoint  
  
  
PK Pharmacokinetic(s)  
PRO  Patient  Reported  Outcomes  
PT Prothrombin  Time  
q.d. Once  a Day 
QMS  Quality  Management  System  
QTcF  QT interval  corrected  by [CONTACT_6550]’s  formula  
RAS Randomized  Set 
RDO  Retrieved  Drop  Out 
RNA Ribonucleic  Acid 
s.c. Subcutaneous  
SAE Serious  Adverse  Event  
SAF Safety  Set 
SBP Systolic  Blood  Pressure  
SD Standard  Deviation  
SjS Sjoegren’s  Syndrome  
SMQ  Standardized  MedDRA  Query  
S[LOCATION_003]R  Suspected  Unexpected  Serious  Adverse  Reaction  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400433] Upper  Limit  of Normal  
UPDD  Urticaria  Patient  Daily  Diary  
UV Ultraviolet  
WHO  World  Health  Organization  
WoCBP  Women  of Child  Bearing  Potential  
  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400434] (e.g., any background therapy)  
Assessment  A procedure  used  to generate  data required  by [CONTACT_131322]  A biological  specimen including,  for example,  blood (plasma,  serum), 
saliva, tissue, urine, stool, etc. taken from a study participant  
Clinical Outcome 
Assessment  (COA)  A measure that describes  or reflects  how a participant  feels,  functions, 
or survives  
Coded Data Personal  Data  which  has been de-identified  by [CONTACT_30760] a code.  
Cohort  A group of individuals who share a common exposure, experience or 
characteristic,  or a group  of individuals  followed -up or traced  over time.  
Control  drug A study drug (active or placebo) used as a comparator to reduce 
assessment  bias,  preserve  blinding of investigational  drug,  assess 
internal study validity, and/or evaluate comparative effects of the 
investigational drug  
Discontinuation from 
study Point/time  when  the participant  permanently  stops  receiving  the study 
treatment and further protocol required assessments or follow -up, for 
any reason. No specific request is made to stop the use of their 
samples or data.  
Discontinuation from 
study treatment  Point/time when the participant permanently stops receiving the study 
treatment  for any reason  (prior  to the planned completion of study  drug 
administration,  if any).  Participant  agrees  to the other  protocol  required 
assessments including follow- up. No specific request is made to stop 
the use of their samples or da ta. 
Dosage  Dose  of the study  treatment  given to the participant  in a time unit (e.g., 
100 mg once a day, 75 mg twice a day)  
Electronic  Data  Capture 
(EDC) Electronic data capture (EDC) is the electronic acquisition of clinical 
study data using data collection systems, such as Web- based 
applications,  interactive  voice  response  systems and clinical  laboratory 
interfaces. EDC includes the use of Electronic Case Report Forms 
(eCRFs) which are used to capture data transcribed from source 
data/documents used at the point of care  
End of the clinical  trial The end of the clinical  trial is defined as the last visit of the last 
participant or at a later point in time as defined by [CONTACT_30761]/time  of participant  entry  into the study  at which  informed consent 
must be obtained. The action of enrolling one or more participants.  
eSource (DDE) eSource Direct  Data  Entry  (DDE) refers  to the capture  of clinical study 
data electronically, at the point of care. eSource Platform/Applications combines source documents and case report forms (eCRFs) into one 
application, allowing for the real time collection of clinical trial 
information  to sponsors  and other  oversight  authorities,  as appropriate  
Estimand  As defined in the ICH E9(R1) addendum, estimand is a precise 
description of the treatment  effect  reflecting  the clinical  question posed 
by [CONTACT_6553].  It summarizes at a population- level what the 
outcomes would be in the same participants under different treatment conditions being compared. Attributes of an estimand include the  
population,  variable  (or endpoint)  and treatment  of interest,  as well as 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400435].  
Investigational  drug/ 
treatment  The drug whose  properties  are being tested  in the study  
Medication  number  A unique  identifier  on the label  of medication  kits 
Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for 
randomization and who did not take study  treatment,  but have  been 
inadvertently randomized into the study  
Off-site Describes  trial activities  that are performed at remote location  by [CONTACT_106623]- 
site healthcare professional,  such  as procedures  performed  at the 
participant's home.  
Other  treatment  Treatment  that may be needed/allowed  during the conduct  of the study 
(i.e., concomitant or rescue therapy)  
Part A sub-division  of a study  used  to evaluate specific  objectives  or contain 
different populations. For example, one study could contain a single 
dose part and a multiple dose part, or a part in participants with 
established disease and in those with newly -diagnosed disease  
Participant  A trial participant  (can be a healthy  volunteer  or a patient).  "Participant" 
terminology is used in the protocol whereas term "Subject" is used in 
data collection.  
Participant  number  A unique number assigned to each participant upon signing the 
informed  consent.  This number  is the definitive,  unique identifier for the 
participant  and should be used  to identify  the participant  throughout  the 
study for all data collected, sample labels, etc.  
Patient -Reported 
Outcome (PRO)  A measurement  based on a report  that comes  directly  from the patient  
about  the status  of a participant's  health condition without  amendment 
or interpretation of the patient's report by a clinician or anyone else  
Period  The subdivisions of the trial design (e.g., Screening, Treatment, Follow - 
up) which are described in the Protocol. Periods define the study 
phases  and will be used  in clinical  trial database setup  and eventually  in 
analysis  
Personal  data Participant  information  collected  by [CONTACT_324384]. This data includes participant identifier information, study information and 
biological samples.  
Premature  participant 
withdrawal  Point/time  when  the participant  exits from the study  prior to the planned 
completion of all study drug administration and/or assessments; at this time all study drug administration is discontinued and no further 
assessments are planned  
Randomization The process  of assigning  trial participants  to investigati onal drug or 
control/comparator drug using  an element  of chance  to determine the 
assignments in order to reduce bias.  
Randomization  number  A unique  identifier  assigned  to each  randomized  participant  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  13 of 133 
Protocol  No. CLOU064A2302   
 
Re-screening  If a participant  fails the initial  screening  and is considered  as a Screen 
Failure, he/she can be invited once for a new Screening visit after 
medical judgment and as specified by [CONTACT_30763] a location that is not the 
investigative site where  the investigator  will conduct  the trial, but is for 
example a home or another appropriate location  
Screen  Failure  A participant  who did not meet  one or more  criteria  that were  required 
for participation in the study  
Source Data/Document  Source data refers  to the initial  record,  document,  or primary  location 
from where  data comes.  The data source  can be a database,  a dataset, 
a spreadsheet or even hard -coded data, such as paper or eSource  
Start  of the clinical trial The start of the clinical  trial is defined as the signature [CONTACT_30832] [CONTACT_324385]; includes 
investigational drug(s), control(s) or background therapy  
Study  treatment 
discontinuation When  the participant  permanently  stops  taking any of the study  drug(s)  
prior to the defined study treatment completion date (if any) for any 
reason;  may or may not also be the point/time  of study  discontinuation  
Tele-visit Procedures  or communications  conducted  using  technology  such  as 
telephone or video- conference, whereby [CONTACT_131327].  
Treatment  arm/group  A treatment  arm/group  defines  the dose  and regimen  or the 
combination, and may consist of [ADDRESS_400436], which might or might not be the same as the study treatment.  
Variable (or endpoint)  The variable (or endpoint)  to be obtained  for each  participant  that is 
required to address the clinical question. The specification of the 
variable might  include whether  the participant  experiences  an 
intercurrent event.  
Withdrawal of study 
consent (WoC) / 
Opposition to use of data 
/biological  samples  Withdrawal of consent from the study occurs when the participant 
explicitly requests to stop use of their data and biological samples 
(opposition to use data and biological samples) AND no longer wishes 
to receive study treatment, AND does not agree to further protocol required assessments.  This request  should  be in writing  (depending on 
local regulations) and recorded in the source documentation.  
Opposition to use data/biological  samples  occurs  in the countries  where 
collection  and processing  of personal  data is justified  by a different  legal 
reason than consent.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  14 of 133 
Protocol  No. CLOU064A2302   
Amendment  1 (23-May-2022) 
Amendment rationale 
Amendment 1 implements recommendations from the US FDA regarding statistical analysis 
for covering intercurrent event handling for COVID -19 related reasons for treatment 
discontinuation and the use of the same  covariates in both primary  and secondary endpoints. In 
addition, feedback received from Health Authorities and Institutional Review Boards (IRBs)/Independent Ethics  Committees  (IECs) for both pi[INVESTIGATOR_9205] 3 trials  (CLOU064A2301 
and CLOU064A2302) was considered to ensure consistency across the program and the protocol amended as indicated below. 
Furthermore, clarifications  and corrections  were made, and Section  4.5 Risks and benefits has 
been  amended  to include updates from  the LOU064  Investigator Brochure  Edition  9 (03-May- 
2022) as indicated below. At the time of this amendment  (V01) release,  enrollment is ongoing with 226 patients  screened 
and 123 patients randomized. 
Changes to the protocol  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using strike through red font for deletions and red underline for insertions. 
•  
• Section  2.2: Methods for handling of intercurrent events have been  updated considering US 
FDA feedback.  
• Section 4.5 : Risks and benefits has been amended to include upda tes from the LOU064 
Investigator Brochure Edition 9. No change to risk- benefit assessment of the study . 
• Section 5.2: Exclusion criteria [ADDRESS_400437] the feedback received from 
Health Authorities, exclusion criteria 19 updated to clarify maximum dose of clopi[INVESTIGATOR_7745].  
• Section 6.2.3: Clarification that immunomodulating biologics are considered prohibited 
medication unde r immunosuppressive medications; prohibition period for live attenuated 
vaccines updated to reflect  feedback  from Health  Authorities;  maximum dose for long- term 
clopi[INVESTIGATOR_157029]. Clarification that live attenuated vaccines are prohibited [ADDRESS_400438] dose of study treatment as consistent with exclusion criteria and Investigator Brochure. Remibrutinib updated with study treatment for clarification.  
• Section  6.6: Clarification  that interruptions  are permitted  related  to study treatment  
• Section  6.7.3: New section  added regarding  treatment  of overdose, to align  with the updated 
[COMPANY_001] protocol template merged with the  
developed with input from industry, regulators, sites, CROs and IRBs  
• Section  8: Order  of assessments clarified.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  15 of 133 
Protocol  No. CLOU064A2302   
• Table 8 -1: Dispense participants' eDiary and Subject's eDiary review removed for Week 
56/Safety  FU/Study completion  visit considering eDiary  completion  ends at Week  52/Study 
discontinuation; Weight added at  Randomization/Baseline  and Week  24 to  allow  for eGFR 
calculation; Rescue medication dispensation and usage removed from Week 56/Safety 
FU/Study completion visit considering eDiary completion ends at Week 52/Study discontinuation; Footnotes  1, 3, and 7 updated for additional clarity; Footnote [ADDRESS_400439] feedback from Health Authorities; Footnotes 17 and 18 added for clarity.  
• Section 8.3.1: Duration of eDiary  completion clarified.  
•  
• Table  8-8: Body temperature  added  to Physical  Examination assessments to  reflect  feedback 
from Health Authorities.  
• Table 8 -9: Hepatitis screening and Hepatitis re- activation monitoring amended as aligned 
with central laboratory testing procedures.  
• Section  9.1.1: Clarified  that participant can request discontinuation  from  study treatment in 
writing  or verbally, definition  of severe/serious  infections  removed to reflect feedback  from 
Health Authorities.  
• Section  9.1.2: Clarified  that participant can request discontinuation  from study in writing  or 
verbally to reflect feedback from Health Authorities.  
• Section 9.2: Clarified that participant can request withdrawal of consent in writing or verbally to reflect feedback from Health Authorities.  
• Section  10.1.1: “Dose Reduced/increased” removed as dose modifications not permitted  
• Section 10.1.3: Reporting timelines and follow -up for SAEs clarified to reflect feedback 
from Health Authorities.  
• Section  12.4.3: Handling of intercurrent events amended considering US FDA feedback.  
• Section 12.4.5: Tippi[INVESTIGATOR_324366]. 
• Section  12.4.6: Handling of intercurrent events amended considering US FDA feedback.  
• Section 12.5.1: Analysis method for absolute change from baseline in ISS7 and HSS7 at Week 12 amended considering US FDA feedback. 
• Section  12.5.7: Deleted  “utility  scores ” from the EQ-5D-5L paragraph  
• Section  15
 : Additional references  added  and two references removed to  align  with  updated 
Investigator Brochure and Section 4.5. 
• Section 16.1 : QTcF increase ≥60 msec from baseline added to the definition of a notable 
QTc value for ECGs for clarification.  
 
Additional minor changes (e.g., correction  of typographical errors) have  been  incorporated 
directly in the protocol with track changes, even if not listed specifically in this section. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  16 of 133 
Protocol  No. CLOU064A2302   
IRBs/IECs  
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (IECs) and Health Authorities.  
The changes described in this amended protocol require IRB/IEC approval prior to implementation.  
The changes herein affect the Informed Consent. Sites are required to update and submit for approval a revised Informed Consent that takes into account the changes described in this protocol amendment. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  17 of 133 
Protocol  No. CLOU064A2302   
Protocol  summary  
Protocol  number  CLOU064A2302  
Full Title A multicenter,  randomized,  double- blind,  placebo -controlled Phase  3 study  of 
remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for  
52 weeks in adult chronic spontaneous urticaria patients inadequately  
contr olled  by H1-antihistamines  
Brief  title A Phase 3 study  of efficacy  and safety  of remibrutinib in the treatment  of 
chronic spontaneous urticaria in adults inadequately controlled by H1- 
antihistamines  
Sponsor and 
Clinical Phase  [COMPANY_001] 
Phase  3 
Investigation  type Drug 
Study  type Interventional  
Purpose  The purpose  of this study  is to establish the efficacy,  safety,  and tolerability 
of remibrutinib (LOU064) 25 mg b.i.d. in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1- 
antihistamines in comparison to placebo.  
Primary Objective(s)  The primary  objective of this study  is to demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with respect to change from baseline in Weekly  Urticaria Activity  Score  (UAS7),  in Weekly  Itch Severity  Score  (ISS7) 
and Weekly Hive Severity Score (HSS7) for the second primary endpoint 
scenario) at Week 12.  
The primary clinical question of interest is: What is the effect of remibrutinib 
treatment versus placebo on the change from baseline in UAS7 score (in 
HSS7 and ISS7 for the second primary endpoint scenario) after 12 weeks of 
treatment in adult participants with CSU who are inadequately controlled by H1-
antihistamine and receiving a stable locally label approved dose of a 
second  generation H1-antihistamine,  regardless  of discontinuation  from study 
treatment for any re ason and regardless of intake of a different second 
generation H1-antihistamine as rescue medication  and considering  strongly  
confounding  prohibited  medication  as an unfavourable  outcome?  
Secondary Objectives  Scenario  #1 with UAS7  as the primary endpoint  
To demonstrate that a greater proportion of participants achieve disease 
activity  control  (UAS7 ≤ 6) at Week 12 when treated with remibrutinib (25 mg 
b.i.d.) compared to placebo -treated participants.  
• The secondary clinical question of interest is:  What is the effect of 
remibrutinib treatment versus placebo on the UAS7 ≤ 6 response after 12 weeks  treatment  in adult  participants  with CSU  who are inadequately 
controlled by H1- antihistamine and receiving a stable locally label 
approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a 
different second generation H1- antihistamine as rescue medication and 
considering strongly confounding prohibited medication as an unfavourable outcome?  
To demonstrate that a greater proportion of participants achieve complete 
absence of hives  and itch (UAS7  = 0) at Week  12 when treated with 
remibrutinib  (25 mg b.i.d.)  compared  to placebo -treated  participants  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  18 of 133 
Protocol  No. CLOU064A2302   
 
 • The secondary clinical question of interest is: What is the effect of 
remibrutinib treatment versus placebo on the UAS7 = 0 response after 12 weeks  treatment  in adult  participants  with CSU  who are inadequately 
controlled by H1- antihistamine and receiving a stable locally label 
approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a 
different second generation H1- antihistamine as rescue medication and 
considering strongly confounding prohibited medication as an 
unfavourable outcome?  
To demonstrate the superiority of remibrutinib (25 mg b.i.d.) versus placebo with respect to a reduction from baseline in the weekly itch 
severity score 
(ISS7) at Week 12  
To demonstrate the superiority of remibrutinib (25 mg b.i.d.) versus placebo 
with respect to a reduction from baseline in the weekly hive severity score 
(HSS7) at Week 12  
To demonstrate that a greater  proportion of  participants  achieve  UAS7 ≤ 6 at 
Week 2 when treated with remibrutinib (25 mg b.i.d.) compared to placebo- 
treated participants  
To demonstrate that a greater proportion of participants who are treated with 
remibrutinib  (25 mg b.i.d.)  achieve Dermatology  Life Quali ty Index  (DLQI)  = 0- 
1 at Week 12 compared to placebo -treated participants  
To demonstrate that remibrutinib (25 mg b.i.d.) treated participants maintain disease activity control (defined as UAS7 ≤ 6) for more weeks compared to 
placebo treated participants over a total of 12 weeks  
To demonstrate that remibrutinib  (25 mg b.i.d.)  treated  participants  have more 
angioedema occurrence- free weeks over a total of 12 weeks compared with 
placebo -treated participants  
To demonstrate the safety  and tolerability  of remibrutinib (25 mg b.i.d.)  
Scenario  #2 with ISS7  and HSS7  as the co-primary  endpoints  
To demonstrate that remibrutinib (25 mg b.i.d.) is superior to placebo in CSU 
with respect to change from baseline in UAS7 at Week 12  
To demonstrate that a greater proportion of participants achieve disease 
activity control (UAS7 ≤ 6) at Week 12 who are tr eated with remibrutinib (25 
mg b.i.d.) compared to placebo- treated participants  
• The secondary clinical question of interest is: What is the effect of remibrutinib treatment versus placebo on the UAS7 ≤ 6 response after 12 weeks  treatment  in adult  participa nts with CSU  who are inadequately 
controlled by H1- antihistamine and receiving a stable locally label 
approved dose of a second generation H1-antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a 
different second generation H1- antihistamine as rescue medication and 
considering strongly confounding prohibited medication as an 
unfavourable outcome?  
To demonstrate that a greater proportion of participants achieve complete 
absence of hives and itch (UAS7 = 0) at Wee k 12 who are treated with 
remibrutinib (25 mg b.i.d.) compared to placebo -treated participants  
• The secondary clinical question of interest is: What is the effect of 
remibrutinib  treatment  versus  placebo on the UAS7  = 0 response  after 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  19 of 133 
Protocol  No. CLOU064A2302   
 
 12 weeks  treatment  in adult  participants  with CSU  who are inadequately 
controlled by H1- antihistamine and receiving a stable locally label 
approved dose of a second generation H1-antihistamine, regardless of 
treatment discontinuation for any reason and regardless of intake of a 
different second generation H1- antihistamine as rescue medication and 
considering strongly confounding prohibited medication as an 
unfavourable outcome?  
To demonstrate that a greater  proportion of  participants  achieve  UAS7 ≤ 6 at 
Week  2 who are treated  with remibrutinib  (25 mg b.i.d.)  compared  to placebo- 
treated participants  
To demonstrate that a greater proportion of participants who are treated with 
remibrutinib (25 mg b.i.d.) achieve DLQI  = 0-1 at Week 12 compared to 
placebo -treated participants  
To demonstrate that remibrutinib (25 mg b.i.d.) treated participants maintain disease activity control (defined as UAS7 ≤ 6) for more weeks compared to 
placebo treated participants over 12 weeks  
To demonstrate that remibrutinib  (25 mg b.i.d.)  treated  participants  have more 
angioedema occurrence- free weeks over 12 weeks compared with placebo - 
treated participants  
To demonstrate  the safety  and tolerability  of remibrutinib  (25 mg b.i.d.)  
Study design This is a global Phase 3 multicenter, randomized, double- blind, parallel - 
group, placebo- controlled study investigating the safety, tolerability, and 
efficacy of remibrutinib (25 mg b.i.d.) in participants with CSU inadequately controlled by [CONTACT_157061] H1 -antihistamines. The study consists of 
four periods, the total study duration is up to 60 weeks: screening period of 
up to [ADDRESS_400440] cell 
degranulation with release of inflammatory mediators including histamine. Bruton’s tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase which is 
indispensable  for Fc epsilon  receptor  (FcεR1) , Fc gamma  receptor  (FcγR)  as 
well as B cell receptor  (BCR) signaling  and a central  signaling kinase  in mast 
cell activation. It has been demonstrated that BTK inhibition can effectively inhibit mast cell activation. Remibrutinib (LOU064) is a low molecular weight 
compound for oral administration that covalently binds and inhibits BTK with high selectivity. In Phase 1, remibrutinib was well -tolerated at all doses 
without any dose -limiting toxicity and showed encouraging blood and skin 
pharmacodynamics (PD) with a favorable safety profile, fully supporting 
further development. The Phase 2b clinical trial CLOU064A2201 
demonstrated clinical efficacy  of remibrutinib [ADDRESS_400441] of approximately 450 randomized female 
and male adult participants (300 in the active arm and 150 in placebo arm) 
with CSU  inadequately  controlled by [CONTACT_324386] H1-antihistamines.  
The screen failure rate is estimated to be 30%, meaning approximately 645 
participants are expected to be screened.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  20 of 133 
Protocol  No. CLOU064A2302   
 
 Participants  will be stratified  based on prior exposure to anti-IgE biologics  and 
geographic  region.  Maximum number  of participants  with prior exposure  to 
anti-immunoglobulin  (Ig) IgE biologics will be limited  to approximately 30%  of 
the total study population.  
Key Inclusion 
criteria  • Signed informed  consent  must  be obtained prior to participation  in the 
study.  
• Male  and female adult  participants  ≥18 years  of age at the time of 
screening.  
• CSU  duration  for ≥ 6 months  prior to screening (defined  as the onset  of 
CSU determined by [CONTACT_157062]).  
• Diagnosis  of CSU  inadequately  controlled by [CONTACT_157061] H1- 
antihistamines at the time of randomization defined as:  
• The presence of itch and hives for ≥6 consecut ive weeks prior to 
screening despi[INVESTIGATOR_324367]  H1-antihistamines 
during this time period  
• UAS7  score  (range 0- 42) ≥16, ISS7  score  (range 0- 21) ≥ 6 and 
HSS7 score (range 0- 21) ≥ 6 during the 7 days prior to 
randomization (Day 1)  
• Documentation of hives  within  three months  before randomization (either 
at screening and/or at randomization; or documented in the participants medical history).  
• Willing  and able to complete  an Urticaria Patient  Daily  Diary  (UPDD)  for 
the duration of the study and adhere to the study protocol.  
• Participants must not have had more than one missing UPDD entry (either  morning or evening) in the 7 days  prior to randomization  (Day  1). 
Key Exclusion criteria  • Participants  having  a clearly  defined predominant  or sole trigger  of their 
chronic urticaria (CU) (chronic inducible urticaria (CINDU)) including urticaria factitia (symptomatic dermographism), cold -, heat -, solar -, 
pressure- , delayed pressure- , aquagenic -, cholinergic -, or contact - 
urticaria  
• Other  diseases  with symptoms  of urticaria  or angioedema,  including but 
not limited to urticaria vasculitis, urticaria pi[INVESTIGATOR_1802], erythema multiforme, mastocytosis, hereditary urticaria, or drug -induced urticaria  
• Any other skin disease associated with chronic itching that might influence in the investigator’s  opi[INVESTIGATOR_324368], 
e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis  
• Evidence of clinically  significant  cardiovascular  (such  as but not limited  to 
myocardial infarction, unstable ischemic heart disease, [LOCATION_001] heart association (NYHA) Class III/IV left ventricular failure, arrhythmia and uncontrolled hypertension  within  12 months  prior to Visit 1), neurological, 
psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opi[INVESTIGATOR_1649], would compromise the safety of the 
participant, interfere with the interpretation of the study results or 
otherwise preclude participation or protocol adherence of the participant  
• Significant  bleeding risk or coagulation disorders  
• History of gastrointestinal bleeding, e.g., in association with use of nonsteroidal  anti-inflammat ory drugs  (NSAID),  that was clinically  relevant  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  21 of 133 
Protocol  No. CLOU064A2302   
 
 (e.g.,  where  intervention  was indicated  or requiring  hospi[INVESTIGATOR_324369])  
• Requirement for anti -platelet medication, except for acetylsalicylic acid 
up to 100 mg/d  or clopi[INVESTIGATOR_324370] 75 mg/d.  The use of dual anti-platelet 
therapy (e.g., acetylsalicylic acid + clopi[INVESTIGATOR_7745]) is prohibited.  
• Requirement  for anticoagulant  medication  (for example,  warfarin or 
Novel Oral Anti -Coagulants (NOAC))  
• History or current hepatic disease including but not limited to acute or 
chronic hepatitis, cirrhosis or hepatic failure or Aspartate 
Aminotransferase (AST)/  Alanine Aminotransferase (ALT)  levels  of more 
than 1.5 x upper limit of normal (ULN) or International Normalized Ratio 
(INR) of more than 1.5 at screening  
Study treatment  • LOU064 25mg  film-coated tablets  (blinded) 
• LOU064 25mg  placebo film-coated tablets  (blinded) 
• LOU064  25mg  film-coated  tablets  (open -label)  
Efficacy 
assessments All efficacy  measures  are Patient  Reported Outcomes  (PROs):  
eDiary assessments 
• Urticaria Patients  Daily  Diary  (UPDD),  which  assesses:  
• Hives  Severity  Score  (HSS)  
• Itch Severity  Score  (ISS)  
• Urticaria Activity  Score  (UAS)  
  
  
  
• angioedema occurrence  
• number  of calls to doctor,  nurse  or nurse  practitioner 
• Angioedema Activity  Score (AAS)  
Pharmacokinetic 
assessments  Assessment  of the concentration of remibrutinib in blood 45 min and 90 
minutes following administration, at Week 2, 12 and 52  
Key safety assessments Adverse  event  (AE) monitoring 
Physical examinations  
Vital signs  
Monitoring of laboratory  markers  in blood  and urine 
Central ECG (electrocardiogram) monitoring  
Other assessments Other  PROs  assessments 
• Dermatology  Life Quality  Index  (DLQI)  
  
  
  
  
  
 
 
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  22 of 133 
Protocol  No. CLOU064A2302   
 
 
Data  analysis The main purpose of this study is to demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with respect to change from baseline in 
UAS7 at Week 12 (for second scenario, in ISS7 and HSS7). A linear mixed 
model with repeated measures (MMRM) will be used to estimate treatment 
differences for change from baseline in UAS7 score (ISS7 and HSS7 for 
second scenario) at Week 12, based on the full analysis set (FAS).  
For secondary  endpoints,  a logistic  regression model  will be used to estimate 
treatment  differences  for disease activity  control  at weeks  2 and 12, complete 
response and DLQI=0/1 endpoints at week 12. Negative binomial regression model  will be used to estimate  treatment differences  for the cumulative  number 
of weeks  achieving AAS7 =  0 response and UAS7<=6 between baseline and 
Week 12.  
The primary and secondary endpoints analyses are planned to use the 
multiple  testing  strategy  to control  the family -wise error  at α=0.025 (one-sided).  
Summary tables will be presented by [CONTACT_6982] (as 
applicable) using descriptive statistics, which include absolute and relative 
frequencies  for categorical  variables  and arithmetic  mean,  standard  deviation  
(SD), minimum, maximum, median and  25th and 75th percentiles for 
continuous variables.  
Key words  BTK inhibitor;  Chronic  spontaneous  urticaria;  Urticaria  activity  score;  Hives 
severity score; Itch severity score  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  23 of 133 
Protocol  No. CLOU064A2302   
1 Introduction  
1.1 Background  
Chronic Spontaneous Urticaria (CSU), also known as Chronic Idiopathic Urticaria (CIU), is 
defined as the  spontaneous occurrence of itchy  wheals (hives),  angioedema or both, lasting  for 
at least 6 weeks  (Zuberbier et al 2014, Zuberbier et al 2018).  The classic description  of urticaria 
is a wheal  and flare with a pale elevated  lesion  and surrounding erythema,  ranging in size from 
a few millimeters  to a few centimeters  across,  usually occurring  in groups and often  coalescing 
to form  large  confluent lesions.  Wheals and angioedema in CSU involve the degranulation 
of mast cells, which release histamine, proteases and cytokines. These mediators induce 
vasodilatation, increase vascular permeability, and stimulate s ensory nerve endings leading to 
swelling, redness and itch ( Kaplan et al 1978, Saini and Kaplan 2018).  
CSU can be debilitating,  is associated  with intense itching  and has a major impact  on patient’s 
quality  of   life,   comparable   to  that  of  severe  coronary  artery   disease 
(Greaves 2003, Powell  et al  2007).  The overall  burden of CSU and CSU- associated 
angioedema for affected patients  is substantial:  CSU and its symptoms have a negative impact 
on numerous aspects of their daily life, including mental health, work productivity, sleep, 
partnership and family life (O'Donnell et al 1997, Maurer et al 201 7, Gonçalo et al 2021).  
Second generation H1-antihistamines  are recommended  as first- line treatment  for patients with 
CSU, but less than 40% of patients respond adequately ( Guillén -Aguinaga et al 2016). While 
up titration of second generation  H1-antihistamines up to 4- fold the approved dose is 
recommended  by [CONTACT_324387] -line therapy ( Zuberbier et al 2018) , 
the efficacy  of up titrated  H1-antihistamines  in CSU  has not been  studied  in larger clinical  trials 
and up titration  is considered  off-label.  The use of H2-antihistamines  and Leukotriene Receptor 
Antagonists (LTRAs) ha s in the past been recommended by [CONTACT_324388][INVESTIGATOR_324371]  H1 -antihistamines  
(Zuberbier et al 2009, Bernstein  et al 2014), although their use has not been well supported by 
[CONTACT_157065]. In the latest version of the treatment guidelines (Zuberbier et  al 2018), neither 
H2-antihistamines nor LTRAs are  perceived to have  sufficient evidence to maintain them as 
recommendable in the algorithm. Short courses of systemic corticosteroids are sometimes added to the treatment regimen; however, they are not recommended in treatment guidelines for long -term use, as this would expose patients to the well -known risk of adverse effects 
associated with chronic systemic corticosteroid use. Omalizumab is an effective third -line 
therapy for CSU patients. However, less than 50% of patients treated with omalizumab reach complete control of signs and symptoms ( Kaplan et al 2016). Therefore, there is a high unmet 
medical need for new treatment options for CSU patients inadequately controlled by H1- antihistamines.  
Bruton’s tyrosine kinase (BTK)  is a cytoplasmic  tyrosine kinase and member  of the TEC  kinase 
family.  BTK is expressed  in selected  cells of the adaptive and innate immune  system  including 
B cells,  macrophages and mast  cells/basophils.  BTK is indispensable for signaling through the 
Fc epsilon receptor  (FcεR1  for IgE),  the activating  Fc gamma  receptors (FcγR  for IgG),  as well 
as the B cell antig en receptor (BCR)  and therefore  an important signaling node in the activation/ 
degranulation of B cells, macrophages, mast cells or basophils ( Rip et al 2018).  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  24 of 133 
Protocol  No. CLOU064A2302   
BTK inhibitors (BTKi) like ibrutinib have been first approved for the treatment of B cell 
malignancies ( Hendriks et al 2014).  Due to the above described  role of BTK in adaptive as well 
as innate immune signaling and associated with that, its role in immune -mediated diseases, 
targeting BTK is regarded as a promising new approach for the treatment of various immune - 
mediated conditions.   
 
Mast cells and basophils play a key role in the pathophysiology of CSU and it has been demonstrated that BTK inhibition leads to blockade of mast cell and basophil activation/degranulation in vitro and to reduced wheal sizes in skin prick tests with patien ts 
suffering   from  IgE-mediated   allergies   (Smiljkovic  et al 2017, Regan et  al 2017, 
Dispenza et al 2017).  Thus, BTK inhibition  is a promising  therapeutic concept  for the treatment 
of CSU.  
Remibrutinib (LOU064) is a low molecular weight compound for oral administration that covalently
   binds   and   inhibits    BTK   with   high   selectivity 
(Angst et al 2020, Gabizon and London 2020). In Phase 1, remibrutinib was well- tolerated at 
all doses without any dose -limiting toxicity and showed encouraging blood and ski n 
pharmacodynamics with a favorable safety profile, fully supporting further development for diseases driven  by [CONTACT_324389],  basophils, and B cells,  such as CSU  (Kaul  et al 2021).  The Phase 
2b clinical  trial CLOU064A2201 primary  endpoint analysis  demonstrated  clinical  efficacy  and 
a fast onset of action of remibrutinib in the treatment of CSU patients as well as a favorable safety profile (for detailed information please refer to the Investigator`s Brochure (IB)).  
Taken  together, remibrutinib  may offer  a novel therapeutic  approach for patients  with CSU  and 
is advanced to Phase 3 clinical development. 
1.2 Purpose  
The purpose of this study is to establish the efficacy, safety, and tolerability of remi brutinib 
(LOU064) 25 mg b.i.d. in adult participants  suffering  from chronic spontaneous urticaria  (CSU) 
inadequately controlled by H1-antihistamines in comparison to placebo. 
Inadequate control of CSU by H1-antihistamines is defined as: 
• The presence of itch and hives for ≥ 6 consecutive weeks prior to  screening  despi[INVESTIGATOR_324372] H1- antihistamines during this time period  
• UAS7  sco re (range 0- 42) ≥ 16, ISS7  score (range 0-21) ≥ 6 and HSS7  score (range 0- 21) 
≥ 6 during the 7  days prior to randomization  (Day 1).  
 
2 Objectives,  endpoints  and estimands  
There are two primary objective scenarios based on regional regulatory precedent and Health 
Authorities’ feedback. These two primary objective scenarios will be tested in two distinct 
testing strategies ( Table  2-1 and Table  2-2 ). Distinctions in the secondary objectives reflect 
the corresponding scenario: the primary objective in one scenario is presented as secondary 
objective(-s) in another. The other secondary  objectives are identical  in both 
scenarios.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  25 of 133 
Protocol  No. CLOU064A2302   
 
Table 2-1 Objectives and related endpoints – Scenario with UAS7  as the primary 
efficacy endpoint 
 
Objective(s)  Endpoint(s)  
 
Primary  objective(s)  Endpoint(s) for primary objective(s)  
• To demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with respect  to change from baseline  in UAS7 
at Week 12  • Absolute change from baseline in UAS7  at 
Week 12  
 
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
• To demonstrate that a greater  proportion 
of participants achieve disease activity control (UAS7 ≤ 6) at Week 12 who are treated with remibrutinib (25 mg b.i.d.) 
compared to placebo -treated  participants  
• To demonstrate that a greater proportion 
of participants  achieve  complete  absence 
of hives and itch (UAS7 = 0) at Week 12 who are treated with remibrutinib (25 mg 
b.i.d.) compared to placebo -treated 
participants  
• To demonstrate the superiority of 
remibrutin ib (25 mg b.i.d.) treated 
participants with respect to a reduction from baseline  in the weekly  itch severity 
score  at Week  12 compared  to placebo- 
treated participants  
• To demonstrate the superiority of remibrutinib (25 mg b.i.d.) treated participants with respect to a reduction from baseline  in the weekly  hive severity 
score  at Week 12 compared to placebo- 
treated participants  
• To demonstrate that a greater proportion of participants  achieve UAS7  ≤ 6 at Week 
2 who are treated with remibrutinib (25 mg b.i.d.) compared to placebo- treated 
participants  
• To demonstrate that a greater  proportion 
of participants who are treated with 
remibrutinib (25 mg b.i.d.) achieve DLQI  
= 0-1 at Week  12 compared to placebo- 
treated participants  
• To demonstrate that remibrutinib (25 mg 
b.i.d.) treated participants maintain disease activity  control  (defined as UAS7  
≤ 6) for more  weeks  compared to placebo 
treated participants over 12 weeks  
• To demonstrate that remibrutinib  (25 mg 
b.i.d.) treated participants have more  • Achievement  of UAS7  ≤ 6 (yes/no)  at Week  12 
 
  
 
• Achievement  of UAS7  = 0 (yes/no)  at Week  12 
 
  
 
 
• Improvement of severity of itch, assessed as 
absolute change from baseline in ISS7  score  at 
Week 12  
 
 
 
• Improvement  of severity  of hives,  assessed  as 
absolute change from baseline in HSS7 score 
at Week 12  
 
 
 
• Achieving early onset of disease activity  
control,  as defined  as achievement  of UAS7  ≤ 6 
(yes/no) at Week 2  
 
 
• No impact on participants' dermatology quality 
of life, as defined by [CONTACT_324390]  = 0-1 
(yes/no) at Week 12  
 
 
• Achieving sustained disease activity control, 
assessed  as cumulative number  of weeks  with 
an UAS7 ≤ 6 response between baseline and 
Week 12  
 
• Number of weeks without angioedema, 
assessed  by [CONTACT_324391]. 01 (Clean)  Confidential  Page  26 of 133 
Protocol  No. CLOU064A2302   
 
 
Objective(s)  Endpoint(s)  
angioedema occurrence- free weeks  over 
12 weeks  compared with placebo -treated 
participants  
• To demonstrate the safety  and tolerability 
of remibrutinib (25 mg b.i.d.) with an AAS7  = 0 response between baseline 
and Week 12  
 
• Occurrence of treatment emergent adverse 
events  and serious  adverse  events  during the 
study  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  27 of 133 
Protocol  No. CLOU064A2302   
 
 
Objective(s)  Endpoint(s)  
 
 
Table 2-2 Objectives and related endpoints - Scenario with ISS7 and HSS7 as 
the co-primary efficacy endpoints 
 
Objective(s)  Endpoint(s)  
 
Primary  objective(s)  Endpoint(s)  for primary  objective(s)  
• To demonstrate that remibrutinib  (25 mg 
b.i.d.)  is superior  to placebo in CSU  with • Absolute change from baseline in ISS7  at 
Week 12  
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  28 of 133 
Protocol  No. CLOU064A2302   
 
 
Objective(s)  Endpoint(s)  
respect  to change from baseline  in ISS7  and 
HSS7 at Week 12  • Absolute change from baseline in HSS7  at 
Week 12  
 
Secondary  objective(s)  Endpoint(s)  for secondary  objective(s) 
• To demonstrate that remibrutinib (25 mg 
b.i.d.) is superior to placebo in CSU with respect  to change from baseline  in UAS7  at 
Week 12  
• To demonstrate that a greater proportion of  
participants achieve disease activity control 
(UAS7  ≤ 6) at Week  12 who are treated with 
remibrutinib (25 mg b.i.d.) compared to placebo -treated participants  
• To demonstrate that a greater  proportion of 
participants achieve complete absence of hives and itch (UAS7 = 0) at  Week 12 who 
are treated with remibrutinib (25 mg b.i.d.) 
compared to placebo -treated participants  
• To demonstrate that a greater  proportion of 
participants achieve UAS7 ≤ 6 at Week 2 
who are treated with remibrutinib (25 mg 
b.i.d.) compared to placebo -treated 
participants  
• To demonstrate that a greater proportion of participants who are treated with remibrutinib  (25 mg b.i.d.)  achieve DLQI  = 0- 
1 at Week 12 compared to placebo -treated 
participants  
• To demonstrate that remibrutinib (25 mg b.i.d.)  treated participants  maintain  disease 
activity control (defined as UAS7 ≤ 6) for more weeks compared to placebo treated 
participants over 12 weeks  
• To demonstrate that remibrutinib (25 mg 
b.i.d.) treated participants have more angioedema occurrence- free weeks  over 12 
weeks compared with placebo- treated 
participants  
• To demonstrate the safety  and tolerability  of 
remibrutinib (25 mg b.i.d.)  •  Absolute change from baseline in UAS7  at 
Week 12  
 
 
•  Achievement  of UAS7  ≤ 6 (yes/no)  at Week 
12 
 
 
 
• Achievement  of UAS7  = 0 (yes/no)  at Week 
12 
 
 
 
• Achieving early onset of disease activity 
control,  as defined as achievement  of UAS7  
≤ 6 (yes/no)  at Week 2 
 
 
• No impact on participants' dermatology 
quality  of life, as defined by [CONTACT_324392] = 0 -1 (yes/no) at Week 12  
 
 
• Achieving  sustained disease activity  control, 
assessed as cumulative number of weeks 
with an UAS7 ≤ 6 response between 
baseline and Week 12  
 
• Number of weeks without angioedema, 
assessed by [CONTACT_324393]7  = 0 response  between 
baseline and Week 12
 
 
• Occurrence  of treatment  emergent  adverse 
events and serious adverse events (SAEs) 
during the study  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400442] the interpretation of the trial results 
(e.g., premature discontinuation of treatment). 
Primary  estimand  for scenario  with  UAS7  as primary  efficacy  endpoint  
The primary  clinical  question of i nterest  is: What  is the effect  of remibrutinib  treatment versus 
placebo on the change from baseline in UAS7 score after 12 weeks treatment in adult 
participants with CSU who are inadequately controlled by H1- antihistamine and receiving a 
stable locally lab el approved dose of a second generation H1- antihistamine, regardless of 
discontinuation from study treatment for any reason and regardless of intake of a different second generation H1- antihistamine as rescue medication and considering strongly 
confounding prohibited medication as an unfavourable outcome? 
The primary  estimand is described by  [CONTACT_6570]: 
1. Population: participants  with inadequately  controlled  CSU despi[INVESTIGATOR_324373] H1- antihistamine who have CSU duration ≥ 6 months, a UAS7 score ≥ 16, 
ISS7 ≥ 6 and HSS7 score ≥ [ADDRESS_400443] 7 days prior to randomization.  
2. Endpoint:  Change in UAS7  from baseline at Week  12. 
3. Treatment of interest: the randomized study treatment (remibrutinib 25 mg b.i.d. or 
placebo) regardless of treatment compliance, with background medication of locally label approved dose second  generation H1-antihistamine,  and a different  second  generation H1- 
antihistamine as rescue medication.  
4. Summa ry Measurement:  the mean difference between treatment groups. 
5. Handling  of intercurrent  events:  
• Discontinuation of study treatment due to  any reason: Treatment policy  strategy  
• Intake of strongly confounding prohibited medication  (e.g., biologics treatment at any 
time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week  
8): Composite strategy  (irrespective  of potential occurrence of other intercurrent 
events)  
• Intake of rescue medication,  switch  of background medication,  intake of other 
prohibited medication: Treatment policy strategy  
Primary  estimand  for scenario  with  ISS7/HSS7  as co-primary  efficacy  endpoints  
The primary  clinical  question of interest is: What  is the effect  of remibrutinib  treatment versus 
placebo on the co -primary endpoints change from baseline in ISS7 score and change from 
baseline in HSS7 score after treatment in adult participants with CSU who are inadequately controlled by H1- antihistamine and receiving a stable locally label app roved dose of a second 
generation H1-antihistamine,  regardless of discontinuation from  study treatment for any reason 
and regardless of intake  of a different second  generation  H1-antihistamine  as rescue medication 
and considering strongly confounding prohibited medication as an unfavourable outcome? 
The primary  esti
 mand is described by  [CONTACT_6570]: 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  30 of 133 
Protocol  No. CLOU064A2302   
1. Population: participants  with inadequately  controlled CSU despi[INVESTIGATOR_324373] H1- antihistamine who have CSU duration ≥ 6 months, a UAS7 score ≥ 16, 
ISS7 ≥ 6 and HSS7 score ≥ [ADDRESS_400444] 7 days prior to randomization.  
2. Endpoint  (co-primary):  Change in ISS7  from baseline  at Week  [ADDRESS_400445]: the randomized study treatment (remibrutinib 25 mg b.i.d. or 
placebo) regardless of treatment compliance, with background medication of locally label approved dose second  generation H1-antihistamine,  and a different  second  generation H1- 
antihistamine as rescue medication.  
4. Summary  Measurement:  the mean  difference  between  treatment  groups. 
5. Handling  of intercurrent  events:  
• Discontinuation of study treatment due  to any reason: Treatment policy  strategy  
• Intake of strongly confounding prohibited medication  (e.g., biologics treatment at any 
time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week  
8): Composite strategy  (irrespective  of potential occurrence of other intercurrent 
events)  
• Intake of rescue medication,  switch  of background medication,  intake  of other 
prohibited medication: Treatment policy strategy  
2.2 Secondary  estimands 
Secondary  estimand on the secondary  endpoint UAS7 ≤ [ADDRESS_400446] is: What  is the effect  of remibrutinib  treatment  versus 
placebo  on the UAS7  ≤ 6 response after 12 weeks treatment  in adult participants  with CSU who 
are inadequately controlled by H1 -antihistamine and receiving a stable locally label approved 
dose of a second generation H1- antihistamine, regardless of treatment discontinuation for any 
reason and regardless of intake of a different second generation  H1-antihistamine as rescue 
medication and considering strongly confounding prohibited medication as an unfavourable outcome?  
The secondary estimand is described by  [CONTACT_6570]: 
1. Population: patients with inadequately controlled CSU despi[INVESTIGATOR_324374] H1-antihistamine  who have CSU  duration ≥ 6 months, a UAS7  score ≥ 16, 
ISS7 score ≥ 6 and HSS7 score ≥ [ADDRESS_400447] 7 days prior to randomization. 
2. Endpoint:  UAS7  ≤ [ADDRESS_400448]: the randomized study treatment (remibrutinib 25 mg b.i.d. or 
placebo)  regardless of treatment  compliance,  with background medication  of locally  label 
approved dose second generation H1- antihistamine, and a different second generation  
H1-antihistamine  as
  rescue medication.  
4. Summary  Measurement:  the odds ratio between  treatment  groups.  
5. Handling  of intercurrent  events:  
• Discontinuation of study treatment due to any reason Treatment policy  strategy  
• Intake of strongly confounding prohibited medication  (e.g., biologics treatment at any 
time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  31 of 133 
Protocol  No. CLOU064A2302   
8): Composite strategy  (irrespective  of potential occurrence of other intercurrent 
events)  
• Intake of rescue medication,  switch  of background medication,  intake  of other 
prohibited medication: Treatment policy strategy  
Secondary  estimand  on the secondary  endpoint  UAS7  = 0 response at week 12 
Similar Estimand  approach  will be implemented  for UAS7  = 0 as for UAS7  ≤ 6. 
Other secondary estimand on the other secondary endpoints as defined in Table 2 -1 and 
Table 2 -2 
Similar Estimand approach will be implemented for these endpoints as the primary Estimand 
or co- primary Estimand.  
 
3 Study  design  
This is a global, multicenter, randomized, double -blind, parallel -group, placebo -controlled 
Phase 3 study investigating the safety, tolerability, and efficacy of remibrutinib (25 mg b.i.d.) in adult participants  with CSU inadequately controlled  by [CONTACT_324386] H1-antihistamines. 
The study consists of four periods, the total study duration is up to 60 weeks ( Figure 3-1):  
• Screening  period:  up to 4 weeks.  
• Double -blind  treatment  period:  24 weeks of double- blind  treatment  with remibrutinib 
(25 mg b.i.d.) or placebo. 
• Open- label  treatment  period:  28 weeks of open- label  treatment with remibrutinib  (25 
mg b.i.d.). 
• Follow- up period:  [ADDRESS_400449] completed Week 24 or discontinued earlier and when a minimum of 150 participants  across both Phase 3 pi[INVESTIGATOR_157037] (a  second, nearly  identical  Phase 3 study will be conducted in parallel) have completed 
the treatment  period at Week  52 (see Section  4.4). All participants  will be on a stable,  locally 
label approved dose of a second  generation H1 -antihistamine (“background therapy”) 
throughout the entire study (starting a minimum of 7 days prior to randomization until the end of the study) . To treat unbearable symptoms of CSU, participants will be allowed to 
use another second generation H1- antihistamine on an as -needed basis (“rescue therapy”). 
Eligible participants will be randomly assigned to the treatment arms in a 2:[ADDRESS_400450] of approximately 450 female and male adult participants (300 in the active arm and 150 in the placebo  arm)  with CSU inadequately controlled by [CONTACT_324386] 
H1-antihistamines at least at locally label approved dose.  Participants will be stratified based 
on prior exposure to anti-IgE biologics and geographic region. 
An extension study is in development. Eligible participants may roll over at Week 52 (after 
com
pleting 52 weeks of treatment and all scheduled assessments planned at this visit). The 
details of the study design and procedures of the extension, if implemented, will be described in a separate protocol. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  32 of 133 
Protocol  No. CLOU064A2302   
 
Figure 3-1 Study Design  
 
 
D-1: Day 1, b.i.d.: bis in die/twice  a day, mg: milligram(s),  Pbo: placebo, PA: Primary  Analysis, 
PE: Primary Endpoint, Scr: Screening, W: Week  
 
[ADDRESS_400451] not adequately  responded to prior treatment 
with H1 -antihistamines and other CSU therapi[INVESTIGATOR_157038]. This Phase 3 study  is 
designed to  confirm and further  evaluate  the efficacy  and safety  of remibrutinib  at a dose  of 25 
mg b.i.d. (as determined by [CONTACT_16646] 2b dose -range finding study CLOU064A2201, see also 
section  Section  4.2) in adult  CSU patients.  It is a randomized, double- blind,  parallel-group, and 
placebo -controlled study that consists of four periods: 
1. Screening  period:  the screening  period  of up to four weeks will allow  the assessment  of 
eligibility of participants and the determination of baseline disease activity.  
2. Double -blind treatment period: a placebo -controlled, double-blind treatment period 
until Week 24. The placebo-controlled, double-blind design is mandatory to enable a robust assessment of the efficacy  of remibrutinib without bias by [CONTACT_324394] (and the resulting significant placebo effect). Furthermore, it is required for a robust assessment  of the safety  profile  of remibrutinib  in comparison  to placebo  over an adequate 
period of time (for further details please see Section 4.3 ). This design is in line with other 
major Phase 3 trials in the field of CSU, e.g., with ligelizumab ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]), which ensures comparability. In order to limit the number of participants exposed to placebo while maintaining the scientific validity of the study, the 
randomization ratio will be 2:1 of active vs. placebo treatment. A placebo comparison up 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  33 of 133 
Protocol  No. CLOU064A2302   
to Week  24 (which  is beyond the primary  endpoint at Week  12) will provide a background 
incidence in the study population for possible safety findings and will ensure a valid 
assessment of the durability of the treatment response. It will support a more robust characterization of the safety profile of remibrutinib, i.e., if safety events are observed in 
both the placebo and remibrutinib arms, it may be inferred that the events are not necessarily related to the study treatment. To limit the duration of placebo treatment, the placebo -controlled treatment period will stop at Week 24, since a period of 24 weeks 
allows a reliable and valid assessment of efficacy and safety in patients with CSU.  
3. Open- label treatment period: during this treatment period of 28 weeks, all participants 
will receive open -label remibrutinib (25 mg b.i.d.). Together with the preceding double- 
blind, placebo-controlled period, a total of up to 52 weeks of remibrutinib (25 mg b.i.d.) treatment will be studied within this trial. This is in line with current CSU treatment guidelines ( Zube rbier et al 2018) and will provide adequate long- term efficacy  and safety 
data to fully characterize the value of remibrutinib (25 mg b.i.d.) in CSU treatment. Switching placebo treated participants to active treatment wi th remibrutinib at Week 24 
gives all participants the opportunity to receive active treatment with remibrutinib within 
the course of this study. 
4. Follow- up period:  a treatment- free follow -up period  of four weeks at the end of the study 
will be implemented for all participants who do not enroll into the extension study (currently in planning stage). This allows the assessment of safety of treatment discontinuation as well as the dynamics of potential re-occurrence of CSU signs and symptoms after treatment discontinuation.  
The study population consists of participants with CSU (UAS7 score ≥ 16, with HSS7 score ≥ 
6 and ISS7 score ≥ 6), who have a duration of CSU of ≥ [ADDRESS_400452] inadequately responded to or did not tolerate anti-IgE biologic treatments are also eligible for this study. Thus, CSU patients with a high 
unmet med ical need are the target population for this study. 
Historically, the treatment paradigm for CSU focused primarily on the key symptom itch, as assessed by [CONTACT_324395] (ISS7). Over the past several years, the emphasis and target  of therap y, as described  in the current CSU  treatment  guidelines 
(Zuberbier et al 2018), have evolved to also integrate the second key  symptom of CSU, which 
is hives. Therefore, UAS7, which is a composite of ISS7 and the weekly  Hives Severity  Score 
(HSS7),  is now recommended, rather  than using ISS7  alone. Thus, the primary  endpoint of this 
study is change in UAS7 from baseline at Week 12 or a co- primary endpoint of change from 
baseline in ISS7  and HSS7  at Week  12. Two separate statistical  analyses will be used to enable 
the two different primary  and consecutive secondary endpoints, in order to fulfill regional  health 
authority requests. They will be assessed in independent testing strategies for all participants. Furthermore, a primary endpoint at Week 12 ensures adequate comparability of the efficacy 
outcomes with other major  Phase 3 trials  in the field of CSU,  e.g., with omalizumab 
(Maurer  et al 2013) or ligelizumab ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]). UAS7- based 
responder analyses (UAS7 ≤ 6 and UAS7=0), the assessment of the impact of remibrutinib treatment on itch (ISS7) and hives (HSS7), the assessment of the impact of remibrutinib 
treatment on dermatology -related  quality  of life (DLQI -response of 0/1), and the assessment  of 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400453]  of remibrutinib  treatment on the number of weeks  without occurrence of angioedema 
(AAS7=0) have been selected as secondary endpoints to further assess the efficacy of 
remibrutinib.  
Assessing remibrutinib (25 mg b.i.d.) as add- on to background medication consisting of a 
locally approved second generation H1- antihistamine follows the recommendations of the 
current treatment guid elines ( Zuberbier et al 2018 ). 
Applying a treatment policy strategy for treatment non -compliance, the use of rescue 
medication  (a second  generation H1-antihistamine  that differs  from  the background medication), 
and most other intercurrent events aims to assess remibrutinib as a CSU therapy (as an add -on 
to background medication) close to a "real -life" situation. Only intercurrent events that are 
likely  to impose a strong bias on the effica cy readout (such as use of highly effective biologics 
with a long half-life) will be handled using a composite strategy. 
Taken together, the study design will allow the investigation of the efficacy and safety of 
remibrutinib in CSU as per current scientif ic, medical, ethical and regulatory standards,  while 
limiting the burden for participants as much as possible.  
4.1.[ADDRESS_400454]- line therapy  to H1 -antihistamine background thera py in CSU patients 
who are not adequately controlled by H1-antihistamines  (Zuberbier et al 2018).  Furthermore,  it 
allows  active  treatment  of participants in the placebo  arm, including the use of additional rescue 
medication. Thus, participants in the placebo arm are not left without CSU treatment.  
4.2 Rationale  for dose/regimen and duration of treatment  
In this study, remibrutinib  will be given  in a dosing regimen  of 25 mg b.i.d. for a duration  of up 
to 52 weeks. A treatment duration of up to 52 weeks is in line with the current treatment guidelines ( Zuberbier et  al 2018) and in  line with  other current major Phase  3 trials  in the CSU 
indication, e.g., with  ligelizumab  ([STUDY_ID_REMOVED] and [STUDY_ID_REMOVED]). Therefore,  it allows  the 
collection of efficacy and safety data for remibrutinib over a treatment duration, which is applied in real -world clinical practice and which allows comparison to other Phase [ADDRESS_400455]  the opportunity to 
roll over after completing 52 weeks of study treatment in this trial.  
Based  on the safety  data from the completed  and ongoing remibrutinib  trials,  the clinical  safety 
profile  of remibrutinib  is favorable and supports the selected  dose of 25 mg b.i.d. In the primary 
endpoint analysis of the dose -range finding Phase 2b study CLOU064A2201 (cut -off date at 
14-Jan-2021), most adverse events (AEs)  were mild in severity, without patterns of clustering 
or dose-dependency. Ongoing clinical  safety  review  of CLOU06 4A2201E1, a long- term 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  35 of 133 
Protocol  No. CLOU064A2302   
extension study of CLOU064A2201,  with a 52-week  treatment period with 100 mg remibrutinib  
b.i.d. did not reveal any safety  signals. In addition, the clinical safety  data from the completed 
Phase 1 studies, which tested doses of remibrutinib up to 600 mg q.d. and 200 mg b.i.d., was 
favorable  and did not raise any concerns. For more  detailed  information  on the safety  profile  of 
remibrutinib, please see Section 4.5 and the Investigator's Brochure. 
In the dose -range finding study CLOU064A2201, the efficacy of remibrutinib as an add- on to 
background therapy of second generation H1- antihistamines was assessed v ersus placebo for 
the following dose regimens: 10 mg q.d., 35 mg q.d., 100 mg q.d., 10 mg b.i.d., 25 mg b.i.d., 100 mg b.i.d. The treatment duration was 12 weeks and the primary endpoint was change in UAS7 score  from baseline at Week 4. The key  secondary  endpoints were defined as change in 
UAS7 score from baseline at Week 12, change in UAS7 score  from baseline over time, 
percentage of participants with UAS7 = 0 (complete absence of hives and itch) over time, and percentage of participants with UAS7 ≤ 6 (dis ease activity control) over time. At the time of 
the primary endpoint analysis, there were 301 participants (40 -47 per arm) among 309 under 
FAS with a UAS7  score at Week  4, and 233 participants  (29-37 per arm) with a UAS7  score at 
Week  12. The treatment groups were  overall well balanced  in terms  of demography and baseline 
disease characteristics.  
The study demonstrated  clinical  efficacy  of remibrutinib  in the treatment of CSU,  with all tested 
doses showing superior efficacy over placebo at Week 4. A dose -response relationship was 
established for the q.d. and b.i.d. remibrutinib dosing regimens compared to placebo with respect to the change from baseline in UAS7 score at Week 4, with the dose- response plateau 
already  achieved  at 10 mg for q.d. dosing (=10 mg total  daily  exposure) and at  25 mg  for b.i.d. 
dosing (=50 mg total daily exposure). 
Figure 4-[ADDRESS_400456] repeated measurement analysis, by [CONTACT_1570] (FAS)  
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  36 of 133 
Protocol  No. CLOU064A2302   
 
Figure 4-2 UAS7  = 0 and UAS7  <= 6 response rate over  time by [CONTACT_1570] 
(as observed) (FAS)  
 
Assessing the higher hurdle UAS7 ≤ 6 (disease activity control) and UAS7 = 0 (total absence 
of itch and hives) response rates enabled further differentiation between the tested doses (Figure 4-1 and Figure 4-2): At Week  4, the remibrutinib  25 mg b.i.d. dosing regimen  achieved 
numerically  higher UAS7  ≤ 6 response rates than all other  tested  doses: 55.8 % under 25 mg 
b.i.d. compared to 43.2%, 40.9%, 42.6%, 34.1%, 44.4%, 4.8% under 10 mg q.d., 35 mg q.d., 100 mg  q.d., 10 mg  b.i.d., 100 mg  b.i.d., placebo (non-responder imputation).  In line with that, 
the 25 mg b.i.d. dosing regimen  also achieved  considerably  higher UAS7=0  response rates  than 
all other tested doses at Week 4: 41.9% under 25 mg b.i.d. compared to 18.2%, 22.7%, 17.0%,  
18.2%, 22.2%, 0.0% under 10 mg q.d., 35 mg q.d., 100 mg q.d., 10 mg b.i.d., 100 mg b.i.d., placebo  (non-responder imputation).  The numeri cally  higher efficacy  of the 25 mg b.i.d. dosing 
regimen  compared  to all other doses was  observed consistently  over time,  with  higher UAS7  ≤ 
6 and UAS7 = 0 response rates from Week 2 throughout Week 12 ( Figure 4-2). Furthermore, 
the [ADDRESS_400457] onset of action, with high response rates already achieved at Week 2 ( Figure 4-2).  
At Week 12, the UAS7 ≤ 6 and UAS7 = 0 response rates for placebo treated participants were relatively  high (31.3% and 15.7%), reflecting  the fluctuating  nature of CSU  (Figure 4-2).  While 
still showing numerical superiority, the q.d. dosing regimens (10 mg q.d., 35 mg q.d., 100 mg 
q.d.) showed a tendency  towards weaker  differentiation  vs placebo  in UAS7  ≤ 6 and UAS7  = 0 
response at Week 12 (UAS7 ≤ 6: 43.2%, 40.9%, 42.6%; UAS7 = 0: 29.4%, 29.4%, 32.4%) (as  
observed), whereas the 25 mg b.i.d. regimen was able to maintain a notable difference (UAS7  
≤ 6: 63.6%, UAS7 = 0: 48.5%). B.i.d. dosing is also supported from a pharmacokinetics, pharmacodynamics and mode -of-action perspective, in order to ensure sustained BTK 
inhibition over [ADDRESS_400458] turn- over of the covalent BTK - 
remibrutinib complex in tissue (see Investigator´s Brochure for details).  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  37 of 133 
Protocol  No. CLOU064A2302   
Taken together, all tested remibrutinib dosing regimens demonstrated superior efficacy in 
treating signs and symptoms of CSU compared to placebo, when assessing the mean change from baseline in UAS7.  However,  when  analyzing  higher hurdle efficacy  endpoints with higher 
discriminatory power (UAS7 ≤ 6  or UAS7 = 0) and later time points with higher placebo 
response rates,  the 25 mg b.i.d. treatment regimen  showed notably higher  efficacy  than the other 
tested regimens, especially than the q.d. regimens.  
A lower  b.i.d. dose (10 mg b.i.d.) or once daily  dosing (35 mg q.d.), does not enable participants 
to achieve the maximum efficacy, which can be achieved with 25 mg b.i.d. dosing, especially when  considering the UAS7  ≤ 6 and UAS7  = 0 response rates.  At the same  time,  higher dosing 
regimens, such as 100 mg b.i.d., are not required to reach m aximum efficacy.  
As the safety data also support the 25 mg b.i.d. dosing regimen (see  Section  4.5 and the 
Investigator's Brochure) with a favorable safety profile and no dose -dependent safety signals, 
remibrutinib 25 mg b.i.d. was selected as the optimal dose for this Phase 3 study. 
4.3 Rationale  for choice of control  drugs  (comparator/placebo)  or 
combination drugs  
Placebo was chosen as a comparator for this trial to adjust for the fluctuating nature of CSU, which can result in a pronounced placebo effect. Therefore, comparison to placebo allows a robust and scientifically  valid  efficacy  assessment.  Furthermore,  comparison to placebo  allows 
a meaningful safety  assessment.  The use of placebo  in this study  population is considered to be 
appropriate since participants will additionally receive background therapy of H1 - 
antihistamines (see  Section  6.1.2) and will have access to additional rescue medication (see 
Section  6.2.4 ). Although it is an inclusion criterion of the study to be inadequately controlled 
by H1- antihistamines, this does not mean that participants do not benefit from H1- 
antihistamines at all. The allowed H1 -antihistamine background treatment still alleviates  
participants´ symptoms to a certain degree. Thus, participants in the placebo arm are not left without treatment during the placebo- controlled period. Furthermore, participants in the 
placebo arm will be switched to active treatment with remibrutinib at W eek 24, giving all 
participants  the opportunity to receive  treatment with remibrutinib  during the course of the trial. 
As the target patient population is hard -to-treat CSU patients with a prior inadequate response 
to second generation H1- antihistamines, the only potential active comparator according to the 
current treatment guidelines would be omalizumab ( Zuberbier et al 2018 ). CSU patients, who 
have already been treated with, and potentially failed to respond to, omalizumab, have  a high 
unmet medical need,  since they are currently  left without approved treatment options. Adding 
omalizumab as an active comparator to the study would significantly restrict the study population, as these omalizumab (or any other anti -IgE biologics) pretreated patients would 
need  to be excluded from the study in order to prevent a potential prior treatment  bias and allow 
a fair comparison, thus preventing  the collection of efficacy and safety data for this  
population. Additionally, the burden for enrolled participants would increase as the 
administration routes of remibrutinib (oral) and omalizumab (subcutaneous (s.c.)) would mandate a double -dummy design w ith placebo injections for participants in the remibrutinib 
arm and 4 -weekly visits throughout the entire study duration (instead of extended periods 
between  visits  after Week  24 as per the current study design). Furthermore,  the long half-life of 
omalizum ab (approximately  4 weeks  vs a half-life of approximately  1 hour for remibrutinib)  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  38 of 133 
Protocol  No. CLOU064A2302   
would mandate a significantly longer treatment- free follow -up period after the end of the 
treatment period. Due to differences in the route of administration (s.c. vs. oral), different PK - 
PD profiles and speed of onset kinetics, omalizumab is not considered an ideal comparator for 
remibrutinib. Lastly, historical comparisons of the data from the confirmatory omalizumab trials to the current remibrutinib trial will be possible, given their similarities with regard to 
patient  population, background medication,  endpoints and the use of placebo  as the control arm 
in the omalizumab studies. 
Taken together, a placebo comparison over [ADDRESS_400459] and scientifically  valid  assessment  of the safety  and efficacy  of remibrutinib. 
The additional comparative information  which  could  be gained by [CONTACT_324396].  
4.4 Purpose  and timing  of interim  analyses/design  adaptations  
A primary  analysis may be conducted when  all participants  have  completed their Week  [ADDRESS_400460] completed the treatment period  (a second, nearly identical Phase 3 study will be 
conducted in parallel). The minimum of 150 participants reaching week 52 should enable 
analysis on a minimum of 100 participants exposed to remibrutinib for 52 weeks considering 
the initial randomization to either the remibrutinib or the placebo arm (2:1).  The results of the 
primary analysis will further inform decision making for the remibrutinib development program.  
After the primary analysis and/or after all participants have entered the open label treatment period, additional optional interim analyses may be conducted to support potential Health Authority  interactions  and requests (these interim  analyses are not expected  to have any impact 
on the conduct or scientific integrity of the study). 
4.[ADDRESS_400461] cell degranulation with release of inflammatory  mediators  including histamine  (Ferrer 2015, Saini  and Kaplan  2018).  Bruton’s 
tyrosine  kinase (BTK)  is a cytoplasmic tyrosine  kinase that is indispensable for FcεR1  signaling 
and a central  signaling  kinase in mast  cell activation. It has been  demonstrated  that 
BTK inhibition can  effectively  inhibit mast  cell activation  and reduce wheal  sizes in  skin  prick 
tests ( Regan  et al 2017, Dispenza et al 2018, Kaul  et al 2019).  In Phase  1, remibrutinib  was 
well-tolerated at all doses without any dose -limiting toxicity and showed encouraging blood 
and skin pharmacodynamics with a favorable safety profile, fully supporting further development for diseases driven  by [CONTACT_324389],  basophils, or B cells,  such as CSU.  Furthermore, 
remibrutinib  has been  shown to effectively  reduce wheal  size in skin prick  tests 
(Kaul  et al 2021)
 . The Phase 2b clinical trial CLOU064A2201 (primary endpoint analysis) 
demonstra ted clinical efficacy  of remibrutinib  in the treatment  of CSU patients with a fast onset 
of action and a favorable safety profile.  
Based on this data, 25 mg b.i.d. has been selected as the optimal dosing regimen for the treatment of CSU patients.  Treatment  with remibrutinib  25 mg b.i.d. resulted  in a substantial  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  39 of 133 
Protocol  No. CLOU064A2302   
reduction of the UAS7  score,  which  measures frequency/intensity  of hives and itch, the two key 
symptoms defining the burden of CSU for affected participants. The benefit for CSU patients 
treated  with remibrutinib  25 mg b.i.d. was also reflected  by [CONTACT_324397] - 
related quality of life (HRQoL), as measured by [CONTACT_157075] (see Investigator´s Brochure for details).  
BTK inhibition is a new therapeutic principle  for the treatment  of CSU that significantly  differs 
from currently available treatment options in terms of its mode of action and route of administration. Remibrutinib may therefore offer a treatment option for patients with contraindications against or inadequate response to approved treatment options for CSU including anti -IgE directed biologics. These patients, for whom a high unmet need for new 
treatments exists, are part of the eligible patient population of this study. In the above - 
mentioned Phase 2b trial CLOU064A2201, remibrutinib  showed a rapid  onset  of action  already 
after the first week of treatment, which is of significant benefit for CSU patients, who often 
have a high current symptom burden. Furthermore, the oral route of administration of remibrutinib offers additional convenience compared to injectable biologics. 
Taken together, the be nefit for study participants is that treatment with remibrutinib could 
substantially improve their CSU signs and symptoms and lead to a better quality of life.  
The available clinical safety experience has documented favorable safety and tolerability of 
remibrutinib. As of 10- Mar-2022, approximately 903 participants (healthy volunteers (HVs) 
and patients suffering from CSU, asthma, Sjoegren’s Syndrome (SjS),  atopic dermatitis  (AD), 
and relapsing multiple sclerosis (RMS)) have been exposed to remibrutinib at doses ranging from 0.5 mg to 600 mg, placebo or comparator. A maximum tolerated dose has not been identified.  
In the final analysis of the Phase 2b trial CLOU064A2201 in patients with CSU, 309 participants (safety  set (SAF)) received remibrutinib  at doses/ regimens up to [ADDRESS_400462]  adverse events (AEs)  were  mild in severity,  without clustering  of specific 
AEs and no apparent dose related pattern was identified.  The most frequent adverse events 
were  reported  in the following  System  Organ  Classes (SOC):  Infections  and infestations  (24.0% 
any remibrutinib  dose vs 21.4% in placebo arm),  Skin and subcutaneous tissue  disorders (16.9% 
vs 4.8%), Nervous system disorders (13.1% vs 16.7%), and Gastrointestinal disorders (11.2% vs 11.9%). The most frequent AEs (defined by [CONTACT_320177] (PT), occurring in ≥ 5% of participants in either Any remibrutinib or placebo arm) were:  
• Headache:  9.7% in any remibrutinib  arm vs. 14.3% in placebo arm 
• Nasopharyngitis: 8.6% in any remibrutinib arm vs. 7.1% in placebo arm  
• CSU:  6.0% in  any remibrutinib  arm vs. 2.4% in  placebo  arm (the events of CSU were 
flares primarily reported by [CONTACT_324398]- free follow -up period) 
In interim analysis 2 (IA2; cut- off May -2021) of the Phase 2b long- term open- label extension 
trial CLOU064A2201E1, data from [ADDRESS_400463] common SOCs (≥ 10% of subjects) were Infections and infestations (23%), Skin and subcutaneous tissue disorders (17.5%), Gastrointestinal disorders  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  40 of 133 
Protocol  No. CLOU064A2302   
(14.2%) and Nervous systems disorders (10.4%). The [ADDRESS_400464] commonly reported PTs were 
headache (6.6%), COVID -19 (4.9%), and diarrhea (4.9%). 
Based on the mode of action of remibrutinib, pre -clinical safety information, drug -drug- 
interaction  studies, and the review  of currently  available literature  as well as safety  information 
of approved BTK inhibitors (e.g., ibrutinib, acalabrutinib and zanubrutinib), the following potential risks of remibrutinib have been identified (see below). Of note, many safety risks identified for ibrutinib and acalabrutinib, two BTK inhibitors approved for the treatment of B cell malignancies (mantle cell lymphoma, chronic lymphocytic leukemia, Waldenstroem´s macroglobulinemia), are less likely related to the pharmacology of BTK inhibition, but rather to the underlying hemato- oncologic disea ses being treated and their associated comedications 
and complications,  such as tumor lysis syndrome, second  primary  malignancies,  etc. Therefore, 
when comparing the safety risks between the approved BTK inhibitors and remibrutinib, the underlying condition of the treated patient population must be taken into consideration. Furthermore, ibrutinib and acalabrutinib have a different target selectivity  profile compared to 
remibrutinib (Angst et al 2020).  
• Infections: BTK is an important signaling  kinase downstream of cell surface receptors  and 
expressed in a number of cell types of the adaptive and innate immune system, including B cells, macrophages, basophils and mast cells. Thus, administration of remibrutinib might be associated with an increased risk for infections and participants shou ld be 
monitored for signs and symptoms of infections and be evaluated promptly. In the completed and ongoing clinical trials with remibrutinib, infections were well balanced between the remibrutinib and placebo arms. Most of the infections observed were mi ld to 
moderate  and did not lead to a change in study treatment. In  the final analysis of the Phase 
2b study CLOU064A2201, infection rates (defined as MedDRA SOC Infections and infestations)  were  comparable  between  any remibrutinib  arm (24.0%) and the placebo  arm 
(21.4%). Most infections reported in the remibrutinib arms were mild in severity and d id 
not lead to treatment discontinuation. 
All participants  in remibrutinib  clinical  trials  are monitored  closely  for signs  and symptoms 
of infections while in the trial. Patients with a known history  of chronic recurrent or active 
ongoing infections  are excluded from the trial (refer to Section  5.2 for details).  In addition, 
the use of live attenuated vaccines should be avoided [ADDRESS_400465] dose of the study drug (see Section 6.2.3 ). 
• Response to vaccination: In general, immunomodulatory  treatments may  diminish vaccine 
efficacy  (Farez et al 2019 ). BTK in
hibition  is expected  to affect  the response to vaccinations 
and result  in reduced  vaccination efficacy.  Due to its immunomodulatory effects,  treatment 
with remibrutinib might be associated with reduced efficacy of vaccinations. There are limited data available on vaccination resp onse in patients treated with BTK inhibitors and 
primarily reported in patients with hematologic malignancies (Pleyer et al 2021, Web
 er et 
al 2021). In ongoing studies with remibrutinib, participants are advised to complete 
necessary  vaccination before starting  treatment with remibrutinib.  If necessary,  vaccination 
with non-live vaccines is allowed during the study. 
1. Effect on p latelet function  - risk for bleeding : BTK is a signaling molecule in one of several 
platelet activation pathways, and clinically relevant effects of remibrutinib on platelet functions were observed in the remibrutinib preclinical toxicology program. The mode of 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400466] on platelet s, similar to 
effects induced by [CONTACT_324399], which has been shown to inhibit clot retraction ( Bye et al 2015). Furthermore, remibrutinib inhibited collagen -induc
 ed platelet 
aggregation. BTK inhibition does not have any impact  on the plasmatic coagulation system 
and, plasmatic coagulation was not affected in the human Phase [ADDRESS_400467] dose of 600 mg remibrutinib. In CSU, in the completed core CLOU064A2201 Phase 2b study, 18 (6.7%) non- serious bleeding events were reported in any remibrutinib arm 
compared to one event on placebo (2.4%); none of the AEs was serious or severe. All the bleeding AEs events reported were mild, except 2 moderate AEs: gingival bleeding and hematuria. Two bleeding events (petechiae and hematuria) led to study treatment discontinuation. There were no notable clinically relevant abnormalities for coagulation parameters, hemoglobin levels and platelet counts noted in these studies. In the interim analysis of the open- label long -term (up to 52 weeks) extension trial CLOU064A2201E1, 
the rate of bleeding events (4.4%) was comparable to that seen in the core trial; all events were  non- serious, all but 2 events  (the purpura and heavy menstrual bleeding in the setting 
of leiomyoma) were  mild in severity.  Potential effects of remibrutinib  on hemostasis should 
be monitored both clinically and by [CONTACT_38183], validated laboratory measures including complete blood count and standard coagulation parameters. Clinical monitoring should focus on skin (bruising, petechiae) and mucosa (e.g., gastro -intestinal (GI) tract bleeding 
including gingival, rectal,  and conjunctival bleeding). i.e.,  Patients  with  a known history  of 
bleeding disorders, or with a history of clinically relevant gastrointestinal bleeding and patients requiring anti- platelet or anticoagulant therapy (other than aspi[INVESTIGATOR_155752] 100 mg/d 
or clopi[INVESTIGATOR_157034] 75 mg/d) are excluded from the trial;  the use of dual anti -platelet 
therapy   (e.g.,  acetylsalicylic   acid  +  clopi[INVESTIGATOR_7745])   is  prohibited  (see  details 
in Section  5.2 a
 nd Section  6.2.3). In case of a significant bleeding event, study treatment 
must be discontinued immediately. Please,  refer to the current IB for further details.  
• Effects  on QT interval : Remibrutinib  is a mild inhibitor of the human ether -a-go-go related 
gene (hERG)  channel (IC50  = 1.4 µM; unbound Cmax -based  average safety  margin  of 43- 
fold based on 100 mg b.i.d. in humans), without affecting other ion channels in a relevant manner. Close  ECG monitoring via Holter recordings in  the FIH  studies (CLOU064X2101 
and CLOU064X1101) documented a minor exposure dependent increase in QTcF with no 
outliers  (i.e., QT-interval  with a frequency  correction  according to Fridericia  (QTcF)  > 480 
msec or increases equal or greater  than  60 msec)  up to  the maximal dose of 600 mg. At  the 
projected  supratherapeutic exposure calculated  based  on the observed Cmax  at 25 mg b.i.d., 
assuming  severe organ impairment and comedication  with a strong CYP3A4  inhibitors such 
as ritonavir (“worst case” scenario), the calculated mean QTcF effect is 2.[ADDRESS_400468].  The predicted  upper 90% 
confidence limit of the QTcF changes is well below [ADDRESS_400469] threshold for cardiac repolarization, indicating a low probability of clinically significant repolarization  effects even  at 2-fold higher  exposure  than that  of the “worst -case” 
scenario. In the interim and final analyses of ongoing and completed Phase 2 studies in participants with CSU, SjS and asthma, no notable trend was observed for the change of ECG over time; no finding in ECG recordings or AEs suggestive of pro- arrhythmic events 
were noted. Patients with a history of major cardiovascular events are excluded from the  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  42 of 133 
Protocol  No. CLOU064A2302   
trial. In addition, triplicate sequential ECG monitoring is implemented in the study to 
monitor potential effects of remibrutinib on QTc and other ECG parameters.  
• Myelomodulation: Treatment emergent grade 3 or 4 cytopenias (neutropenia, 
thrombocytopenia and anemia) were reported in participants with hematologic malign ancies 
treated with ibrutinib and acalabrutinib. Again, the underlying hemato- oncologic diseases 
of these participants and their frequent association with such events should be taken into consideration here. All cytopenias reported in the final analysis of  CLOU064A2201 were 
mild. Participants are closely monitored for signs and symptoms of cytopenia while in the trial, and those with a history of hematological disorders or with markedly altered hematologic  parameters at baseline are excluded  from the study  (see details  in Section  5.2).  
• Drug -drug interactions : Oxidative metabolism is the major clearance pathway of 
remibrutinib and expected to be predominantly mediated by [CONTACT_097]3A4 with minor contribution of other cytochrome P450 (CYP) enzymes (e.g., CYP2C9, CYP1A1). At the dose used in this study (25 mg remibrutinib  b.i.d.), co-administration  of CYP3A4  inhibitors 
(even of strong ones) will not result in exposure levels of remibrutinib that are associated with clinically relevant QT prolongation. Likewise, co -administration of even strong 
CYP3A4 inhibitors with 25 mg remibrutinib b.i.d. will not increase exposure levels of remibrutinib  beyond exposure levels  that can  be reached  with  100 mg  remibrutinib  b.i.d., a 
dose that was well -tolerated in CLOU064A2201 and was not associated with any safety 
signals,  based  on the interim analysis.  Therefore,  only co-administration  of strong CYP3A4 
inhibitors is prohibited in this study. Concomitant administration of moderate and strong inducers of CYP3A4 is also prohibited during the study (see  Table  6-3). Remibrutinib can 
be co -administered with oral contraceptives such as ethinylestradiol or levonorgestrel 
without a major impact on their exposure and efficacy. Remibrutinib has been shown to 
inhibit some efflux and uptake transporters (such as P -glycoprotein, OATP1B, Mate1, 
OAT3, organic cation transporter 1 and BCRP). However, at a dose of 25 mg b.i.d. only inhibition of BCRP  remains  as a minor  risk which  is planned  to be investigated in a clinical 
drug- drug interaction study. Therefore, concomitant administration of remibrutinib with 
respective BCRP substrates with a small safety margin may be administered with caution (see Table 6 -2) 
• Reproductive toxicity : Remibrutinib  is not genotoxic or mutagenic  in in vitro  or in 
vivo studies. No effects on fertility or embryo -fetal development were observed in rats up 
to the highest dose, while in rabbits a no- observed -adverse- effect -level at 100 mg/kg/day 
was established.  At doses ≥300 mg/kg/day body weight loss, marked  low food consumption, 
and moribundity were noted, as well as a higher incidence of external fetal malformations (see details in Investigator's Brochure). For the approved BTK inhibitors, embryo -fetal 
toxicity in animals is reported (see national prescribing information). Highly effective methods of contraception  must be practiced.  Women  of child -bearing potential 
(WoCBP)  will be informed that taking the study treatment may involve unknown risks to 
the fetus if pregnancy were to occur during the trial and must agree that,  in order to 
participate in the trial, they must adhere to the contraception requirements outlined in the exclusion criteria.  If there  is any question that  the participant  will not reliably  comply,  they 
should not be entered or continue in the study. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  43 of 133 
Protocol  No. CLOU064A2302   
For detailed information on potential risks associated with remibrutinib, please refer to the 
Investigator’s Brochure. 
In summary, CSU patients with  inadequate response to H1-antihistamines  (and other available 
treatment options if applicable)  participating  in this clinical trial may significantly  benefit  from 
treatment with remibrutinib. Additionally, this trial will help to improve the understanding of 
remibrutinib in the management of CSU and potentially enable the development of a novel, innovative, oral drug that could improve the quality  of life of CSU patients beyond the limited 
treatment modalities currently available. Potential risks are mitigated as far as possible by [CONTACT_157076]/exclusion criteria, study procedures, very close clinical and laboratory monitoring, periodic review of safety data by [CONTACT_23275] (DMC), and study drug discontinuation rules. As with investigational drugs in general, not all safety risks are known. Participants and investigators participating in this trial will be informed should important new safety information become available.  
Considering all aspects, the risk -benefit assessment fully supports this trial with remibrutinib 
25 mg b.i.d. 
4.6 Rationale  for Public Health Emergency mitigation  procedures  
During a Public  Health  emergency  as declared  by [CONTACT_131340],  i.e., pandemic, 
epi[INVESTIGATOR_6519],  mitigation  procedures to ensure participant safety  and trial integrity 
are listed  in relevant  sections.  Notification  of the Public health  emergency  should be discussed 
with [COMPANY_001] prior to implementation of mitigation procedures, and permitted/approved by [CONTACT_6588].  
 
[ADDRESS_400470] of approximately 450 randomized female and male adult 
participants (300 in the active arm and 150 in the placebo arm) with CSU inadequately 
controlled by [CONTACT_157061] H1- antihistamines (at least at locally label approved dose).  
The screen failure rate is estimated to be 30%, meaning approximately 645 participants are expected to be screened.  
Participants will be stratified based on prior exposure to anti- IgE biologics and geographic 
region; maximum number of participants with prior exposure to anti -IgE biologics will be 
limited to approximately 30% of the total study population. 
Participants who drop out after they have been randomized will not be replaced.  
5.[ADDRESS_400471]  meet  all of the following criteria: 
1. Signed informed consent must be obtained prior to participation in the study  
2. Male and female  adult  participants  ≥18 years of age at the time of screening  
3. CSU duration for ≥ 6 months prior to screening  (defined  as the onset of CSU determined 
by [CONTACT_157077]) 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  44 of 133 
Protocol  No. CLOU064A2302   
4. Diagnosis of CSU inadequately controlled  by [CONTACT_157061] H1-antihistamines at the 
time of randomization defined as:  
• The presence of itch and hives for ≥ 6 consecutive weeks prior to screening  despi[INVESTIGATOR_324375] H1- antihistamines during this time period  
• UAS7  score (range 0-42) ≥ 16, ISS7  score (range  0-21) ≥ 6 and HSS7 score (range 0- 
21) ≥ 6 during the 7 days prior to randomization (Day 1)  
5. Documentation of hives  within  three  months before  randomization (either  at screening 
and/or at randomization; or documented in the participants` medical history) 
6. Willing  and able to complete an Urticaria  Patient  Daily  Diary  (UPDD)  for the duration of 
the study and adhere to the study protocol 
7. Participants  must not have had more  than one missing  UPDD  entry  (either morning or 
evening) in the 7 days prior to randomization (Day 1) 
5.[ADDRESS_400472] be based on 
central laboratory results. In case eligibility criteria are not met for specific laboratory parameters, these may be re- tested a maximum of once during the screening period. 
No additional exclusions may be applied by [CONTACT_093], in order to ensure that the study population will be representative of all eligible participants.  
1. Use of other investigational drugs within 5 half-lives, or within 30 days (for small molecules)  prior to Screening or until the expected  pharmacodynamic (PD)  effect  has 
returned  to baseline (for biologics), whichever is longer; or longer if required  by [CONTACT_13125]  
2. Previous use of remibrutinib  or other BTK inhibitors  
3. History  of hypersensitivity to any of the study treatments  or its excipi[INVESTIGATOR_297176] 
4. Participants  having a clearly  defined predominant or sole trigger of their chronic urticaria 
(chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), cold-, heat- , solar -, pressure-, delayed pressure- , aquagenic -, cholinergic -, or contact- 
urticaria  
5. Other diseases with symptoms of urticaria or angioedema, including but not limited to urticaria  vasculitis,  urticaria  pi[INVESTIGATOR_324376], erythema multiforme,  mastocytosis,  hereditary 
urticaria, or drug-induced urticaria 
6. Any other skin disease associated with chronic itching that might influence in the 
investigator’s  opi[INVESTIGATOR_157032],  e.g., atopic dermatitis,  bullous 
pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis  
7. Participants  taking medications prohibited by [CONTACT_760] (see Table  6-3) 
8. Known  history  or evidence of ongoing alcohol or drug abuse within  the last 6 months 
before randomization  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  45 of 133 
Protocol  No. CLOU064A2302   
9. History of malignancy of any organ system (other than localized basal cell carcinoma of 
the skin or in situ cervical  cancer),  treated  or untreated, within  the past 5 years,  regardless 
of whether there is evidence of local recurrence or metastases  
10. Pregnant or nursing (lactating) women  
11. Women of child-bearing potential (WoCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 7 days after stoppi[INVESTIGATOR_1460].  Highly 
effective contraception methods include:  
• Total  abstinence (when  this is in line with  the preferred  and usual lifestyle  of the 
participant).  Periodic  abstinence (e.g., calendar, ovulation, symptothermal,  post- 
ovulation methods) and withdrawal are not acceptable methods of contraception 
• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) total hysterectomy or bilateral tubal  ligation  at least six week s before 
taking investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_104]  
• Male sterilization  (at least 6 months prior to screening). For female  participants  on the 
study, the vasectomized male partner should be the sole partner for that participant  
• Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of contraception  
 
 
In case of use of oral contraception  women  should have been  stable on the same pi[INVESTIGATOR_6522] a 
minimum of [ADDRESS_400473]  had 12 months of natural  (spontaneous) 
amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor 
symptoms). Women  are considered not of child  bearing  potential if they are post- 
menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal  ligation  at least six weeks ago. In the case of 
oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6492]- up hormone level assessment is she considered not of ch ild bearing potential.  
If local  regulations deviate from the contraception  methods listed  above to prevent 
pregnancy, local  regulations apply and will be described  in the informed  consent  form  (ICF).  
12. Major  surgery  within  8 weeks prior to screening  or planned surgery for the duration of the 
study  
13. a History  of live attenuated  vaccine within  6 weeks prior to randomization  or 
requirement to receive these vaccinations at any time during the study  
14. Evidence of clinically significant cardiovascular (such as but not limited to myocardial infarction, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, arrhythmia  and uncontrolled hypertension within  12 months prior  to Visit 1), neurological, 
psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological disorders, gastrointestinal disease or immunodeficiency that, in the investigator's opi[INVESTIGATOR_1649], would 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  46 of 133 
Protocol  No. CLOU064A2302   
compromise  the safety  of the participant,  interfere  with the interpretation  of the study 
results or otherwise preclude participation or protocol adherence of the participant  
15. Uncontrolled disease states,  such as asthma,  or inflammatory  bowel  disease,  where  flares 
are commonly treated with oral or parenteral corticosteroids  
16. Hematology parameters  at screening:  
• Hemoglobin: < 10 g/dl 
• Platelets: < 100 000/mm3 
• Leucocytes:  < 3 000/mm3 
• Neutrophils: < 1 500/mm3 
17. Significant bleeding risk or coagulation disorders  
18. a History  of gastrointestinal bleeding, e.g., in association  with use of nonsteroidal anti- 
inflammatory drugs (NSAID), that was clinically relevant (e.g., where intervention was 
indicated or requiring hospi[INVESTIGATOR_157043])  
19. a Requirement  for anti-platelet medication, except  for acetylsalicylic  acid up to 100 
mg/d or clopi[INVESTIGATOR_157034] 75 mg/d. The use of dual anti-platelet therapy (e.g., acetylsalicylic acid + clopi[INVESTIGATOR_7745]) is prohibited.  
20. Requirement  for anticoagulant medication  (for example, warfarin  or Novel  Oral Anti- 
Coagulants (NOAC))  
21. History  or current hepatic disease including but not limited  to acute or chronic hepatitis, 
cirrhosis or hepatic failure or Aspartate Aminotransferase (AST)/ Alanine Aminotransferase (ALT) levels of more than 1.5 x upper limit of normal (ULN) or International Normalized Rat io (INR) of more than 1.[ADDRESS_400474], or estimated Glomerular Filtration  Rate (eGFR)  < 45ml/min  (using  the Cockcroft- Gault equation) at screening  
23. Evidence of an ongoing Hepatitis  C infection  (e.g., defined by [CONTACT_324400]  C 
virus ribonucleic acid (HCV-RNA) at screening) and/or an ongoing Hepatitis B infection (defined by [CONTACT_324401] B virus surface antigen (HBsAg) and/or hepatitis B virus (HBV) -DNA at scr eening; participants who are positive for anti- hepatitis B core 
(HBc)  antibodies but who are negative for antibodies against HBsAg and HBV- DNA can 
be included into the study if they agree to monitoring for HBsAg and HBV- DNA re - 
activation)  
24. Known or suspected ongoing, chronic or recurrent infectious disease including but not limited  to opportunistic infections (e.g., tuberculosis,  atypi[INVESTIGATOR_324377],  listeriosis 
or aspergillosis) and/or known positivity for Human Immunodeficiency Virus (HIV) infection.  HIV antigen/antibody tests will be performed to determine HIV status if 
required according to local regulations. 
 
6 Treatment  
6.1 Study  treatment  
[COMPANY_001]  Global Clinical Supply (GCS)  will supply the following  IMPs  in the trial in 
appropriately labeled bottles: 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  47 of 133 
Protocol  No. CLOU064A2302   
- LOU064  25mg (blinded)  
- LOU064  25mg placebo (blinded)  
- LOU064  25mg (open- label) 
No other supplies apart from these would be provided by [CONTACT_157078] (GCS).  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  48 of 133 
Protocol  No. CLOU064A2302   
6.1.1 Investigational and control drugs  
Table 6-1 Investigational and control drug 
 
Investigational/ 
Control Drug  Pharmaceutical 
Dosage Form  Route of 
Administration  Presentation  Sponsor (global 
or local)  
LOU064 25 mg Film coated tablet  Oral use Double blind [COMPANY_001]  Pharma 
AG 
LOU064 25 mg 
matching  Placebo  Film coated tablet  Oral use Double blind [COMPANY_001]  Pharma 
AG 
LOU064 25 mg Film coated tablet  Oral use Open label [COMPANY_001]  Pharma 
AG 
6.1.2 Additional  study treatments  
No other treatment beyond investigational drug and control drug (remibrutinib  and placebo) are 
included in this trial.  
Participants will take background medication (second generation H1- antihistamines at locally 
label approved doses) with a stable regimen during the study ( Section  6.2.1). For rescue 
medication, see Section 6.2.4. 
6.1.3 Treatment  arms/group 
Participants will be assigned at Day 1 to either remibrutinib 25 mg b.i.d. or matching placebo 
in a ratio of 2:1. At week  24 participants  in the placebo arm will be switched  to active treatment. 
Each participant will take one film- coated tablet in the morning and one film -coated tablet in 
the evening  
 
6.1.4 Treatment duration  
The planned duration of treatment is  52 weeks. Participants may discontinue from study 
treatment earlier at the discretion of the investigator or the participant, e.g., due to adverse events (see Section  9.1) or lack/loss of efficacy.  Eligible participants may roll over into the 
planned extension study at Week 52 (after completing all scheduled assessments planned at these visits). The details of the study design and procedures of the extension, if implemented, will be described in a separate protocol.  
There are a total of [ADDRESS_400475] dispensing visit occurs at Week 40.  
6.2 Other  treatment(s)  
6.2.[ADDRESS_400476]  take a second  generation H1-antihistamine  at a locally 
label  approved dose (background therapy). Background therapy  should not be changed until the 
Week 12 visit and should only be changed thereafter if medically required (i.e., adverse 
reactions  that are attributable  to background therapy as per investigator judgment). For detailed  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  49 of 133 
Protocol  No. CLOU064A2302   
information on the background medication, refer to the corresponding national prescribing 
information.  
Prior medication for treatment of CSU will be recorded in the  Electronic Case Report Forms 
(eCRF).  In addition, all concomitant medication  at screening  and prior medication  that has been 
terminated  within  [ADDRESS_400477] 
the participant to notify the study site about any new medications (including medications that are not related to the treatment of CSU) he/she takes after the participant was enrolled into the study, ideally before initiating a new treatment.  
All medications, procedures, and significant non- drug therapi[INVESTIGATOR_014] (including physical therapy and 
blood transfusions) administered after the participant was enrolled into the study must be recorded on the appropriate eCRFs.  
Each concomitant medication must be individually assessed against all exclusion criteria/prohibited  medication. If in doubt, the investigator should contact [CONTACT_157079] a participant or allowing a new medication to be started. If the participant  is already  enrolled, contact [CONTACT_324402]. 
6.2.2 Permitted concomitant therapy requiring caution and/or action  
Remibrutinib has been shown to inhibit the BCRP transporter at the intestinal level. As a 
consequence, co-administration  with remibrutinib  can lead to exposure increases area under the 
curve of  > 1.5- fold. Therefore, concomitant administration of remibrutinib with respective 
BCRP substrates may be accomplished with caution. BCRP substrates with a small safety margin may be administered 2 hours before or after remibrutinib (staggered dosing).  
Table 6-2 Permitted concomitant therapy requiring caution and/or  action  
Medication  Period  Guidance  
Oral BCRP  substrates  that may 
have increased exposure when 
co-administered with 
remibrutinib (pi[INVESTIGATOR_2830], rosuvastatin, sulfasalazine and ubrogepan)  [ADDRESS_400478] 
medication or administer  2hr 
before or after remibrutinib 
(staggered dosing)  
 
6.2.3 Prohibited medication 
Use of the treatments displayed in the below table are not allowed during the specified time 
period.  
Table 6-3 Prohibited medication  
 
Medication  Prohibition period  Action  taken  
Biologics  for treatment  of CSU 
(including omalizumab and ligelizumab)  4 months prior to 
randomization until end of 
treatment  Discontinue biologic  treatment 
and closely monitor for 
potential associated adverse events.  
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  50 of 133 
Protocol  No. CLOU064A2302   
 
 
Medication  Prohibition period  Action  taken  
Routine (more  than 3 doses 
over a 5 day period) oral 
corticosteroids  30 days  prior to screening  until 
end of treatment  
Oral corticosteroids are only 
allowed as an additional rescue therapy for CSU AFTER Week 12 , on an as - 
needed basis for unbearable Discontinue routine corticosteroids if medically justifiable and closely monitor 
for potential associated 
adverse events. If discontinuation of routi ne 
corticosteroids  is not possible,  
 symptoms  as per Section  6.2.4 . discontinue  study  treatment.  
Other  preparations  of  
corticosteroids  (CS) with limited   
systemic  exposure  for non-  
CSU  indications  (e.g.,  intra-  
nasal  or any topi[INVESTIGATOR_324378]) can be  
used  on an as-needed  basis.   
i.v./IM/IA  corticosteroids  30 days  prior to screening  until Discontinue  i.v./IM/IA  
 end of treatment  corticosteroids  if medically  
  justifiable  and closely  monitor  
  for potential  associated  
  adverse  events.  If 
  discontinuation  of i.v./IM/IA  
  corticosteroids  is not possible,  
  discontinue  study  treatment.  
Leukotriene  antagonists  From  screening  until end of Discontinue  Leukotriene  
(including  montelukast  and treatment  antagonists  and closely  monitor  
zafirlukast)   for potential  associated  
  adverse  events.  
H2-antihistamines  From  screening  until end of Discontinue  H2-antihistamines  
 treatment  and closely  monitor  for 
  potential  associated  adverse  
  events.  
First generation  antihistamines  From  screening  until end of Discontinue  first generation  
 treatment  antihistamines  and closely  
  monitor  for potential  associated  
  adverse  events.  
Second  generation  From  7 days  prior to Discontinue  all second  
antihistamines  other  than  the randomization  until end of generation  H1-antihistamines  
participant's  defined  treatment  but the defined  background  
background  medication  and  and rescue  medication  and 
rescue  medication   closely  monitor  for potential  
  associated  adverse  events.  
Other  30 days  or 5 half-lives Discontinue  immunosuppressiv  
immunosuppressive/immunom  (whichever  is longer)  prior to e/immunomodulating  
odulating  medication  with or screening  until end of treatment  medication  if medically  
without  known  effect  on CSU  justifiable  and closely  monitor  
including  but not limited  to  for potential  associated  
hydroxychloroquine,   adverse  events.  If 
methotrexate,  cyclosporine  A,  discontinuation  not possible,  
cyclophosphamide,  tacrolimus   discontinue  study  treatment.  
and mycophenolate  mofetil    
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  51 of 133 
Protocol  No. CLOU064A2302   
 
Medication  Prohibition  period  Action  taken  
Intravenous  (i.v.) [ADDRESS_400479] dose of study treatment  Discontinue study  treatment.  
Strong  inhibitors  of CYP3A4  From 2 weeks prior 
randomization until end of 
treatment  Discontinue CYP3A4  inhibitor  if 
medically  justifiable  and closely 
monitor  for potential  associated 
adverse events. If 
discontinuation not possible, 
discontinue study treatment  
Moderate  and strong  inducers  From  2 weeks  prior Discontinue  CYP3A4  inducers  
of CYP3A4  randomization  until end of 
treatment  if medically justifiable and 
closely monitor for potential associated adverse events.  If 
discontinuation not possible, 
discontinue study treatment.  
Anticoagulant  medication  (for From  screening  until end of Only if medically  justifiable,  
example, warfarin, or Novel 
Oral Anti-Coagulants  (NOAC))  treatment  discontinue anticoagulant 
medication and interrupt  study 
medication until anticoagulant effects  have  ended.  Otherwise 
discontinue study treatment. 
Closely monitor coagulation 
parameters and associated 
adverse events.  
  Clinical monitoring should 
focus on skin (bruising, petechiae) and mucosa (e.g., 
gastro- intestinal tract bleeding 
including  gingival  and rectal,  or 
conjunctival bleeding). In case of a significant bleeding event, 
study treatment must be 
discontinued immediately.  
Anti-platelet  medication  except  From  screening  until end of Only if medically  justifiable,  
for acetylsalicylic  acid up to treatment  discontinue  anti-platelet  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  52 of 133 
Protocol  No. CLOU064A2302   
 
 
Medication  Prohibition period  Action  taken  
100 mg/d or clopi[INVESTIGATOR_157034] 
75 mg/d.  The use of dual anti- 
platelet therapy (e.g., acetylsalicylic acid + 
clopi[INVESTIGATOR_7745]) is prohibited.  medication and interrupt study 
medication until anti -platelet 
effects have ended. Otherwise discontinue study treatment. 
Closely monitor coagulation 
parameters and associated adverse events. Clinical 
monitoring should focus  on skin 
(bruising, petechiae) and mucosa (e.g., gastro -intestinal 
tract bleeding  including gingival 
and rectal, or conjunctival bleeding). In case of a 
significant bleeding event,  
study treatment must be 
discontinued immediately.  
 
6.2.4 Rescue medication  
H1-antihistamines: In addition to being used as background medication, second generation 
H1-antihistamines  are allowed  as rescue medication,  used on an as needed  basis for participants 
with CSU flare-ups of unbearable symptoms  during screening,  treatment and follow -up periods. 
The selection of the rescue medication H1 -antihistamine should be made only once for an 
individual participant  and recorded  in the source document. For each individual participant,  the 
H1-antihistamine used as rescue medication must differ from th e H1 -antihistamine used 
as background medication . The daily  dose of H1-antihistamine  rescue medication 
should not exceed 4 -fold of the approved dose, as recommended by [CONTACT_324403] ( Zuberbier et al 2018).  For detailed  information  on the rescue medication, 
refer to the corresponding national prescribing  information.  A change of  the rescue  medication 
for an individual participant is only permitted in case of adverse reactions that are,  in the 
judgment of the investigator, attributable to rescue medication.  
Oral corticosteroids:  Prior  to Week  12, any corticosteroid  use for CSU is prohibited.  After 
the Week  12 primary  endpoint , participants  will be permitted  to use oral corticosteroids such 
as prednisone or its equivalent, as rescue medication  if needed for CSU flare-ups of unbearable 
symptoms. The selection of the oral corticosteroid to be used as rescue medication after Week 
12, should be made only once for an individual participant. A switch of oral corticosteroids as rescue medication for an individual is not permitted ex cept due to an AE.  Rescue oral 
corticosteroid  use will be limited  to 3 days in a 30- day period  and a maximum of 9 days in 
total after  Week  12 to  avoid any confounding suppression of signs and symptoms of CSU.  The 
recommended dose is 20 - 50 mg prednisone or equivalent per day, which is in line with the 
current urticaria treatment guidelines (Zuberbier et al 2018 ). 
Rescue
 medication  will be sourced  locally.  Use of H1-antihistamine  rescue medication  only for 
CSU must be recorded in the eDiary  by [CONTACT_2299] (number of tablets taken) and the  name 
[CONTACT_324430]  (eCRF).  All relevant 
information for oral corticosteroid rescue therapy will be captured in the appropriate eCRF.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  53 of 133 
Protocol  No. CLOU064A2302   
6.3 Preparation and dispensation  
Each  study site will be supplied with study drug in packaging as described  under investigational 
and control drugs section. 
A unique medication number is printed on the study medication label.  
Investigator staff will identify the study medication kits to dispense to the participant by 
[CONTACT_324404] (IRT) and obtaining  the medication number(s). 
The study medication  has a 2-part label  (base plus tear-off label),  immediately  before dispensing 
the medication kit to the participant, site personnel will detach the outer part of the label from the packaging and affix it to the source document. 
As per  Section  4.6, during a Public Health emergency as declared by [CONTACT_324405], i.e., 
pandemic, epi[INVESTIGATOR_6519], that limits or prevents on- site study visits, delivery of 
Investigational Medicinal Product (IMP) directly to a participant’s home may  be permitted (if 
allowed  by [CONTACT_131349]) in the 
event the Investigator has decided  that an on-site visit by [CONTACT_131350], and that it is in the interest of the participant’s health to administer the study 
treatment even without performing an on -site visit. The dispatch of IMP from the site to the 
participant’s home remains under the accountability of the Investigator. Each shipment/provisioning will be for a maximum of 1 -months supply. In this case, phone calls, 
virtual contacts (e.g., tele  consult) or visits  by [CONTACT_6624]/home  nursing to the participant's home 
at the time of a planned on- site visit will occur for instructional purposes, safety monitoring, 
investigation of any adverse events, ensuring participants continue to benefit from treatment, and discussion of the participant's health  status  until  it is safe for the  participant to  visit  the site 
again.  
6.3.1 Handling of study treatment and other treatment  
[IP_ADDRESS] Handling of study treatment  
Study treatment must be received by a designated person at the study site, handled and stored safely  and properly and kept in a secured  location  to which  only the investigator and designated 
site personnel have access. Upon receipt, all study treatment mus t be stored according to the 
instructions specified on the labels.  
Clinical supplies are to be dispensed  only in accordance with the protocol. Technical  complaints 
are to be reported to the respective [COMPANY_001] Country Organization Quality Assurance. 
Medication  labels will be in the local  language and comply with the legal  requirements of each 
country. They will include storage conditions  for the study treatment  but no information  about 
the participant except for the medication number.  
The investigator must maintain an accurate record of the shipment and dispensing of study 
trea
tment in a drug accountability  log. Monitoring  of drug accountability  will be performed  by 
[CONTACT_157084], and at the completion of the trial.  
Participants will be asked to return all unused study treatment and packaging at each site visit during the study and at the end of the study, or at the time of discontinuation of study treatment.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  54 of 133 
Protocol  No. CLOU064A2302   
The site may destroy and document destruction of unused study treatment, drug labels and 
packaging as appropriate in compliance with site processes,  monitoring  processes,  and per local 
regulation/guidelines. Otherwise, the investigator will return all unus ed study treatment, 
packaging, drug labels,  and a copy of the completed  drug accountability  log to the field monitor 
or to the [COMPANY_001] address provided in the investigator folder at each site. 
[IP_ADDRESS] Handling of other  treatment  
Not applicable.  
6.3.2 Instruction for prescribing and taking study treatment  
Every participant should take one film -coated tablet of remibrutinib 25 mg or placebo in the 
morning and in the evening, respectively, with a 12 hour interval at approximately the same 
time every day. The study medication may be taken with or without a mea l but participants 
should adhere to  their choice throughout the study. If taken  without food, the study medication 
should be taken with a glass of water (250 milliliters (ml)) at least [ADDRESS_400480] meal and 1 hour before  the next meal.  Participan ts should be instructed  to swallow  whole tablets  and 
not to chew or break them. 
  
If vomiting occurs during the course of treatment, participants should not take the study treatment again before the next scheduled dose.  
Participants should be instructed not to make up missed doses. A missed dose is defined as a case when the full dose is not taken within 6 hours after the approximate time of the usually morning/evening dosing. That dose should be omitted and the participant should continue treatment with the next scheduled dose.  
H1-antihistamines  taken  as either  as background medication  or rescue medication, respectively, 
should be taken according to the local treatment instructions. 
All kits of study treatment assigned  by [CONTACT_131352].  
6.4 Participant numbering,  treatment  assignment,  randomization 
6.4.1 Participant  numbering 
Each participant is identified in the study by a Participant Number (Participant No.), that is 
assigned when the participant is enrolled for screening and is retained for the participant 
throughout his/her participation in the trial. A new Participant No. will be assigned at every subsequent enrollment if the participant is re -screened. The Part icipant No. consists of the 
Center  Number (Center No.) (as assigned  by [CONTACT_324406]) with a sequential 
participant number suffixed to it, so that each participant’s participation is numbered uniquely across  the entire  database.  Upon signing the informed  consent form,  the participant  is assigned 
to the next sequential Participant No. available. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  55 of 133 
Protocol  No. CLOU064A2302   
A new ICF will need  to be signed if  the investigator chooses to  re-screen  the participant after  a 
participant has screen failed, and the participant will be assigned a new Participant No.  
6.4.2 Treatment assignment, randomization  
At the randomization visit,  all eligible participants will be randomized via IRT to one of the 
treatment arms. The investigator or his/her delegate will contact [CONTACT_157086]/exclusion criteria. The IRT will assign a randomization number to the participant, which  will be used to link the participant to a treatment arm and will 
specify  a unique medication  number for the first package of study treatment  to be dispensed  to 
the participant.  
The randomization numbers will be generated using the following procedure to ensure that treatment assignment is unbiased and concealed from participants and investigator staff. A participant randomization list will be produced by [CONTACT_6609] a validated system that automates the random assignment of participant numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to medication numbers. A separate medication list will be  produced by [CONTACT_157087] (GCS) using a validated system that automates the random assignment of medication numbers to packs containing the study treatment. 
Randomization
 will be stratified  by [CONTACT_146275] -IgE biologic  use and geographic 
region; maximum number of participants with prior exposure  to anti -IgE biologics will be 
limited to app roximately 30% of the total study population. 
The randomization scheme for participants  will be reviewed  and approved by a member  of the 
Randomization Office.  
6.[ADDRESS_400481] of the trial will remain  blinded to the identity  of the treatment during 
the double- blind  treatment period (i.e., up to week  24) from  the time of randomization  until the 
final database lock.  
The following methods will be used to maintain  the blind:  
(1) Randomization data will be kept strictly confidential until the time of final database lock, 
and will not be accessible by  [CONTACT_131551]:  
• The designated [COMPANY_001] study team members involved in the primary  analysis  
• The bioanalyst  (to avoid the unnecessary  analysis of placebo  samples)  
• An independent analysis t eam who need  to prepare DMC reports.  
(2) The identity of the treatments will be concealed by [CONTACT_6611], labeling, schedule of administration, appearance, taste, and odor. 
At the time of the primary  analysis,  a selected  [COMPANY_001] Team  will create  and review  unblinded 
interim reports. No access will be given to the study team conducting the ongoing trial until 
final database lock.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  56 of 133 
Protocol  No. CLOU064A2302   
 
 
U
nblinding a single participant at the study site for safety reasons (necessary for participant 
management) will occur via an emergency  system  in place at the site. As a result,  the particip ant 
should be discontinued from the study treatment. 
The DMC will review semi -blinded interim reports created by [CONTACT_157089]. 
More details will be provided in the DMC charter.  
6.6 Dose  escalation  and dose modification  
Investigational or other study treatment  dose adjustments are not permitted.  
Study treatment  interruptions are permitted  in order  to manage the following events:  
• Management of bleeding events: in case of planned surgery with clinical significant 
bleeding risk, interruption  of study treatment  7 days before the surgery is required; after 
recovery, participant may re -start study treatment after 7 days.  
• Management of participants in case of Hepatitis B re- activation (new appearance of 
detectable  HBV- DNA or positive HBsAg):  participants should start antiviral treatment 
according to local clinical practice and interrupt study treatment until HBV -DNA and 
HBsAg reach an undetectable level, and then re- start study treatment.  
Study treatment  interruption  for other than the above reasons is only permitted  if, in the opi[INVESTIGATOR_8574],  a participant  is deemed  to be at a significant safety  risk unless administration 
of investigational treatment  is temporarily  interrupted. In such cases study  treatment should be 
interrupted  only during the time that this risk is present  and ongoing. Study treatment can be re- 
started at the next scheduled visit after resolution of the safety risk.  
6.6.[ADDRESS_400482] promote compliance by [CONTACT_324407]’s 
safety and the validity of the study. The participant must also be instructed to contact [CONTACT_121942]/she is unable for any reason  to take the study treatment as 
prescribed.  Compliance will be assessed  by [CONTACT_54075]/or study personnel at each visit 
using tablet  counts (if applicable)  and information  provided by [CONTACT_2299]. This information 
should be captured in the source document at each visit. All study treatment dispensed and 
returned must be recorded in the Drug Accountability Log. 
 
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400483] often, discontinuation from study treatment and knowledge of the possible treatment assignments are sufficient  to treat a study participant who presents with an emergency  condition. 
Emergency  treatment  code  breaks are performed  using the IRT.  When  the investigator contacts 
the system to break a treatment code for a participant, he/she must provide the requested participant identifying information and confirm the necessity to break the treatment code for the participant. The investigator will then re ceive details of the investigational drug treatment 
for the specified participant and a fax or email confirming this information. The system will automatically  inform the [COMPANY_001]  monitor for the site and the study team  that the code  has been 
broken. If the IRT  system  is not available  for technical  reasons,  the IRT help desk can facilitate 
emergency code break requests.  
It is the investigator’s responsibility  to ensure that there is a dependable procedure in place to 
allow access to the IRT/code break cards at any time in case of emergency. The investigator will provide: 
• protocol number  
• participant  number  
In addition, oral and written  information  to the partici pant must  be provided on how to contact 
[CONTACT_5657]/her backup in cases of emergency,  or when  he/she is unavailable,  to ensure that un-blinding 
can be performed at any time.  
The appropriate personnel  from the study site and [COMPANY_001]  will assess whether  study treatment 
should be discontinued for any participant whose treatment code has been  broken inadvertently 
for any reason. 
Study treatment must be discontinued after emergency unblinding and the participant will be 
withdrawn from the trial and would not be el igible for enrollment into the planned open -label 
extension study. 
6.7.3 Treatment  of overdose  
No clinical data are available to assess the risk of overdose. Based on preclinical data it is 
concluded that remibrutinib  has a low potential to cause acute toxicity,  e.g., in case of accidental 
overdosing. Single and multiple  ascending doses of remibrutinib  up to 600 mg were  studied in 
healthy volunteers with no dose -limiting toxicities identified. With the 25 mg b.i.d. dose used 
in this study, the potential of remibrutinib to cause acute toxicity is assessed as low.  
There is no specific antidote to remibrutinib; therefore, adverse events will be managed 
symptomatically according to standard of care and applicable clinical guidelines.  
In the event of an overdo se, the Investigator should:  
• Contact [CONTACT_10990].  
• Closely  mo
 nitor the participant  for any AE/SAE  and laboratory abnormalities . 
• Document the quantity of the excess dose as well as the duration of the overdose.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  58 of 133 
Protocol  No. CLOU064A2302   
7 Informed  consent  procedures  
Eligible participants may only be included in the study after providing (witnessed, where 
required by [CONTACT_6617]), Institutional Review Board (IRB)/Independent Ethics 
Committee (IEC)- approved informed consent.  
If applicable, in cases where the participant's representative(s) gives consent (if allowed according  to local  requirements),  the participant  must be informed  about the study to the extent 
possible given his/her level of understanding. If the participant is capable of doing so, he/she must indicate agreement by [CONTACT_30803].  
Informed consent must be obtained before conducting any study- specific procedures (e.g., all 
of the procedures described in the protocol). The process of obtaining informed consent must be documented in the participant source documents. 
[COMPANY_001]  will provide to investigators in a separate  document a proposed informed  consent form 
that complies  with the International Council for Harmonization  of Technical  Requirements for 
Pharmaceuticals for Human Use (ICH) E6 good clinical practice (GCP) guidelines and 
regulatory requirements and is considered appropriate for this study. Any changes to the 
proposed consent form suggested by [CONTACT_324408]/IEC.  
Information about common side effects already known about the investigational treatment can 
be found in the Investigator's Brochure (IB).  This information  will be included in the participant 
informed  consent  and should be discussed  with the participant during the study as needed. Any 
new information regarding the safety profile of the investigational drug that is identified between IB updates will be communicated as appropriate, for example, via an investigator notification or an aggregate safety finding. New information might require an update to the informed consent and then must be discussed with the participant. 
The following informed consents are included in this study:  
• Main study consent, which also includes:  
  
 
 
• As applicable,  Pregnancy Outcomes Reporting Consent for female  participants who took 
study treatment 
•  
•  
Women  of child -bearing  potential must  be informed  that taking  the study treatment  may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order 
to participate in the study they must adhere to the contraception requirements. 
  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400484] be provided to [COMPANY_001]  after IRB/IEC 
approval.  
Participants  might be asked  to complete an  optional questionnaire to  provide  feedback  on their 
clinical trial experience.  
As per  Section  4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e., pandemic, epi[INVESTIGATOR_324379],  that may challenge the ability  to obtain 
a standard  written  informed  consent  due to limits  that prevent an on-site visit,  Investigator may 
conduct the informed consent discussion remotely (e.g., telephone, videoconference) if 
allowable by a local Health Authority.  
Guidance issued  by [CONTACT_324409] (e.g., the presence of an impartial witness,  sign/dating separate ICFs 
by [CONTACT_6622], etc.). 
 
8 Visit  schedule and assessments  
The Assessment  Schedule ( Table  8-1) lists all of the assessments and when  they are performed. 
All data obtained from these assessments must be supported in the participant’s source documentation.  
Participants should be seen for all visits/assessments as outlined in the assessment schedule 
(Table  8-1) or as close to the designated day/time as possible. Missed or rescheduled visits 
should not lead to automatic discontinuation. 
For participants who discontinue from study treatment refer to  Section 9.1.1. 
Participants who discontinue from the study  or withdraw their consent/oppose the use of their 
data/biological samples should be scheduled for a final evaluation visit, if they agree, as soon 
as possible, at which time all of the assessments listed for the final visit will be performed. At this final visit,  all dispensed  investigational product should be reconciled,  and the adverse event 
and concomitant medications not previously reported must be recorded on the CRF. 
The "X" in the table  denotes the assessments to be recorded  in the clinical database or received 
electronically from a vendor. The "S" in the table denotes the assessments that are only in the 
participant's source documentation and do not need to be recorded in the clinical database. 
As per Section 4.6, during a Public Health emergency as declared by [CONTACT_324410] i.e., pandemic, epi[INVESTIGATOR_324380]- site study visits, 
alternative methods of providing continuing care may be implemented by [CONTACT_6623]. If allowed by [CONTACT_324411],  phone calls,  virtual contacts (e.g., tele consult) or visits  by [CONTACT_6624]/  home nursing 
staff to the participant´s  home, can replace on- site study visits,  for the duration  of the disruption 
until it is safe for the participant to visit the site again.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  60 of 133 
Protocol  No. CLOU064A2302   
The preferred  sequence of assessments during study  visits  is PRO  completion, ECG collection, 
followed by [CONTACT_18651], and blood sampling. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  61 of 133 
Protocol  No. CLOU064A2302   
 
Table 8-1 Assessment  Schedule  
 
Period  Screening  Treatment  Follow -up Unscheduled 
visit 
 
 
Visit Name   
 
[CONTACT_324431]/ 
Randomization  
1 
week 21 
week 4 
week  8 
week  121 
week 16 
week 20 
week 24 
week 32 
week 40  
Early treatment 
discontinuation  
week 52/Study 
discontinuation1  
week 56/Safety 
FU/Study 
completion   
Unscheduled 
visit 
Days  -28 to -1 1 15 29 57 85 113 141 169 225 281  365 394 - 
Informed consent  X               
IRT transaction  X X  X X X X X X X X X X   
Inclusi on / 
Exclusion  criteria  X X              
Randomization  X              
Demogra phy X               
Pregnancy and 
assessments of 
fertility2  
XS  
S   
S  
S  
S  
S  
S  
S  
S  
S  
S  
S  
S  
S 
Evidence of 
urticaria  S S              
Hepatit is screen  X               
Relevant medical 
history  X               
Dispens e 
participants'  eDiary3 S           
S S   
CSU History and 
prior urticaria 
treatment   
X               
Cardiov ascular 
history  X               

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  62 of 133 
Protocol  No. CLOU064A2302   
 
Period Screening  Treatment  Follow -up Unscheduled 
visit 
 
 
Visit Name   
 
[CONTACT_324431]/ 
Randomization  
1 
week 21 
week 4 
week  8 
week  121 
week 16 
week 20 
week 24 
week 32 
week 40  
Early treatment 
discontinuation  
week 52/Study 
discontinuation1  
week 56/Safety 
FU/Study 
completion   
Unscheduled 
visit 
Days  -28 to -1 1 15 29 57 85 113 141 169 225 281  365 394 - 
Physical 
Examination4 S S S S S S S S S S S S S S S 
Height and  Weight5 X X    X   X   X X X X 
Vital Signs  X X X X X X X X X X X X X X X 
Electrocardiogram 
(ECG)  X X  
X6    
X6   
X   
X  
X6 X X 
Subject's  eDiary 
review7  
S S S S S S S S S S S S  
S 
DLQI8  X  X  X   X   X X  X 
Study d rug 
dispensation   
X  
X X X X X X X X     
Background 
medication 
dispensation and 
compliance 
assessment16  
 
X  
 
X   
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
 
X  
Rescue medication 
dispensation and 
usage10  
X  
X   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X   

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  63 of 133 
Protocol  No. CLOU064A2302   
 
Period  Screening  Treatment  Follow -up Unscheduled 
visit 
 
 
Visit Name   
 
[CONTACT_324431]/ 
Randomization  
1 
week 21 
week 4 
week  8 
week  121 
week 16 
week 20 
week 24 
week 32 
week 40  
Early treatment 
discontinuation  
week 52/Study 
discontinuation1  
week 56/Safety 
FU/Study 
completion   
Unscheduled 
visit 
Days  -28 to -1 1 15 29 57 85 113 141 169 225 281  365 394 - 
Clinical Chemistry  X X X X X X X X X X X X X X X 
Hematology  X X X X X X X X X X X X X X X 
Urinalysis  X X X X X X X X X X X X X X X 
Coagulation Panel X X  X  X   X  X X X X X 
Hepatitis B 
re-activation  
monitoring14     
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X 
Eligibi lity 
assessment for 
extension  study17              
X   

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  64 of 133 
Protocol  No. CLOU064A2302   
 
Period  Screening  Treatment  Follow -up Unscheduled 
visit 
 
 
Visit Name   
 
[CONTACT_324431]/ 
Randomization  
1 
week 21 
week 4 
week  8 
week  121 
week 16 
week 20 
week 24 
week 32 
week 40  
Early treatment 
discontinuation  
week 52/Study 
discontinuation1  
week 56/Safety 
FU/Study 
completion   
Unscheduled 
visit 
Days  -28 to -1 1 15 29 57 85 113 141 169 225 281  365 394 - 
Prior and 
concomitant 
medication   
X 
Adverse Events  X 
Study  completion 
information  X 
1 Participant  to come fasting  for ≥8 h (ideally  overnight)  to visits: Baseline/Randomization,  week  2, week  [ADDRESS_400485] (e.g., prohibited by [CONTACT_427]), a urine or serum test can be performed at the local laboratory.  
3 Participants eDiary will be returned to site at either  week 52/study discontinuation.  
4 Complete physical  exam  at screening,  short  physical  exam  at all subsequent  visits  including body  temperature monitoring (per local practice)  
[ADDRESS_400486] dose 
7 eDiary  includes  UPDD (Urticaria  Patient  Daily  Diary)  with UAS (Urticaria Activity  Score, part of UPDD)  and AAS (Angioedema Activity Score), eDiary  to be completed 
from screening to week 52/study discontinuation  
8 Completed in the patient’s  eDiary  during  site visit. Order  of completion:  DLQI  . All questionnaires  should  be completed prior to 
any other physician assessment.  
  
 . 
14 Hepatitis  B re-activation monitoring only for participants  who were HBsAg negative and HBcAb (anti-HBc) positive with a negative HBV DNA  test at Screening.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  65 of 133 
Protocol  No. CLOU064A2302   
 
Period  Screening  Treatment  Follow -up Unscheduled 
visit 
 
 
Visit Name   
 
[CONTACT_324431]/ 
Randomization  
1 
week 21 
week 4 
week  8 
week  121 
week 16 
week 20 
week 24 
week 32 
week 40  
Early treatment 
discontinuation  
week 52/Study 
discontinuation1  
week 56/Safety 
FU/Study 
completion   
Unscheduled 
visit 
Days  -28 to -1 1 15 29 57 85 113 141 169 225 281  365 394 - 
16Dispensation for background medication covers prescription, dispensation and/or instruction of the participant on dosing and use of background medication and 
protocol  requirements,  considering different  procedures  for the provision of background medication at investigational  sites. At Week  56/Safety  FU/Study  completion visit 
only compliance to be checked 
[ADDRESS_400487] completed Week  52 visit, not applicable at Study  discontinuation visit 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400488] been assessed and the participant is eligible for enrollment in 
the study  the baseline visit can be scheduled (this may be prior  to the maximum  28 day screening 
period duration). 
Evaluation of participant eligibility for laboratory parameters listed in  Section  5.[ADDRESS_400489] number. The investigator/qualified site staff will record if the 
participant was re- screened on the re -screening eCRF and any applicable screening numbers 
the participant was issued prior to the current screening number. 
The date of the new informed  consent signature [CONTACT_324432]. For re-screening,  all screening  assessments 
must be performed per protocol.  
8.1.1 Information to be collected on screening failures  
Participants who sign an informed consent form and are subsequently found to be ineligible 
prior to  randomization  will be considered  a screen  failure.  The reason  for screen  failure  should 
be recorded on the appropriate Case Report Form. The demographic information, informed consent, and Inclusion/Exclusion pages must also be completed for screen failure participants. No other data will be entered  into the clinical database for participants  who are screen  failures, 
unless the participant experienced a serious adverse event (SAE) during the screening phase (see SAE section for reporting details). If the participant fails to be randomized, the IRT must be notified with in 2 days of the screen fail that the participant was not randomized. 
Participants who are randomized and fail to start treatment, e.g., participants randomized in error, will be considered an early terminator. The reason for early termination should be recorded on the appropriate Case Report Form. 
8.2 Participant demographics/other  baseline characteristics  
Baseline CSU activity will be assessed using the eDiary from Day - [ADDRESS_400490]  on the 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  67 of 133 
Protocol  No. CLOU064A2302   
safety and efficacy pa rameters in the study. Relevant medical history (including evaluation of 
inclusion/exclusion criteria, CSU history and cardiovascular history) and current medical 
condition present before signing the informed consent will be captured. Where possible, diagnoses, and not symptoms, will be recorded. Data on participants’ family history of malignancies will be collected on the respective eCRF page, only when a participant has a malignancy event reported during the study, to assess possible risk factors related to any malignancies.  
Country- specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with CRF.  
8.3 Efficacy  
8.3.1 eDiary assessments  
All participants  will be provided with  an electronic  device (eDiary)  that contains the following 
Patient Reported Outcomes (PRO) assessments: Urticaria Patient Daily Diary (UPDD) and Angioedema Activity Score (AAS).  
Site and participants will receive appropriate training  and guidance on the use of the eDiary  and 
will receive clear instructio ns on the completion of the assessments. 
Assessments  will be completed  twice  daily  (UPDD),  once daily  (AAS, if triggered by  [CONTACT_157096]) from screening to week 52/study discontinuation. 
In general,  participants  complete  eDiary  question naires at home and independent of study visits. 
Participants  will be instructed  to complete  eDiary  entries after they took their study medication 
throughout the treatment period. The DLQI,  questionnaires will be administered 
during respective visits on site and should be completed prior to any other study specific 
procedure. Site personnel must allow participants to complete the questionnaire on their own without any assistance from the site staff.  In the case that participants  cannot come to site  
(see Section  4.6),  the DLQI,   will be available on their 
electronic device.  
[IP_ADDRESS] Urticaria Patient Daily Diary (UPDD)  
UPDD includes Urticaria  Activity  Score  (UAS)  which  assesses twice  daily  severity  of itch and 
number of hives, use of rescue medication, sleep and activity interference, angioedema occurrence,  its management  and records the calls to a healthcare professional  (HCP) 
(see Section  16.4 ). The components are presented in the Table  8-2 and the relevant weekly 
scores are described below.  
Table 8-2 UPDD 
 
Diary  component  When assessed  
Urticaria Activity  Score  (UAS)  
• Itch severity  
• Number  of hives  Morning and evening 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  68 of 133 
Protocol  No. CLOU064A2302   
 
 
Diary  component  When assessed  
Sleep interference Morning 
Daily  activity  interference  Evening  
Rescue  medication use Evening  
Angioedema:  
• Whether  patient  had an epi[INVESTIGATOR_1865] 
• If patient  had an epi[INVESTIGATOR_1865],  how did they 
manage it  Evening  
Contact  [CONTACT_324412]  
 
[IP_ADDRESS].1  Weekly  Hives  Severity  Score  (HSS7)  
The hives (wheals) severity score, defined by [CONTACT_157098], will be recorded by [CONTACT_324413],  on a scale of 0 (none) to 3 (> 12 hives/12 hours; 
Table  8-3 ). A weekly score (HSS7) is derived by [CONTACT_201065] 7 
days preceding the visit. The possible range of the weekly score is therefore 0 – 21. 
 
Table  8-3 Hives  Severity  Score   
Score   Hives  (Wheals)  (every  12 hours)  
0  None  
1  1-6 hives/12 hours  
2  7-12 hives/12  hours  
3  > 12 hives/12  hours  
[IP_ADDRESS].2  Weekly  Itch Severity  Score  (ISS7) 
The severity  of the itch will be recorded  by [CONTACT_324414],  on a scale 
of 0 (none) to 3 (severe)  (Table  8-4).  A weekly  score (ISS7)  is derived  by [CONTACT_157102] 7 days preceding  the visit.  The possible range  of the weekly  score is therefore 
0 - 21. 
 
Table  8-4 Itch Severity  Score   
Score   Pruritus  (Itch)  (every  12 hours)  
0  None  
1  Mild (minimal  awareness,  easily  tolerated)  
2  Moderate  (definite  awareness,  bothersome  but 
tolerable)  
3  Severe  (difficult  to tolerate)  
[IP_ADDRESS].3  Weekly  Urticaria  Activity  Score  (UAS7)  
The UAS7 is the sum of the HSS7 score and the ISS7 score. The possible range of the weekly 
UAS7 score is 0 – 42 (highest activity). 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  69 of 133 
Protocol  No. CLOU064A2302   
 
 
 
 
 
 
 
8.
[IP_ADDRESS]  Angioedema occurrence  
Angioedema occurrence is recorded once daily in the evening in the eDiary by [CONTACT_2299]. 
Reporting the occurrence  of angioedema will be used as opening question for the assessment  of 
the AAS (see Section  [IP_ADDRESS]). Actions and/or treatments related to those angioedema 
occurrences will be also recorded in the eDiary as follows (multiple answers possible):  
• Did nothing  
• Took some prescription  or non-prescription medication  
• Called my  doctor, nurse or nurse practitioner 
• Went to see my  doctor, nurse or nurse practitioner 
• Went to the emergency  room at the hospi[INVESTIGATOR_307]  
• Was hospi[INVESTIGATOR_324381]. 01 (Clean)  Confidential  Page  70 of 133 
Protocol  No. CLOU064A2302   
[IP_ADDRESS].8  Number of calls to doctor or nurse  
The number of calls to doctor, nurse or nurse practitioner because of the participant’s skin 
condition will be recorded once daily in the eDiary by [CONTACT_2299]. 
[IP_ADDRESS] Angioedema Activity  Score (AAS)  
AAS is recorded once daily  in the evening in the eDiary  by [CONTACT_2299]. This validated tool 
assesses occurrence of epi[INVESTIGATOR_157048]. As an openin g question, the occurrence of 
angioedema in the UPDD (see  Section  [IP_ADDRESS].7) will be used. If participants answer this 
opening question in the UPDD with “no”, AAS  score for this day is 0. If “yes” is the answer  to 
the opening question in the UPDD, the participant will continue to answer questions about the 
duration, severity and impact on daily functioning and appearance of the angioedema (see Section  16.4 ). A score between  0 and 3 is assigned  to every  answer  field.    
8.3.2 Other  Patient  Reported Outcomes (PRO)  assessments  
[IP_ADDRESS] Dermatology Life Quality  Index (DLQI) 
The Dermatology Life Quality  Index (DLQI)  is a 10- item (grouped in 6 domains) dermatology- 
specific quality of life (QoL) measure ( Finlay  and Khan  1994). The DLQI was validated for 
patients  aged  [ADDRESS_400491] 
of their skin condition on various aspects of their lives thinking about the previous 7 days. 
An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease - 
related  QoL).  Domain  scores  are calculated  for: Symptoms and Feelings (0-6), Daily  Activities 
(0-6), Leisure (0-6), Work and School (0- 3), Personal Relationships (0 -6), Treatment (0 -3). 
The overall DLQI score range was split into score bands ( Hongbo et al 2005) and validated in 
terms of their meaning/relevance to patients as follows:  
Table 8-[ADDRESS_400492] on patient's life 
DLQI band Significance  of score  
 
0-[ADDRESS_400493]  on patient's  life 
2-[ADDRESS_400494]  on patient’s  life 
6-[ADDRESS_400495]  on patient’s  life 
11-[ADDRESS_400496]  on patient’s  life 
21-[ADDRESS_400497]  on patient’s  life 
A DLQI  score of > [ADDRESS_400498] on patients’  life and justification  for a 
biologic prescription for example in psoriasis ( Finlay  2005). The DLQI questionnaires are 
completed  at visits  detailed  in Table  8-1 in the eDiary.  The DLQI  should be completed  prior to 
any other assessment and prior to administration of investigational medication.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  71 of 133 
Protocol  No. CLOU064A2302   

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  72 of 133 
Protocol  No. CLOU064A2302   
 
  
 
 
 
 
8.
3.3 Appropriateness of efficacy assessments  
UAS7:  The UAS7  score is a unified, simple,  well-established  and validated  tool, recommended 
by [CONTACT_324415]-world  clinical  practice  as well as in clinical trials  with urticaria  patients 
(Młynek et  al 2008, Hawro  et al 2018, Zuberbier et al 2018 ). It is based on the assessment of 
the two key urticaria signs and symptoms, wheals and pruritus, which are documented by [CONTACT_102], making this score especially valuable. The use of the UAS7 facilitates comparison of study results across different trials, since it is used in other major Phase 3 trials in  the CSU 
indication as well (e.g., with ligelizumab).  
AAS7:  The AAS7 score is a unified, simple and validated tool, recommended by [CONTACT_324416] ( Weller  et al 2013, Zuberbier et al 2018). The use of the AAS7 facilitates 
comparison of study results across different trials, since it is used in other major Phase 3 trials in the CSU indication as well (e.g., with ligelizumab). 
  
8.
3.4 Other assessments: evidence of urticaria  
T
he investigator must confirm the presence of urticaria (i.e., the presence of hives) in each 
participant befo re randomization by [CONTACT_157105]. In the absence of active 
disease at the screening and/or randomization visit, the following will be acceptable: (a) a clearly identifiable photograph of the participant that is no older than 3 months showing the presence of urticaria,  (b) the investigator must  have seen the participant  with active  CSU in the 
past 3 months, or (c) the presence of hives/wheals must have been documented in the medical record of the participant by a physician trained in the manag ement of urticaria in the past 3 
months.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  73 of 133 
Protocol  No. CLOU064A2302   
8.4 Safety 
Safety assessments are specified below with the assessment schedule detailing when each 
assessment is to be performed.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  74 of 133 
Protocol  No. CLOU064A2302   
For details on AE collection  and reporting,  refer to AE section.  
As per Section  4.6, during a Public Health emergency as declared by [CONTACT_6620] i.e., pandemic, epi[INVESTIGATOR_6519], that limits or prevents on -site study 
visits,  regular phone or virtual calls can occur (every  4 weeks or more  frequently  if needed)  for 
safety monitoring and discussion of the participant´s health status until it is safe for the 
participant to visit the site again.  
Table 8-8 Physical assessments  
 
Assessment  Specification  
Physical  examination  A complete physical  examination (performed at 
Screening) will include the examination of general appearance, skin, neck (including 
thyroid), eyes, ears, nose, throat, lungs, heart, 
abdomen, back, lymph nodes, extremities, vascular, neurological and body temperature 
measurement (per local practice).  If indicated 
based on medical history and/or symptoms, rectal, external genitalia, breast, and pelvic 
exams will be performed.  
A short physical exam (performed at all visits except Screening) will include the examination 
of general appearance, assessment of the skin 
for signs  of urticaria  and other  skin lesions,  body 
temperature measurement (per local practice) 
and vital signs (blood pressure (BP) [systolic 
blood pressure (SBP) and diastolic blood 
pressure (DBP)] and pulse).  
Information for all physical examinations must  
be included in the source documentation at the study site. Clinically relevant findings that are 
present prior to signing informed consent must be recorded on the appropriate CRF that 
captures medical history. Significant findings 
made after signing informed  consent  which  meet 
the definition of an Adverse Event must be 
recorded as an adverse event.  
Vital signs  Vital signs  include  BP and pulse  measurements. 
After the participant has been sitting for five minutes, with back supported and both feet 
placed on the floor, systolic and diastolic blood 
pressure will be measured three times using an automated validated device, e.g., OMRON, with 
an appropriately sized cuff. The repeat sitting 
measurements will be made at 1 - 2 minute 
intervals and the mean of the three 
measurements will be used. In case the cuff 
sizes available are not large enough for the participant's arm circumference, a 
sphygmomanometer  with an appropriately  sized 
cuff may be used.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  75 of 133 
Protocol  No. CLOU064A2302   
 
Assessment  Specification  
 Clinically  notable  vital signs  are defined in 
Section 16.1 . 
Height  and weight  Height in centimeters (cm) and body weight (to 
the nearest  0.1 kilogram (kg) in indoor  clothing,  
but without  shoes)  will be measured as specified 
in Table 8 -1. 
8.4.1 Laboratory evaluations  
A central  laboratory  will be used for analysis of all specimens detailed  in this section  (Table  8-9) 
unless noted otherwise.  Details on the collections, shipment of samples  and reporting of results 
by [CONTACT_82672].  
If participants  cannot visit the site for protocol specified  safety  lab assessments (per Section  4.6), 
an alternative lab (local) collection may be used.  
Clinically  notable laboratory findings are defined in Section 16.1. 
Clinically significant abnormalities must be recorded on the relevant section of the eCRF 
capturing medical history/current medical conditions/AEs. 
Table 8-[ADDRESS_400499] Name  
[CONTACT_6675], Hemoglobin,  [in the case  of clinically 
significant anemia the following parameters will be assessed: Ery. Mean Corpuscular 
Hemoglobin (MCH), Ery. Mean Corpuscular 
Hemoglobin Concentration (MCHC), Ery. Mean Corpusc ular Volume (MCV)], Platelets, 
Erythrocytes, Leukocytes, and Differential (Basophils, Eosinophils, Lymphocytes, 
Monocytes, Neutrophils, Bands)  
Chemistry  Albumin, Alkaline phosphatase (ALP), Alanine 
Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma -glutamyl 
transferase (GGT), Lactate dehydrogenase (LDH), Calcium, Magnesium, Phosphate, 
Chloride, Sodium, Potassium, Creatinine, 
Creatine Kinase (C K), Direct Bilirubin, Indirect 
Bilirubin (in case of clinically significant 
elevation),  Total  Bilirubin,  Total  Cholesterol,  Low 
Density Lipoprotein (LDL) Cholesterol, High - 
Density Lipoprotein (HDL) Cholesterol, Total Protein, Triglycerides, Urea Nitrogen or Urea, 
Uric Acid, Amylase, Lipase.  
C-reactive  protein (CRP),  estimated Glomerular 
Filtration Rate (eGFR): in all patients at screening, baseline, weeks 12, 24 and 52 and 
when deemed necessary by [CONTACT_324417].  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400500] Name  
 [CONTACT_324433], 
weeks 2, 12 and 52.  
Urinalysis  Done on site (unless prohibited by [CONTACT_259138], then sample to be sent to central laboratory) Macroscopic  Panel  (Dipstick)  (Color, 
Bilirubin, Occult Blood, Macroscopic Blood, Glucose,  Ketones,  Leukocytes  esterase,  Nitrite, 
pH, Protein, Specific Gravit y, Urobilinogen)  
Coagulation  Prothrombin time (PT), International normalized 
ratio (INR),  Activated  partial  thromboplastin time 
(APTT)  
Hepatitis  screening Hepatitis B screening: Antibodies against 
Hepatitis B virus core antigen (HBcAb or anti - 
HBc); antibodies against Hepatitis B virus 
surface  antigen  (anti-HBs or HBs-Ab); Hepatitis 
B virus surface antigen (HBsAg)  
Hepatitis B- Deoxyribonucleic acid (HBV - 
DNA), only in participants who are positive 
for anti-Hepatitis  B virus  Core  (HBcAb  or anti- 
HBc).  
Hepatitis C screening: Hepatitis C virus antibodies (anti -HCVAb) and Hepatitis C- 
Ribonucleic  acid (HCV -RNA,  only in participants 
who are positive for anti -HCVAb)  
Hepatitis  B re-activation monitoring  Only in participants  who are positive  for HBc-Ab 
(anti-HBc positive) and negative for anti -HBsAg 
and HBV-DNA  at screening:  HBsAg,  HBV- DNA 
HIV testing  HIV test performed at screening,  only when 
required by [CONTACT_427].  
Additional  tests  
Follicle -stimulating  hormone  (FSH) (for female 
participants with unclear fertility status)  
Pregnancy  Test Serum  / Urine  pregnancy  test for WoCBP  (refer  
to 'Pregnancy  and assessments  of fertility' 
Section 8.4.3 ) 
8.4.2 Electrocardiogram (ECG)  
Electrocardiograms (ECGs) must be recorded  according to the ECG investigator manual. The 
preferred  sequence of cardiovascular  data collection  during study visits  is ECG collection  first, 
followed by [CONTACT_18651], and blood sampling. The Fridericia QT correction formula (QTcF) should be used for clinical decisions. 
Triplicate [ADDRESS_400501]- 
dose assessments should be collected (refer to  Table  8-1 ), post dose assessment should be 
measured   

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400502] for clinically significant ECG findings 
throughout the study and especially at baseline before administration of study treatment.  
In the event that a clinically significant ECG abnormality is identified at the site (e.g., severe arrhythmia, conduction abnormality of QTcF > 450 ms (males)/ 460 ms (females)), a copy of 
the assessment  is sent to the core laboratory  for expedited review  if applicable, and the ECG  is 
repeated to  confirm the diagnosis. If the participant is hemodynamically compromised, the 
investigator or a medically  qualified  person must  initiate  appropriate safety  procedures without 
delay (for example cardioversion).  
Additional, unscheduled, safety ECGs may be repeated at the discretion of the investigator at 
any time during the study as clinically  indicated. For any ECGs  with participant safety  concerns, 
two additional ECGs must be performed to confirm the safety find ing. 
Clinically significant abnormalities must be recorded on the CRF as either medical history/current medical conditions or adverse events as appropriate.  
8.4.[ADDRESS_400503] pregnancy testing at 
screening  (serum),  at randomization  (Day  1, before administration  of study medication  (urine)), 
and every 4 weeks thereafter (urine). Where the visit interval is greater than [ADDRESS_400504], in the case that participants  cannot visit  the site  an alternative  (local  lab) 
can be used. If positive the participant must be discontinued from study treatment. If participants are not able to perform a home urine pregnancy test (e.g., if prohibited by [CONTACT_427]), a urine or serum test can be performed at the local laboratory as directed by [CONTACT_8647].  
A communication  process  should be established  with the participant  so that the site is informed 
and can verify the pregnancy test results (e.g., following country- specific measures).  
Additional pregnancy testing might be performed if requested by  [CONTACT_5277].  
Assessments of fertility  
Medical documentation of oophorectomy, hysterectomy, or bilateral tubal ligation must be retained  as source documents. Subsequent hormone level  assessment  to confirm the woman  is 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400505] also be available as source documentation in the following 
cases:  
1. Surgical bilateral oophorectomy without a hysterectomy  
2. Reported 12 months of natural (spontaneous) amenorrhea with an appropriate clinical 
profile.  
In the absence of the above medical  documentation, FSH testing  is required  of any female 
participant regardless of reported reproductive/menopausal status at screening/baseline.  
8.4.4 Appropriateness of safety measurements  
The selected  safety  monitoring  assessments (including laboratory assessments covering clinical 
chemistry, hematology, coagulation status and immunoglobulins, as well as clinical and 
physical assessments,  triplicate  ECG monitoring and general  AE assessments)  are reliable  and 
well-established  standard measures which  allow  valid  and close  safety  monitoring  of the trial´s 
patient population, with regards to their disease, to the compound they are treated with, remibrutinib, and also to their overall medical safety.  
8.5 Additional  assessments 
8.5.1 Clinical  Outcome Assessments (COAs) 
Trial Feedback  
This study includes an optional anonymized questionnaire, the  ‘Trial Feedback Questionnaire’  
for trial participants  to provide feedback  on their clinical  trial experience at 3 timepoints: at the 
start,  during and at the end of the trial. Individual trial participant responses will not be reviewed 
by [CONTACT_431]. Responses may be used by [CONTACT_324418]. This questionnaire does not ask questions about the trial participant’s disease, symptoms, treatment effect or adverse events and therefore is not considered as trial data.  
  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  79 of 133 
Protocol  No. CLOU064A2302   

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  80 of 133 
Protocol  No. CLOU064A2302   
 
9 Discontinuation  and completion  
9.1 Discontinuation  from  study treatment  and from  study  
9.1.1 Discontinuation from study treatment  
Discontinuation of study treatment for a participant occurs when  study treatment is permanently 
stopped for any reason  (prior to the protocol planned completion of study  drug administration) 
and can be initiated by [CONTACT_6633].  
The investigator must discontinue s tudy treatment  for a given  participant  if, he/she believes that 
continuation would negatively impact the participant's well -being. 
Discontinuation from study  treatment is required under the following circumstances:  
• Participant  decision (requested  in writing  or verbally)  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  81 of 133 
Protocol  No. CLOU064A2302   
• Pregnancy  
• Use of prohibited tr eatment requiring study  treatment discontinuation as detailed  
in Table  6-3 or discontinuation of highly effective  methods of contraception as detailed 
in Section 5.2 
• Any situation  in which  continued study  participation  might result in a safety  risk to the 
participant  
• Following emergency unblinding  
• Emergence of the following  AEs:  
• any adverse events that in the judgement of investigator,  taking  into consideration the 
participant's overall status, prevents the participant from continuing participation in 
the study, including:  
• hypersensitivity reactions,  
• severe/serious infections,  
• clinically  significant spontaneous bleeding events  
• new confirmed  diagnosis of malignancy of any organ system  
(other than localized  basal  cell carcinoma  of the skin or in situ cervical  cancer)  
• Platelets  < 75 000/mm3 
• Abnormal renal  laboratory results requiring  discontinuation (see Section  16.3) 
• Abnormal liver laboratory  results requiring discontinuation (see  Section 16.2) 
• Any other laboratory  abnormalities  that in the judgment of the investigator, taking 
into consideration the participant’s overall status, prevents the participant from continuing participation in the study 
• participant  received  a live virus  vaccination during  the study 
If discontinuation from  study treatment occurs,  the investigator should make  a reasonable effort 
to understand the primary  reason  for the participant’s  discontinuation from  study treatment and 
record this information.  
All participants who discontinue from study treatment prematurely should complete the Earl y treatment discontinuation visit at the time of treatment discontinuation.  
For participants who discontinue from study treatment prior to week 12, where possible they should be requested  to return  for visits  after  the Early  treatment discontinuation visit  as per the 
Assessment Schedule ( Table  8-1)
 up to and including the week 12 timepoint. At the week 12 
timepoint the study  discontinuation visit should be performed ). If 
the participant declines to continue with assessments as per the visit schedule up to week 12, then they should complete the safety follow -up visit after the Early treatment discontinuation 
visit.  
Participants who discontinue from study treatment after week 12 should complete the safety follow -up visit indicated in the Assessment Schedule ( Table 8 -1) whenever possible. 
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact [CONTACT_6635],  or with a person  pre-designated  by [CONTACT_2299]. 
This telephone contact [CONTACT_6636]. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  82 of 133 
Protocol  No. CLOU064A2302   
After d iscontinuation from study treatment, at a minimum, in abbreviated visits, the following 
data should be collected at clinic visits or via telephone/email contact:  
• New / concomitant treatments  
• Adverse Events  / Serious  Adverse Events  
The investigator must also contact [CONTACT_6637]’s discontinuation from 
study treatment. 
If discontinuation occurs because treatment code has been broken, please refer to Emergency 
breaking of treatment code section.  
9.1.2 Discontinuation f rom study  
Discontinuation from study is when the participant permanently stops receiving the study treatment, and further protocol- required assessments or follow -up, for any reason, including 
participant’s decision (requested in writing or verbally).  
If the particip ant agrees,  a final evaluation  at the time of the participant’s  study discontinuation 
should be made as detailed in the assessment table (refer to Section 8 ). 
9.1.[ADDRESS_400506]  to follow -up 
For participan ts whose status is unclear because they fail to appear for study visits without 
stating  an intention to  discontinue from  study treatment or discontinue from  study or withdraw 
consent/oppose to the use of their data/biological samples, the investigator must show "due diligence"  by [CONTACT_324419], e.g., 
dates of telephone calls,  registered  letters,  etc. A partic ipant  should not be considered  as lost to 
follow -up until due diligence has been completed or until the end of the study. 
9.2 Withdrawal  of informed  consent/Opposition to use 
data/biological samples  
Withdrawal  of consent/opposition to use data/biological samples occurs when a participant:  
• Explicitly  requests to stop use of their biological samples and/or data (opposition  to use 
participant’s data and biological samples)  
and 
• No longer wishes to receive study treatment 
and 
• Does  not want  any further visits  or assessments (including further study- related  contacts)  
This request should be in writing or verbally (depending on local regulations) and recorded in 
the source documentation. 
In this situation, the investigator  should make  a reasonable effort  (e.g., telephone, e- mail,  letter) 
to understand the primary reason for the participant’s decision to withdraw their 
consent/opposition to use data/biological samples and record this information.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  83 of 133 
Protocol  No. CLOU064A2302   
Where  consent to the use of Personal  and Coded Data  is not required in a certain  country's legal 
framework, the participant therefore cannot withdraw consent. However, they still retain the 
right to object to the further collection or use of their Personal Data.  
Study treatment must b e discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.  
Further attempts to contact [CONTACT_6639] -up. 
If the participant agrees, a final evaluation at the time of the participant’s withdrawal of 
consent/opposition to use data/biological samples  should be made as detailed  in the assessment 
table (refer to Section 8 ). 
[COMPANY_001]  will continue to retain and use all research results (data) that have already been 
collected for the study evaluation, including processing of biological samples that has al ready 
started at time of consent withdrawal/opposition. No new Personal Data (including biological 
samples) will be collected following withdrawal of consent/opposition. 
9.[ADDRESS_400507] been documented and followed -up 
appropriately by [CONTACT_737],  enrolls  into the planned open- label  extension study following 
completion of the  52-week treatment period or, in the event of an early study termination 
decision, the date of that decision. 
Participants who complete participation in the 52- week treatment period of this trial may be 
eligible  to receive remibrutinib  as part of an open-l abel extension study (under development) if 
they meet the eligibility criteria defined in the extension study protocol.  
The open- label extension will require endorsement in participating countries and sites as per 
local laws and regulations.  
For participan ts not willing or ineligible to roll over into the extension study and who want to 
continue receiving remibrutinib every effort will be made to continue provision of study 
treatment prior  to the investigational  treatment  becoming available  in the respective  country, if 
in the opi[INVESTIGATOR_871], they are still deriving clinical benefit from remibrutinib.  
9.4 Early  study termination  by [CONTACT_131360]. 
Reasons for early termination:  
• Unexpected, significant,  or unacceptable safety  risk to participants  enrolled in the study 
• Decision  based  on recommendations  from applicable board(s) after review  of safety  and 
efficacy data 
• Discontinuation of study drug development  
In taking the decision to terminate,  [COMPANY_001] will always consider participant welfare  and safety. 
Should early  termination  be necessary,  participants  must be seen as soon as possible and treated  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400508] the participant to schedule the study discontinuation and study 
completion visits (as appropriate) and provide instruction regarding study drug intake. The investigator may be informed of additional procedure s to be followed in order to ensure that 
adequate consideration  is given to the protection  of the participant’s  interests.  The investigator 
or sponsor depending on local regulation will be responsible for informing IRBs/IECs of the early termination of the trial.  
 
10 Safety monitoring,  reporting and committees  
10.1 Definition  of adverse events and reporting  requirements 
10.1.1 Adverse events  
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavourable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a clinical investigation participant  after providing written  informed  consent  for participati on in the study. 
Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.  
The investigator has the responsibility for managing the safety of individual participant and identifying adverse e vents.  
[COMPANY_001]  qualified  medical  personnel will be readily  available to advise on trial related  medical 
questions or problems.  
The occurrence of adverse events must be sought by [CONTACT_105]- directive  questioning of the participant 
at each visit during the study. Adverse events also may be detected when they  are volunteered 
by [CONTACT_324420], laboratory 
test findings, or other assessments . 
Adverse events must be recorded  under the signs, symptoms, or diagnosis associated  with them, 
accompanied  by [CONTACT_6644]  (as far as possible) (if the event is serious  refer 
to Section 10.1.2):  
1. The severity  grade:  
• mild: usually  transient in nature and generally  not interfering with normal activities  
• moderate: sufficiently  discomforting to interfere with normal activities  
• severe:  prevents normal activities  
2. Its relationship  to the study treatment.  If the event is due to lack of efficacy  or progression 
of underlying illness (i.e., progression of the study indication) the assessment of causality will usually  be ‘Not suspected.’ The rationale for thi s guidance is that the symptoms of a 
lack of efficacy or progression of underlying illness are not caused by [CONTACT_6645], they happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression of underlying disease can only  be evaluated  meaningfully  by [CONTACT_6646], not on a 
single participant  
3. Its duration (start and end dates or ongoing) and the outcome must be reported  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  85 of 133 
Protocol  No. CLOU064A2302   
4. Whether it constitutes  a SAE  (see Section  10.1.2 for definition  of SAE)  and which 
seriousness criteria have been met  
5. Action taken regarding with study treatment.  
All adverse events must be treated appropriately. Treatment may include one or more of the  
following:  
• Dose  not changed  
• Drug interrupted/permanently  discontinued  
6. Its outcome (i.e., recovery status or whether it was fatal) 
Conditions that were already present at the time of informed consent should be recorded in 
medical history of the participant.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Adverse event monitoring should be continued for at least [ADDRESS_400509] be followed  until its resolution or until it is judged to 
be permanent (e.g., continuing at the end of the study), and assessment must be made at each 
visit (or more  frequently,  if necessary)  of any changes in severity,  the suspected  relationship to 
the interventions required to treat it, and the outcom e. 
Information about adverse drug reactions for the investigational drug can be found in the 
Investigator's Brochure (IB).  
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:  
• they induce clinical signs or symptoms  
• they are considered clinically  significant 
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_6533]. See  Section  16.[ADDRESS_400510] abnormaliti es. 
10.1.2 Serious adverse events  
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s),  symptom(s),  or medical  conditions(s) which  meets  any one of the following 
criteria: 
• fatal 
• life-threatening  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  86 of 133 
Protocol  No. CLOU064A2302   
Life-threatening  in the context of a SAE  refers to a reaction  in which  the participant  was at risk 
of death  at the time of the reaction; it does not refer  to a reaction  that hypothetically might  have 
caused death if it were more severe (please refer to the ICH -E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth  defect  
• requires inpatient hospi[INVESTIGATOR_869], unless 
hospi[INVESTIGATOR_062]:  
• routine  treatment  or monitoring  of the studied  indication, not associated  with any 
deterioration in condition 
• elective  or pre-planned treatment  for a pre-existing  condition that is unrelated  to the 
indication under study and has not worsened since signing the informed consent 
• social  reasons and respi[INVESTIGATOR_131305]’s 
general condition 
• treatment on an emergency  outpatient basis for an event not fulfilling  any of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• is medically  significant,  e.g., defined as an event that jeopardizes the participant or may 
require medical or surgical intervention to prevent one of the outcomes listed above 
Medical  and scientific  judgment should be exercised  in deciding whether other situations  should 
be considered serious reactions,  such as important medical  events that might  not be immediately 
life threatening or result  in death  or hospi[INVESTIGATOR_131306]. Such events should be 
considered as “medically significant.” Examples of such events are intensive treatment in an emergen cy room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that 
do not result  in hospi[INVESTIGATOR_324382] (please refer  to the ICH- 
E2D Guidelines). 
All new malignant n
 eoplasms will be assessed  as serious under “medically  significant”  if other 
seriousness criteria are not met.  
Any suspected  transmission  via a medicinal  product of an infectious  agent  is also considered  a 
serious adverse reaction.  
All reports of intentional misuse and abuse of the pro duct are also considered serious adverse 
event irrespective if a clinical event has occurred (see Section 10.1.5).  
10.1.[ADDRESS_400511] be reported to [COMPANY_001] safety immediately, without undue delay, but under no circumstances later than with in 24 hours of obtaining knowledge of the events (Note: If more 
stringent, then local regulations regarding reporting timelines prevail). Detailed instructions regarding the submission process and requirements are to be found in the investigator folder provided to each site. Information about all SAEs is collected and recorded on the electronic Serious Adverse Event (eSAE) (with paper backup if required) Serious Adverse Event Report  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  87 of 133 
Protocol  No. CLOU064A2302   
Form; all applicable sections of the form must be completed i n order to provide a clinically 
thorough report. 
1. Screen  Failures (e.g., a participant who is screened but is not treated or randomized): 
SAEs  occurring after the participant  has provided informed  consent  until the time the 
participant is deemed a Screen Failure must be reported to [COMPANY_001] with 24 hours of 
learning of its occurrence.  
2. Randomized OR Treated  Participants: SAEs  collected  between  time participant signs ICF 
until [ADDRESS_400512] be reported as follow -up to the original epi[INVESTIGATOR_6538],  without undue delay, but under no circumstances later than within  24 hours of the 
investigator receiving  the follow-up information  (Note:  If more  stringent, then local  regulations 
regarding reporting timelines prevail). An SAE occurring at a different time interval or otherwise considered completely unrelated to a previously reported one must be reported separately as a new event.  
If the SAE  is not previously  documented in the Investigator’s  Brochure or Package Insert  (new 
occurrence) and is thought to be related to the study treatment, a Chief Medical Officer and Patient Safety (CMO & PS) Department associate may urgently require further information from the investigator for health  authority  reporting. [COMPANY_001]  may  need  to issue an  Investigator 
Notification  (IN) to inform all investigators involved in any study with the same study treatment 
that this SAE has been reported. 
Suspected  Unexpected  Serious Adverse Reactions (S[LOCATION_003]Rs)  will be collected  and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_400513] administration of study treatment should only be reported to [COMPANY_001] Safety if the investigator suspects a causal 
relationship to study treatment, unless otherwise specified by [CONTACT_1769]/regulations.  
10.1.[ADDRESS_400514] 
be reported  to [COMPANY_001]  within  24 hours of learning of its occurrence. The pregnancy should be 
followed up to determine outcome, including spontaneous or voluntary termination, details of 
the birth,  and the presence or absence  of any birth  defects,  congenital abnormalities,  or maternal 
and/or newborn complications. 
Pregnancy should be recorded and reported by [CONTACT_324421]  (CMO&PS).  Pregnancy follow -up should be recorded  on the Targeted 
Follow-up pregnancy - Infant status  form and should include an assessment  of the possible 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400515] be reported.  
After consent is provided, the pregnancy  reporting will occur  up to one year after the estimated 
date of delivery.  
10.1.5 Reporting of study treatment errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or monitoring of a medicine while under the control of a healthcare professional, participant or consumer (European Medicines Agency definition).  
Misuse refers  to situations  where  the medicinal product is intentionally  and inappropriately used 
not in accordance with the protocol. 
Abuse  corresponds  to the persistent  or sporadic, intentional  excessive use of a medicinal  product, 
which is accompanied by [CONTACT_3584]. Study treatment errors and uses outside of what is foreseen in the protocol will be recorded on 
the appropriate CRF  irrespective  of whether or not associated  with an AE/SAE and reported to 
Safety only if associated with an SAE. Misuse or abuse will be collected and reported in the 
safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
Table 10-1 Guidance for capturing the study treatment errors  including 
misuse/abuse  
Treatment error type Document in Dosing  
CRF (Yes/No)  Document in AE 
eCRF  Complete  SAE form  
Unintentional  study 
treatment error  Yes Only if associated with 
an AE  Only if associated with 
an SAE 
 
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE 
For more information on AE and SAE definition and reporting requirements, please see the 
respective sections..  
10.2 Additio nal Safety  Monitoring  
10.2.1 Liver  safety monitoring  
To ensure participant  safety  and enhance reliability  in determining  the hepatotoxic potential of 
an investigational drug, a standardized  process for identification,  monitoring and evaluation of 
liver events has to be followed. 
Please refer to Table  16-1 in Section  16.2 for complete  definitions  of liver laboratory triggers.  
Once  a participant is exposed  to study  treatment,  every  liver event defined in Table 16-1 s hould 
be followed  up by [CONTACT_6648], as summ arized  below. 
Additional   details   on   actions   required  in   case   of  liver  events   are  outlined 
in Table 16-2 and Table 16-3. Repeat  liver chemistry  tests (i.e., ALT,  AST,  TBL,  PT/INR,  ALP 
and GGT) to confirm elevation. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400516] 
results recorded on the appropriate CRF. 
• If the initial elevation  is confirmed, close  observation of the participant  will be initiated, 
including consideration of treatment interruption if deemed appropriate.  
• Discontinuation of the investigational  drug (refer to Section  9.1 and Section  16.2),  if 
appropriate  
• Hospi[INVESTIGATOR_131308]  
• Causality  assessment  of the liver event  
• Thorough follow -up of the liver event should include, based  on investigator's discretion:  
• serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more  detailed  history  of symptoms  and prior or concurrent diseases,  history 
of concomitant drug use, exclusion of underlying liver disease 
All follow -up information and procedures performed must be recorded as appropriate in the 
CRF.  
10.2.2 Renal safety monitoring  
Once  a participant is exposed  to study  treatment,  the following  two categories of abnormal renal 
laboratory alert values should be assessed during the study period: 
• Serum  creatinine  increase  ≥ 25% compared  to baseline during normal hydration status 
• Any one of the following: 
• Urine  protein -creatinine  ratio (PCR)  ≥1g/g or ≥100  mg/mmol,  OR 
• New onset dipstick proteinuria ≥ 3+, OR 
• New onset dipstick  hematuria  ≥ 3+ (after  excluding menstruation, UTI,  extreme 
exercise, or trauma)  
Abnormal renal event findings must be confirmed after ≥24 hours but ≤ [ADDRESS_400517] 
assessmen
t. 
Once a participant is exposed to study treatment, renal laboratory alerts or renal safety events as defined in  Table  16-4 should be followed up by [CONTACT_157112] 16-5. 
10.3 Committees  
10.3.1 Data  Monitoring Committee  
This study will include a data monitoring  committee  (DMC)  which  will function independently 
of all other individuals associated with the conduct of this clinical trial, including the site investigators participating in the study. The DMC will assess at def ined intervals the progress 
of a clinical trial, safety data, and critical efficacy variables and recommend to the sponsor whether to continue, modify, or terminate a trial.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400518]  been  trained.  Automatic  validation  programs check  for data discrepancies in the 
eCRFs, allow modification and/or verification of the entered data by [CONTACT_6649].  
The investigator/designee is responsible for assuring that the data (entered into eCRF) is complete, accurate, and that entry and updates are performed in a timely manner. The Investigator must certify that the data entered are complete and accurate.  
After final database lock, the investigator will receive copi[INVESTIGATOR_157052].  
All data should be recorded, handled, and stored in a way that allows its accurate reporting, 
interpretation, and verification.  
11.2 Database  management  and quality  control 
[COMPANY_001]  personnel (or designated  Contract Research  Organisation  (CRO))  will review  the data 
entered by [CONTACT_5375]. Electronic data queries stating the nature of the problem and requesting clarification will be created for discrepancies and missing  values and sent to the investigational site via the Electronic  Data  Capture (EDC)  system. 
Designated investigator site staff are required to respond promptly to queries and to make any necessary changes to the data.  
Concomitant treatments  and prior medications entered  into the database will be coded using  the 
World Health Organization (WHO) Drug Reference List, which employs the Anatomical Therapeutic Chemical  (ATC)  classification  system.  Medical  history/current medical  conditions 
and adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) terminology.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  91 of 133 
Protocol  No. CLOU064A2302   
Dates of screenings, randomizations, screen failures and study completion, as well as 
randomization codes and data about all study treatment (s) dispensed to the participant and all 
dosage changes will be tracked using an Interactive Response Technology (IRT). The system will be supplied by a vendor, who will also manage the database. The data will be sent electronically to [COMPANY_001] (or a designated CRO) at specific timelines.  
Each  occurrence of a code break  via IRT will be reported  to the clinical team  and monitor.  The 
code break functionality  will remain  available until study shut down or upon request  of [COMPANY_001].  
Once all the necessary actions have been completed and the database has been declared to be 
complete  and accurate,  it will be locked  and the treatment  codes will be unblinded and made 
available for data analysis. Any changes to the database after that time can only  be made after 
written agreement by [CONTACT_188660].  
11.3 Site monitoring  
Before   study   initiation,   at  a  site  initiation   visit  or   at  an  investigator’s   meeting, 
a [COMPANY_001] /delegated CRO representative will review the protocol and data capture 
requirements (i.e., electronic  source (eSource) DDE  or eCRFs)  with the investigators and their 
staff. During the study, [COMPANY_001]  employs several methods of ensuring protocol and GCP 
compliance and the quality/integrity of the sites’ data. The field monitor will visit the site to 
check the completeness of participant records, the accuracy of data capture / data entry, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment, and to ensure that study treatment is being stored, dispensed, and accounted for according to specifications. Key study personnel must be avai lable to assist the field monitor during these 
visits. Continuous remote monitoring of each site’s data may be performed by a centralized [COMPANY_001]/delegated  CRO/CRA organization. Additionally,  a central  analytics organization may 
analyze  data & identify  risks & trends  for site operational parameters,  and provide reports 
to [COMPANY_001] clinical teams to assist with trial oversight.  
The investigator must maintain source documents for each participant in the study, consisting of case and visit notes  (hospi[INVESTIGATOR_131310])  containing  demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on CRFs must be traceable to these source documents in the participant's  file. The investigator must  also keep  the original informed  consent  form signed by 
[CONTACT_2299] (a signed copy is given to the participant). 
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry. [COMPANY_001]  monitoring standards require full 
verification  for the presence  of informed  consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for  all primary variables. Additional 
checks of the consistency of the source data with the CRFs are performed according to the 
study- specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  92 of 133 
Protocol  No. CLOU064A2302   
12 Data analysis and statistical  methods  
The analysis will be conducted at the time of the primary analysis and on all participants' data 
at the time the trial ends. Any data analysis carried  out independently by [CONTACT_268316]. 
12.1 Analysis  sets 
The following analysis sets will be used in this trial: 
Randomized set (RAS): The RAS set consists of all randomized participants, regardless of whether or not they receive a dose of study drug. Participants  will be analyzed  according to the 
treatment they are assigned.  
The Full Analysis Set (FAS) comprises all participants to whom study treatment has been assigned by [CONTACT_17628]. FAS will be used for all efficacy variables, unless otherwise stated.  Mis-randomized participants (mis -randomized in IRT) will be included in  the 
Randomized set but will be excluded from FAS. 
Mis- randomized participants are defined as cases where IRT contacts were made by [CONTACT_324422]’s final 
randomization eligibility and no study medication was administered to the participant. 
The Safety  Set (SAF)  includes all participants who received  at least one dose of study treatment, 
whether or not being randomized. Participants  will be analyzed  according to the study treatment 
received. The safety  set will be used in the analysis of all safety  variables.  The actual  treatment 
will be defined as the treatment received over the study. In case of error in dispensation, the 
actual treatment will correspond to the treatment which was given most often.  
12.[ADDRESS_400519]  deviation, median, 25th and 
75th percentiles, minimum, and maximum will be presented.  
The duration of exposure in weeks to remibrutinib  and placebo  will be summarized  by [CONTACT_6490], by [CONTACT_324423]. The duration of study will also be summarized by 
[CONTACT_1570]. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  93 of 133 
Protocol  No. CLOU064A2302   
Concomitant medications and significant non- drug therapi[INVESTIGATOR_324383], by [CONTACT_6490].  
12.4 Analysis  supporting  primary  objectives 
This section  will detail  the statistical  analysis of the primary  estimand. Details  of the hypothesis 
testing  strategy  including primary  and secondary  endpoints to handle multiplicity  are provided 
in Section 12.5.1 . 
12.4.1 Definition  of primary  endpoint(s)  
Primary  estimand  for scenario  with  UAS7  as the primary  efficacy  endpoint  
The primary  clinical  question of interest  is: What  is the effect  of remibrutinib  treatment versus 
placebo on the change from baseline in UAS7 score at Week 12 after treatment in adult 
participants with CSU who are inadequately controlled by H1- antihistamine and receiving a 
stable locally label approved dose of a second generation H1 -antihistamine, regardless of 
treatment discontinuation for any reason and regardless of intake of a different second generation H1- antihistamine as rescue medication and considering strongly confounding 
prohibited medication as an unfavourable outcome?  
The primary  efficacy  endpoint is the absolute change from baseline in UAS7  score at Week  12, 
which is the UAS7 score at Week 12 minus the UAS7 score at baseline. The UAS7 is the sum of the HSS7 score and the ISS7 score, and ranges from 0 -42. Weekly scores (HSS7 and ISS7 
scores) will be derived by [CONTACT_201065] [ADDRESS_400520]  is: What  is the effect  of remibrutinib  treatment versus 
placebo  on the change from baseline in ISS7  and change from  baseline in HSS7  score at Week 
12 after treatment in adult participants with CSU who are inadequately controlled by H1- antihistamine and receiving a stable locally label approved dose of a second generation H1 - 
antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1- antihistamine as rescue medication and considering 
strongly confounding prohibited medication as an unfavourable outcome? 
The co-primary  efficacy  endpoints are the absolute change from  baseline in ISS7  score at Week 
12 and absolute change from baseline in HSS7 score at Week 12, which is the ISS7 score 
(respectively HSS7 score) at Week 12 minus the ISS7 score (respectively HSS7 score at baseline). The weekly scores ISS7 and HSS7 range from [ADDRESS_400521] for the primary  endpoint being tested is that the absolute change 
from baseline in UAS7 score at Week 12 in remibrutinib is not superior to the placebo group i.e.,: 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  94 of 133 
Protocol  No. CLOU064A2302   
H01: µ remibrutinib ≥µPlacebo versus H A1: µ remibrutinib < µ Placebo  
where  µ is the mean  change from baseline  in UAS7  at Week  12. 
A linear mixed model with repeated measures (MMRM) will be used to estimate treatment 
differences for change  from  baseline in UAS7  score at Week  12, based  on the FAS.  The MMRM 
model will include treatment  group, baseline UAS7  score,  randomization  strata  variables,  week 
and both interaction of treatment by [CONTACT_157117]7 score by [CONTACT_157120]. Repeated measures within participant are model ed using an unstructured 
covariance of the error  terms. Additional important covariates may be added to the model. For 
the primary analysis, data up to Week 12 will be used in the model. 
The detailed  testing  strategy  including the primary  endpoint analysis is provided in Section  12.5. 
Statistical model, hypothesis, and method of analysis for scenario with  ISS7/HSS7 as the 
co-primary efficacy endpoints  
The statistical hypothesis test for the co -primary endpoints tests the union null hypothesis that 
the absolute change from baseline in ISS7 score at Week 12 in remibrutinib is not superior to 
the placebo group or the absolute change from baseline in HSS7 score at Week 12 in 
remibrutinib is not superior to the placebo group i.e.,: 
H
01a: µ remibrutinib ≥µPlacebo versus H A1a: µ remibrutinib < µ Placebo 
where µ is the mean change from baseline in ISS7 at Week 12. H
01b: µ remibrutinib ≥µPlacebo versus H A1b: µ remibrutinib < µ Placebo 
where  µ is the mean  change from baseline in HSS7  at Week  12. 
The union null hypothesis is rejected if both elementary null hypotheses (H01a, H01b) are 
rejected.  
A linear mixed model with repeated measures (MMRM) will be used to estimate treatment differences for change from baseline in ISS7 score (respectively HSS7)  at Week 12, based on 
the FAS. The MMRM model will include treatment group, baseline ISS7 score (respectively HSS7), randomization strata variables, week and both interaction of treatment by [CONTACT_324424]7 score (respectively HSS7) b y week as fixed effects. Repeated 
measures within participant are modeled using an unstructured covariance of the error terms. Additional important covariates may be added to the model. For the primary analysis, data up to Week 12 will be used in the model. 
The detailed  testing  strategy  including the primary  endpoint analysis is provided in Section  12.5. 
12.4.3 Handling of intercurrent events of primary estimand 
Participants who discontinue from study treatment early  due to any reason will be encouraged 
to stay in the study following the procedures. Every effort will be made to continue to follow 
participants who discontinued from study treatment up to Week 12. These are considered as Retrieved drop out (RDO) participants.  
The analysis will account  for different  intercurrent events as explained in the following: 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  95 of 133 
Protocol  No. CLOU064A2302   
• Discontinuation of study treatment prior to Week  12 due to any reason:  ignore (Treatment 
policy strategy), i.e., data collection will be maintained and available measurements post - 
treatment discontinuation will be used as if they had been obtained under the treatment 
assigned at randomization: RDO data collected after study treatment discontinuation  will 
be used for analysis. 
• Intake of rescue  medication  as per protocol, or switch  of background medication, or intake 
of other prohibited medication, or participants non -compliant to treatment prior to Week 
12: ignore (Treatment policy strategy), data collected after these events will be used for analysis.  
• Intake of strongly confounding prohibited medication (e.g., biologics treatment at any time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8): (Composite strategy) measurements  after this event  will be excluded from the analy sis and 
will be imputed using the worst value of the endpoint (e.g., 42 for UAS7 score at week 12 and 21 for co-primary endpoints ISS7 score or HSS7 score at week 12). 
12.4.4 Handling of missing  values not related to intercurrent  event  
The UAS7  score is derived  from the sum of the HSS7  score and the ISS7  score.  The HSS7  and 
ISS7 score will be derived by [CONTACT_201087] 7 days preceding 
the visit, respectively. The daily score (HSS and ISS) will be calculated by [CONTACT_201088],  respectively.  If one of the morning or evening  scores 
is missing, the non- missing score for that day (morning or evening) will then be used as the 
daily score. 
For each weekly  score from  the UPDD (i.e., HSS7,  ISS7),  if one or more  of the daily  scores are 
missing, the following principles will be applied to handle the missing data: 
• The weekly UAS7  is the sum of both the HSS7  score and the ISS7  score and will be 
missing if at least one of them is missing.  
• If a participant has at least 4 non -missing daily (morning or evening) scores within the 7 
days prior to the study visit,  the weekly  score for HSS or ISS will be calculated  as the sum 
of the available eDiary scores of that week, divided by [CONTACT_154562]-missing days, 
multiplied by 7. 
• If there are less than 4 non -missing daily scores within the prior 7 days, then the weekly 
score for HSS or ISS will be considered  as missing  for that week.  Accordingly, no UAS7 
can be calculated.  
Participants who discontinue from study treatment early  due to any reason will be encouraged 
to stay in the study following the procedures. Every effort will be made to continue to follow participants  who discontinued from study treatment.  These are considered  as RDO participants.  
For any intercurrent events handled with treatment policy strategy: If no RDO data was col
lected after study  treatment permanent discontinuation, missing data will be imputed based 
on the following rules:  
• For participants  in the a ctive  treatment arms,  if sufficient  RDO data,  missing  data will be 
imputed using MI based on observed RDO data in the corresponding active arm. If not 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  96 of 133 
Protocol  No. CLOU064A2302   
feasible (e.g., very limited  RDO data),  missing  data will be imputed based  on observed 
data in the placebo arm under the assumption of jump to reference (J2R) using MI.  
• For participants  in the placebo  arm, if sufficient RDO data,  missing  data will be imputed 
using MI based on observed RDO placebo arm data. If not feasible (e.g., ver y limited 
RDO  data),  missing  data will be imputed  using MI under the MAR assumption  based  on 
the observed placebo arm data.  
12.4.5 Sensitivity analyses  
The following sensitivity analysis will be performed for the primary estimand to assess the 
robustness of the e stimation  in the presence of deviations from the assumptions specified  in the 
primary  analysis.  The sensitivity  analysis  will be implemented  with the same  target population, 
the primary variables and the summary measure as for the primary estimand, but using the different assumptions or handling of intercurrent events.  
Sensitivity  analysis : The change from baseline in UAS7,  ISS7  and HSS7  score at week  12 will 
be im puted using zero (i.e., no clinical improvement from baseline) for the intercurrent event 
of “Intake of strongly confounding prohibited medication  (e.g., biologics treatment  at any time 
before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week 8)” handled with composite strategy.  
12.4.[ADDRESS_400522]  is: What  is the effect  of remibrutinib  treatment versus placebo 
on the change from baseline in UAS7 score  (respectively for co -primary endpoints ISS7 and 
HSS7)  after 12 weeks  treatment in adult  patients with CSU who are inadequately controlled  by 
H1-antihistamine  and receiving  a stable locally  label  approved dose of a second generation H1- 
antihistamine, regardless of treatment discontinuation for any reason and regardless of intake of a different second generation H1- antihistamine  and rescue medication, and as if strongly 
confounding prohibited medic ation was not taken? 
The supplementary estimand  is described  by [CONTACT_324425]: 
1. Population: patients with inadequately controlled CSU despi[INVESTIGATOR_157036] H1-antihistamine  who have CSU  duration ≥ 6 months, a UAS7  score ≥ 16, 
ISS7 score ≥ 6 and HSS7 score ≥ [ADDRESS_400523] 7 days prior to randomization. 
2. Endpoint:  C
 hange in UAS7  (respectively  for co-primary  endpoints ISS7  and HSS7)  from 
baseline at Week 12.  
3. Treatment of interest: the randomized study treatment (remibrutinib 25 mg b.i.d. or 
placebo) regardless of treatment compliance, with background medication of local approved second generation H1-antihistamine,  and a different  second  generation H1- 
antihistamine as rescue medicat ion. 
4. Summary Measurement:  the mean difference between treatment groups. 
5. Handling  of intercurrent  events:  
• Discontinuation of study treatment due  to any reason: Treatment policy  strategy  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  97 of 133 
Protocol  No. CLOU064A2302   
• Intake of strongly confounding prohibited medication  (e.g., biologics treatment at any 
time before Week 12, cyclosporin after Week 8, systemic corticosteroids after Week  
8): Hypothetical strategy  (irrespective  of potential occurrence of other intercurrent 
events)  
• Intake of rescue medication,  switc h of background medication,  intake  of other 
prohibited medication: Treatment policy strategy  
12.5 Analysis  supporting  secondary  objectives 
12.5.1 Efficacy  endpoint(s)  
• Improvement of UAS7,  assessed  as absolute change from baseline in  UAS7  score at  Week 
12 (For scenario with ISS7/HSS7 as the co- primary efficacy endpoints).  
The absolute change from baseline in UAS7  score at Week 12 will be analyzed using MMRM 
modeling including treatment group, baseline UAS7 score, randomization strata variables, week 
and both interaction of treatment by [CONTACT_157117]7 score by [CONTACT_157120].  
• Disease activity  control at  Week  12, assessed  as % of participants achieving  UAS7 ≤  6. 
The proportion of participants with UAS7 ≤ 6 at Week 12 will be analyzed using a logistic 
regression model including treatment group, region, prior exposure to anti -IgE biologics and 
baseline UAS7 score as covariate.  
• Comple te absence of hives and itch  at Week  12, assessed  as % of participants  achieving 
UAS7 = 0.  
The proportion of participants with UAS7 = 0 at Week 12 will be analyzed using a logistic regression model including treatment group, region, prior exposure to anti -IgE biologics and 
baseline UAS7 score as covariate.  
• Improvement of severity  of itch,  assessed  as absolute change from baseline in  ISS7  score 
at Week 12 (For scenario with UAS7 as the primary efficacy endpoint). 
The absolute change from baseline in ISS7 score at Week 12 will be analyzed using MMRM modeling including treatment  group, baseline ISS7  score,  randomization  strata  variables,  week 
and both interaction of treatment by [CONTACT_324424]7 score by [CONTACT_157120].  
• Improvement of severity  of hives, assessed  as absolute change from baseline in  HSS7 
score at Week 12 (For scenario with UAS7 as the primary effi cacy endpoint). 
The absolute change from baseline in HSS7 score at Week 12 will be analyzed using MMRM modeling including treatment  group, baseline HSS7  score,  randomization  strata  variables,  week 
and both interaction of treatment by [CONTACT_324426] o f baseline HSS7 score by [CONTACT_157118].  
• Disease activity  control at Week  2, assessed  as proportion of participants  achieving 
UAS7 ≤ 6.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  98 of 133 
Protocol  No. CLOU064A2302   
The proportion of participants with UAS7  ≤ 6 at Week 2 will be analyzed using a logistic 
regression model including treatment group, region, prior exposure to anti -IgE biologics and 
baseline UAS7 score as covariate.  
• No impact  on participants’ dermatology  quality  of life  at Week  12, assessed  as proportion 
of participants achieving DLQI = 0 -1. 
An overall score will be calculated according to the scoring manual. The proportion of 
participants with overall DLQI scores ≤ 1 at Week 12 will be analyzed using a logistic regression model whic h includes treatment group, region, prior exposure to anti -IgE biologics 
and baseline DLQI score.  
• Cumulative number of weeks that  participants  achieve  UAS7  ≤ 6 responses between 
baseline and Week 12.  
The cumulative number of weeks achieving UAS7  ≤ 6 response between  baseline and Week  12 
will be derived based on the eDiary. The cumulative number of weeks achieving UAS7 ≤ 6 response between  baseline and Week  12 will be modelled using a negative binomial regression 
model with log link, using treatment group, region, and prior exposure to anti -IgE biologics. 
The number of weeks stay on the trial will be used as an offset. 
• Cumulative number of weeks that  participants  achieve  AAS7  = 0 responses between 
baseli ne and Week 12. 
The cumulative  number of weeks achieving AAS7  = 0 response between  baseline and Week  12 
will be derived based on the AAS eDiary and UPDD diary. A weekly AAS7 score will be derived by [CONTACT_201089] 7 days preceding the visit,  and ranges from  0 to 
105. If the AAS7 assessment is missing, it will be considered as a non- response for the 
cumulative number of weeks that participants achieve AAS7 = 0 response calculation.  
The cumulative  number of weeks achieving A AS7 = 0 response between  baseline and Week  12 
will be modelled using a negative binomial regression model with log link, using treatment group, region, prior exposure to anti-IgE biologics and baseline AAS7 = 0 status. 
Statistical model, hypothesis, and me thod of analysis for scenario with UAS7 as the 
primary efficacy endpoint  
Testing  strategy  
The following null hypotheses (H0)  will be tested  against the respective alternative  hypotheses 
(HA) in a closed testing procedure  (Bretz  et al 2009), thus controlling the family -wise type I 
error which is set to 0.025 (one- sided):  
Primary:  
UAS7  score change from baseline  at Week 12 
H
01: µ remibrutinib ≥µPlacebo versus H A1: µ remibrutinib < µ Placebo  
where  µ is the mean  change from baseline in UAS7  at Week  12, 
Secondaries:  
• UAS
7 ≤ 6 at Week  12 
H02: p remibrutinib ≤pPlacebo versus H A2: p remibrutinib >pPlacebo  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  99 of 133 
Protocol  No. CLOU064A2302   
where  p is the proportion of participants  achieving  UAS7  ≤ 6 at Week  12, 
• UAS7  = 0 at Week  12 
H03: p remibrutinib ≤pPlacebo versus H A3: p remibrutinib >pPlacebo  
where  p is the proportion of participants  achieving  UAS7  = 0 at Week  12, 
• ISS7  score change  from baseline  at Week  12 
H04: µ remibrutinib ≥µPlacebo versus H A4: µ remibrutinib < µ Placebo  
where  µ is the mean  change from baseline in ISS7  at Week  12, 
• HSS7  score change from baseline  at Week 12 
H05: µ remibrutinib ≥µPlacebo versus H A5: µ remibrutinib < µ Placebo  
where  µ is the mean change from baseline in HSS7 at Week 12, 
• UAS7  ≤ 6 at Week  2 
H06: p remibrutinib ≤pPlacebo versus H A6: p remibrutinib >pPlacebo  
where  p is the proportion of participants  achieving  UAS7  ≤ 6 at Week  2, 
• DLQI  = 0/1 at Week  12 
H07: p remibrutinib ≤pPlacebo versus H A7: p remibrutinib >pPlacebo  
where  p is the proportion of participants  achieving  DLQI  = 0/1 at Week  12, 
• Cumulative  number  of weeks with  an UAS7  ≤ 6 response between  baseline  and Week 
12 
H08: µ remibrutinib ≤µPlacebo versus H A8: µ remibrutinib > µ Placebo  
where  µ is the mean  cumulative  number of weeks  that participants achieve UAS7  ≤ 6 response 
between baseline and Week 12, 
• Cumulative  number  of weeks with  an AAS7=  0 response between  baseline  and Week 
12 
H09: µ remibrutinib ≤µPlacebo versus H A9: µ remibrutinib > µ Placebo  
where  µ is the mean  cumulative  number of weeks  that participants achieve AAS7  = [ADDRESS_400524]  represents  the significance  level.  The arrow  and value  inside  the square 
represent the "alpha- propagation".  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400525] hypothesis is tested with full level alpha (0.025 one -sided). If significant, the second 
hypothesis is tested with full- level alpha; otherwise, the testing procedure stops. The testing is 
strictly  hierarchical,  so that null hypotheses can be tested  along the pre- defined  order at the level 
assigned  until a null hypothesis cannot be rejected,  at which  point the testing  stops. Furthermore, 
the testing strategy reflects the separation of primary and secondary endpoints, so that 
hypotheses related to secondary endpoints will only be tested if the null hypothesis related to the primary endpoint is rejected.  
Statistical model, hypothesis, and method of analysis for scenario with  ISS7/HSS7 as the 
co-primary efficacy endpoints  
Testing  strategy  
The following null hypotheses (H
0) will be tested  against  the respective alternative  hypotheses 
(HA) in a closed testing procedure  (Bretz  et al 2009), thus controlling the family -wise type I 
error which is set to 0.025 (one- sided):  
Co-Primary:  
• ISS7  score change from  baseline at  Week  12 
H01a: µ remibrutinib ≥µPlacebo versus H A1a: µ remibrutinib < µ Placebo 
where  µ is the mean  change from baseline in ISS7  at Week  12, 
• HSS7  score change from baseline  at Week 12 
and H 01b: µ remibrutinib ≥µPlacebo versus H A1b: µ remibrutinib < µ Placebo 
where  µ is the mean  change from baseline in HSS7  at Week  12, 
Secondaries:  
• UAS7  score change from baseline  at Week 12 
H02: µ remibrutinib ≥µPlacebo versus H A2: µ remibrutinib < µ Placebo  
where  µ is the mean  change from baseline in UAS7  at Week  12, 
• UAS7  ≤ 6 at Week  12 
H03: p remibrutinib ≤pPlacebo versus H A3: p remibrutinib >pPlacebo  
where  p is the proportion of participants  achieving  UAS7  ≤ 6 at Week  12, 
• UAS7  = 0 at Week  12 
H04: p remibrutinib ≤pPlacebo versus H A4: p remibrutinib >pPlacebo  
where  p is the  proportion of participants  achieving UAS7 = 0 at Week  12, 
• UAS7≤  6 at Week  2 
H05: p remibrutinib ≤pPlacebo versus H A5: p remibrutinib >pPlacebo  
where  p is the proportion of participants  achieving  UAS7  ≤ 6 at Week  2, 
• DLQI  = 0/1 at Week  12 
H06: p remibrutinib ≤pPlacebo versus H A6: p remibrutinib >pPlacebo  
where  p is the proportion of participants  achieving  DLQI  = 0/1 at Week  12, 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  101 of 133 
Protocol  No. CLOU064A2302   
• Cumulative  number  of weeks with  an UAS7≤6  response between  baseline  and Week 
12 
H07: µ remibrutinib ≤µPlacebo versus H A7: µ remibrutinib > µ Placebo  
where  µ is the mean  cumulative  number of weeks  that participants achieve UAS7  ≤ 6 response 
between baseline and Week 12, 
• Cumulative  number  of weeks with  an AAS7=  0 response between  baseline  and Week 
12 
H08: µ remibrutinib ≤µPlacebo versus H A8: µ remibrutinib > µ Placebo  
where µ is the mean cumulative number of weeks that participants achieve AAS7=0 response 
between baseline and Week 12, 
A graphical representation  of the testing  strategy  is presented  in Figure 12-2 
Figure 12-2 Testing strategy with ISS7/HSS7 as the co-primary endpoints  
 
The value  inside the circle  represents  the significance  level.  The arrow  and value  inside  the square 
represent the "alpha- propagation".  
The first two hypotheses are tested:  both H 1a and H 1b are tested  with full level  alpha  (0.025 one- 
sided) and only if both are rejected,  then H2 hypothesis is tested  with full-level  alpha;  otherwise, 
the testing procedure stops. The testing is strictly hierarchical, so that null hypot heses can be 
tested  along the pre- defined  order at the level  assigned  until a null hypothesis cannot be rejected, 
at which point the testing stops. Furthermore, the testing strategy reflects the separation of 
primary and secondary endpoints, so that hypotheses related to secondary endpoints will only be tested if both null hypotheses related to the co- primary endpoints are rejected. 
12.5.2 Safety endpoints  
For all safety analyses, the SAF will be used. All listings and tables will be presented by [CONTACT_1570].  
Safety summaries (tables, figures) include only data from the on -treatment period with the 
exception of baseline data which  will also be summarized  where  appropriate (e.g., change from 
baseline summaries).  In addition, a separate  summary  for death  including  on treatment  and post 
treatment deaths will be provided. In particular, summary  tables for adverse events (AEs) will 
summarize only on- treatment events, with a start date during the on -treatment period 
(treatment -emergent AEs).  
The on-tr
eatment  period lasts from the date of first administration  of study treatment to [ADDRESS_400526] on: 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  102 of 133 
Protocol  No. CLOU064A2302   
• the date of  the last actual  dose intake of remibrutinib double- blind 
• the date of first dose intake of open -label  treatment 
Adverse events  
All information  obtained on adverse events will be displayed by [CONTACT_131373].  
The number (and percentage) of participants with treatment emergent adverse events (events 
started after the first dose of study medication or events present prior to start of double -blind 
treatment but increased  in severity  based  on preferred  term) will be summarized  in the following 
ways:  
• by [CONTACT_3148],  primary  system  organ class and preferred  term.  
• by [CONTACT_3148], primary  system organ class,  preferred term and maximum  severity.  
• by [CONTACT_3148], Standardized MedDRA  Query  (SMQ) and preferred  term.  
Separate summaries  will be provided for study medication  related  adverse events,  death, serious 
adverse events, other significant adverse events leading to discontinuation by [CONTACT_324427]. 
The number (and proportion) of participants with adverse events of special interest for 
remibrutinib (related to identified and potential risks) will be summarized by [CONTACT_324428]. 
A participant  with multiple  adverse  events within  a primary  system  organ  class is only counted 
once towards the total of the primary system organ class.  
Vital signs  
All vital signs data will be listed by [CONTACT_1570], participant, and visit/time and if ranges 
are available,  abnormalities  (and relevant changes) will be flagged. Summary sta tistics will be 
provided by [CONTACT_10659].  
12-lead ECG  
PR, QRS,  QT, QTcF,  and RR intervals  will be obtained from 12-lead ECGs  for each participant 
during the study. ECG data will be read and interpreted centrally. 
All ECG data will be listed  by [CONTACT_2948], participant  and visit/time,  abnormalities  will be 
flagged. Summary statistics will be provided by [CONTACT_10659]/time.  
Clinical  laboratory evaluations  
All laboratory  data will be listed  by [CONTACT_2948],  participant,  and visit and if normal ranges 
are available abnormalities will be flagged. Summary statistics for the change from baseline 
will be provided by [CONTACT_10659]. Shift tables using the low/normal/high/ (low and  
high) classification will be used to compare baseline to th e worst on- treatment value.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  103 of 133 
Protocol  No. CLOU064A2302   
  
 
 
 
 
 
 
 
 
     
 
 
 
  
 
 
 
 
  
  
 
12.5.7 Patient reported outcomes  
 
 
 
 
 
  
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  104 of 133 
Protocol  No. CLOU064A2302   
 
 
D
ermatology Life Quality Index (DLQI)  
 
 
The proportion of participants achieving DLQI = 0- 1 will be provided by [CONTACT_29013].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400527] completed the treatment period (a second, nearly identical Phase 3 study will be conducted in parallel). The minimum of 150 participants reaching week 52 should enable analysis on a minimum of 100 participants expos ed to remibrutinib for 52 weeks, considering 
the initial randomization to either the remibrutinib or the placebo arm (2:1). The results of the primary analysis will further inform decision -making for the remibrutinib development 
program. Formal testing of the primary endpoint and key secondary endpoints will only be 
performed at the primary analysis time point; thus, no adjustment for multiplicity is required.  
After the primary  analysis and/or after all participants entered the open label treatment period, 
additional optional interim analyses may be conducted at the discretion of the Sponsor to support potential Health Authority requests and interactions (these interim analyses are not expected  to have any impact  on the conduct or scientific  integrity  of the study). The decision to 
conduct optional interim analyses and the timing of these analyses will be documented in the Statistical Analysis Plan prior to the conduct of any interim analysis.  These interim analyses 
will be performed and interpreted by [CONTACT_324429].  
12.8 Sample size calculation  
12.8.1 Primary  endpoint(s)  
In order to fulfill registration and ICH E1 requirements on the number of participants treated 
for 6 months and 12 months in the development program, a sample size of 300 participants in 
the active arm and 150 in the placebo arm is targeted. Hence, the total sample size is 450 
randomized participants.  
From an efficacy point of view, the sample size justification is based on UAS7 change from baseline (for scenario with one primary endpoint), ISS7 and HSS7 change from baseline (for scenario  with co-primary  endpoints) and achievement  of UAS7  ≤ 6 and UAS7  = 0 at Week  12. 
To avoid assigning an unnecessary  large  number of participants  to placebo,  participants will be 
randomized in a 2:1 ratio to remibrutinib 25 mg b.i.d. and placebo arms, respectively. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  106 of 133 
Protocol  No. CLOU064A2302   
All calculations were performed with nQuery  Advisor [IP_ADDRESS] and Ri386 4.0.2 softwares.  
For scenario  with  UAS7  as the primary  efficacy  endpoint 
UAS7 chan ge from baseline at Week 12 
Approximately 10% drop- out is expected at week 12, thus with 270 participants in the active 
arm and 135 participants  in the placebo  arm, this gives a nominal power of more  than > 99% to 
detect  a difference  between  remibrutinib  and placebo  if the mean  change of UAS7  from baseline 
to Week [ADDRESS_400528] deviation of 
approximately 12 (based on the primary endpoint analysis of Phase 2b study (CLOU064A2201)), based on a t-test, assuming type I error 0.025 (one-sided). 
For scenario  with  ISS7/HSS7  as the co-primary  efficacy  endpoints 
ISS7 change from baseline at Week 12  
Approximately 10% drop- out is expected at week 12, thus with 270 participants in the active 
arm and 135 participants  in the placebo  arm, this gives a nominal power of more  than > 99% to 
detect  a difference between  remibrutinib  and placebo if the mean  change of ISS7  from baseline 
to Week [ADDRESS_400529] deviation of 
approximately 6 (based  on the primary  endpoint analysis of Phase 2b study (CLOU064A2201)), 
based on a t-test, assuming type I error 0.025 (one- sided).  
HSS7  change from baseline at  Week  12 
Approximately 10% drop- out is expected at week 12, thus with 270 participants in the active 
arm and 135 participants in the placebo arm, this  gives a nominal power of more than  > 99% 
to detect a difference  betw een remibrutinib and placebo if the mean change of HSS7 from 
baseline to Week [ADDRESS_400530] deviation of approximately 6 (based  on the primary  endpoint analysis of Phase 2b study (CLOU064A2201)), 
based on a t-test, assuming type I error 0.025 (one- sided).  
With 300 participants in the active arm and 150 participants in the placebo arm randomized in this study, this gives a power of more than > 90% to detect a difference  between remi brutinib 
and placebo  in both mean  change of ISS7  and HSS7  from baseline  to Week  12 when  correlation 
between  endpoints is 0 (conservative assumption, as higher the correlation  is, higher the power 
is). 
12.8.2 Secondary  endpoint(s)  
Achievement  of UAS7  = 0 at Week  12 
Similarly,  with approximately  10% drop-out at week  12, then with 270 participants  in the active 
arm and 135 participants  in the placebo  arm, this gives a nominal power of more  than > 99% to 
detect a difference between remibrutinib and placebo arm assuming a proportion of complete response (UAS7  = 0) of 0.[ADDRESS_400531] with a 0.025 one -sided signi ficance level.  
Achievement  of UAS7  ≤6 
 at Week  12 
Similarly,  with approximately  10% drop-out at week  12, then with 270 participants  in the active 
arm and 135 participants  in the placebo  arm, this gives a nominal power of more  than > 99% to 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400532] a difference between remibrutinib and placebo arm assuming a proportion of disease 
activity  control response  (UAS7  ≤ 6) of 0.[ADDRESS_400533] with a 0.025 one- sided significance 
level.  
The primary and secondary endpoints analyses are planned to use the multiple testing strategy to control the family -wise error at α = 0.025 (one -sided). It is considered, however, this 
hierarchical  approach could  impact the sample size compared to the separate endpoint approach, 
which depends on how the recycled alpha will be used. In both scenarios, the “family- wise” 
power (power to reject all null hypotheses) is > 90% when correlation between endpoints is 0 (Higher the correlation is, higher the power is).  
 
13 Ethical  considerations  and administrative procedures  
13.1 Regulatory and ethical  compliance 
This clinical study was designed and shall  be implemented,  executed  and reported  in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local  regulations (including European Directive  2001/20/EC, US CFR 21), and with the ethical 
principles laid down in the Declaration of Helsinki. 
13.2 Responsibilities  of the investigator  and IRB/IEC  
Before  initiating  a trial, the investigator/institution  must obtain  approval/favorable opi[INVESTIGATOR_131312]/Independent Ethics  Committee  (IRB/IEC) for the trial protocol, 
written  informed  consent form,  consent form  updates,  participant recruitment procedures (e.g. , 
advertisements)  and any other written  information  to be provided to participants.  Prior to study 
start,  the investigator  is required to sign a protocol signature [CONTACT_131378]/her  agreement 
to conduct the study in accordance with these documents and all of the instructions and procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] 
monitors,  auditors,  [COMPANY_001]  Quality  Assurance representatives,  designated  agents of [COMPANY_001], 
IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is requested  by a regulatory  authority, the investigator must inform [COMPANY_001]  immediately  that this 
request has been made.  
13.[ADDRESS_400534]. In addition, after study completion (defined as last patient last  visit) 
and finalization  of the study report the results  of this trial will be submitted  for publication and 
posted in a publicly accessible database of clinical  trial results,  such as the [COMPANY_001]  clinical  trial 
results website and all required Health Authority websites (e.g., Clinicaltrials.gov, EudraCT 
etc.).  
For details on the [COMPANY_001]  publication policy including authorship criteria,  please  refer  to 
the [COMPANY_001] publication policy training materials that were provided at the trial investigator 
meetings.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400535] Quality Management System (QMS) that includes all activities 
involved in quality as surance and quality control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.  
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], 
independent from those involved in conducting, monitoring  or performing  quality control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducted to assess GCP  compliance with global and local  regulatory  requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes. 
13.[ADDRESS_400536] ribution to study participants at the timepoints indicated. If compliance is 
impacted by [CONTACT_6664], sites may discuss modifications to these requirements with [COMPANY_001].  
• Thank You letter 
• Plain  language trial summary  - after CSR publication  
• Individual study results - after CSR publication  
• Trial  Feedback  Questionnaires  (TFQ)  - 3 timepoints: at the start,  during and at the end of 
the trial.  
 
[ADDRESS_400537] be considered a protocol amendment, and unless such an amendment is agreed upon by [CONTACT_6669]/IEC  and Health  Authorities, where  required, it cannot be implemented.  
14.[ADDRESS_400538] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to implementation.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  109 of 133 
Protocol  No. CLOU064A2302   
Only amendments that are required for participant safety may be implemented immediately 
provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected  to take any immediate  action  required for the safety  of any participant  included in this 
study, even  if this action  represents a deviation from the protocol. In such cases,  [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400539] D, Gessier  F, Janser  P, et al (2020) Discovery  of LOU064 (Remibrutinib),  a Potent and 
Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase. J Med Chem p. 5102-5118. 
Bernstein  JA, Lang  DM, Khan  DA, et al (2014) The diagnosis and management  of acute  and 
chronic urticaria: 2014 update. J Allergy Clin Immunol p. 1270-7. 
 
Bretz  F, Maurer  W, Brannath W, et al (2009) A graphical approach  to sequentially  rejective 
multiple test procedures. Stat Med p. 586-604. 
Brukinsa® Prescribing Information (2021) BeiGene, Brukinsa (zanubrutinib) 80 mg capsule 
(Internet). Available from: <https://www.brukinsa.com/prescribing-information.pdf>  
(Accessed 22 -Mar-2022). 
Brukinsa® SmPC  (2022) BeiGene,  Brukinsa (zanubrutinib) 80 mg capsule (Internet).  Available 
from: <https://www.ema.europa.eu/en/documents/product- information/brukinsa -epar-product-  
information_en.pdf> (Accessed 22- Mar-2022). 
Bye AP, Unsworth AJ, Vaiyapuri S, et al (2015) Ibrutinib inhibits platelet integrin αIIbβ3 
outside- in signaling and thrombus stability but not adhesion to collagen. Arterioscler Thromb 
Vasc Biol; 35(11):2326-35. 
Calquence® Prescribing Information (2019) [COMPANY_008], Calquence (acalabrutinib) 100 mg 
capsules (Internet).  Available from: <https://www.azpi[INVESTIGATOR_24309].com>  (Accessed  26-Apr-2022).  
Calquence®  SMPC  (2021) [COMPANY_008],  Calquence (ascalabrutinib) 100 mg capsules 
(Internet). Available from: <https://www.ema.europa.eu/en/documents/product-  
information/calquence- epar-product-information_en.pdf> (Accessed 26- Apr-2022). 
Dispenza MC, Pongracic JA, Singh AM, et al (2018) Short- term ibrutinib  therapy suppresses 
skin test responses and eliminates IgE -mediated basophil activation in adults with peanut or 
tree nut allergy. J. Allergy Clin. Immunol. p. 1914-1916.e7. 
Dispenza MC, Regan JA, Bochner BS (2017) Potential applications of Bruton's tyrosine 
kinase inhibitors  for the prevention of allergic  reactions.  Expert Rev Clin Immunol p. 921- 
923. 
Ferrer  M (2015)  Immunological events in chronic spontaneous urticaria.  Clin Transl Allergy  
p. 30.  
Farez et al (2019) Practice guideline update summary: Vaccine- pr eventable infections and 
immunization  in multiple  sclerosis:  Report of the Guideline Development, Dissemination,  and 
Implementation  Subcommittee of the American  Academy  of Neurology. Neurology. 2019 Sep 
24;93(13):584- 594 
Finlay  AY (2005) Current severe psoriasis and the rule of tens. Br. J.  Dermatol.  p. 861- 7. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  111 of 133 
Protocol  No. CLOU064A2302   
Finlay  AY, Khan  GK (1994) Dermatology Life Quality  Index (DLQI) --a simple  practical 
measure for routine clinical use. Clin. Exp. Dermatol. p. 210-6. 
Futatani T, Watanabe C, Baba Y, et al (2001) Bruton's tyrosine kinase is present in normal 
platelets  and its absence  identifies  patients with X-linked  agammaglobulinaemia and carrier 
females. Br J Haematol p. 141 -9. 
Gabi zon R, London N (2020) A Fast and  Clean BTK Inhibitor. J Med  Chem p. 5100- 5101.  
Gonçalo M, Gimenéz -Arnau  A, Al-Ahmad  M, et al (2021) The global burden of chronic 
urticaria for the patient and society. Br J Dermatol p. 226-236. 
Greaves MW (2003) Chronic idiopathic urticaria.  Curr Opin Allergy  Clin Immunol p. 363- 8. 
Guillén -Aguinaga S, Jáuregui Presa  I, Aguinaga-Ontoso E, et al (2016) Updosing nonsedating 
antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta - 
analysis. Br J Dermatol p. 1153-1165. 
 
 
Hawro  T, Ohanyan T, Schoepke N, et al (2018) The Urticaria  Activity  Score -Validity, 
Reliability, and Responsiveness. J Allergy Clin Immunol Pract p. 1185-1190.e1. Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton's tyrosin e kinase in B cell 
malignancies. Nat Rev Cancer p. 219-32. Hongbo Y, Thomas CL, Harrison  MA, et al (2005) Translating  the science of quality  of life 
into practice: What do dermatology life quality index scores mean? J. Invest. Dermatol. p. 
659-64. 
Imbruvica
® Prescribing  Information  (2020) JanssenCilag  International NV, Imbruvica 
(ibrutinib)  [ADDRESS_400540] capsules  (Internet).  Available  from: 
<https://www.imbruvica.com/files/prescribing -information.pdf>  (Accessed  on 26- Apr-2022).  
Imbruvica® SmPC  (2022) Janssen -Cilag  International NV, Imbruvica (ibrutinib) [ADDRESS_400541] Characteristics. Available from < https://www.ema.europa.eu/en/documents/product -info
 rmation/imb ruvica -epar-product - 
information_en.pdf> (Accessed on 26- Apr-2022). 
Kaplan  A, Ferrer M, Bernstein  JA, et al (2016) Timing  and duration of omalizumab  response 
in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol p. 474-81. 
Kaplan  AP, Horáková Z, Katz  SI (1978) Assessment  of tissue fluid  histamine  levels  in 
patients with urticaria. J Allergy Clin Immunol p. 350 -4. 
Kaul  M, Storim J, End P, et al (2019) LOU064: A highly selective and potent covalent  oral 
BTK inhibitor with promising pharmacodynamic effects in skin p. 333-376. Kaul  M. et al (2021) Remibrutinib  (LOU064): A selective potent oral BTK inhibitor with 
promising clinical safety and pharmacodynamics in a randomized phase I trial p. 1-13. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400542]  F, et al (2017) The burden of chronic spontaneous urticaria 
is substantial: Real -world evidence from ASSURE-CSU. Allergy p. 2005-2016. 
Maurer  M, Rosén  K, Hsieh  HJ, et al (2013) Omalizumab  for the treatment of chronic 
idiopathic or spontaneous urticaria. N Engl J Med p. 924-35. 
 
 
 
Młynek A, Zalewska-Janowska A, Martus P, et al (2008) How to assess disease activity  in 
patients with chronic urticaria? Allergy p. 777-80. 
O'Donnell BF, Lawlor  F, Simpson J, et al (1997) The impact of chronic urticaria  on the 
quality of life. Br J Dermatol p. 197-201. 
 
Pleyer  et al (2021) Effect  of Bruton tyrosine kinase inhibitor on efficacy  of adjuvanted 
recombinant hepatitis B and zoster vaccines. Blood. 2021 Jan 14;137(2):185-189 
Powell  RJ, Du Toit GL, Siddique N, et al (2007) BSACI  guidelines for the management of 
chronic urticaria and angio -oedema. Clin Exp Allergy p. 631-50. 
Regan JA, Cao Y, Dispenza MC, et al (2017) Ibrutinib, a Bruton's tyrosine kinase inhibitor 
used for treatment of lymphoproliferative  disorders,  eliminates  both aeroallergen  skin test and 
basophil activation test reactivity. J. Allergy Clin. Immunol. p. 875-879.e1. 
 
 
Rip J, Van De r Ploeg  EK, Hendriks RW, et al (2018) The Role  of Bruton's Tyrosine Kinase in 
Immune Cell Signaling and Systemic Autoimmunity. Crit Rev Immunol p. 17 -62. 
Saini  SS, Kaplan  AP Chronic Spontaneous Urticaria: The Devil's  Itch. J Allergy  Clin 
Immunol Pract p. 1097-1106. 
Smiljkovic  D, Blatt K, Stefanzl  G, et al (2017) BTK inhibition  is a potent approach to block 
IgE-mediated histamine release in human basophils. Allergy p. 1666-1676. 
Weber  et al (2021) Balancing Potential  Benefits and Risks  of Bruton Tyrosine Kinase 
Inhibitor Therapi[INVESTIGATOR_157054] -19 Pandemic. Neurol 
Neuroimmunol Neuroinflamm 2021;8:e10  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  113 of 133 
Protocol  No. CLOU064A2302   
 
 
Wel
ler K, Groffik  A, Magerl  M, et al (2013) Development, validation, and initial results  of 
the Angioedema Activity Score. Allergy p. 1185-92. 
Zuberbier T, Aberer  W, Asero  R, et al (2014) The EAACI/GA(2)  LEN/EDF/WAO  Guideline 
for the definition, classification, diagnosis, and management of urticaria: the 2013 revision 
and update. Allergy p. 868-87. 
Zuberbier T, Aberer  W, Asero  R, et al (2018) The EAACI/GA²LEN/EDF/WAO guideline for 
the definition, classification, diagnosis and management of urticaria. Allergy p. 1393-1414. Zuberbier T, Asero  R, Bindslev- Jensen  C, et al (2009) EAACI/GA(2)LEN/EDF/WAO 
guideline: management of urticaria. Allergy p. 1427-43. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  114 of 133 
Protocol  No. CLOU064A2302   
16 Appendices 
16.1 Appendix 1: Clinically  notable laboratory values and vital signs  
The following  specific criteria  have  been  identified  for this study. Should these  criteria  be met, 
a re- test must be done within [ADDRESS_400543] assessment. Discontinuation of the study 
treatment should be considered if the abnormal hematology parameter is confirmed:  
• Hemoglobin: < 10 g/dl 
• Platelets: < 75 000/mm3 
• Leukocytes: < 3 000/mm3 
• Neutrophils: < 1 500/mm3 
For all other laboratory assessments, the central laboratory will flag laboratory values falling 
outside of the normal ranges on the central laboratory report (which the investigator should review  and sign-off) and the investigator will report any values  considered  clinically  significant 
in the eCRF.  
Refer  to Section  16.2 for clinically  notable laboratory  values  for hepatotoxicity. 
Refer  to Section  16.3 for clinically  notable laboratory  values for nephrotoxicity. 
Notable values for vital signs and change from baseline will be summarized.  
Notable values are defined  as follows: 
• heart rate of < 50 or > 100 bpm  
• systolic blood pressure of < 90 and ≥ 140 mmHg  
• diastolic  blood  pressure of < 60 and ≥ 90 mmHg  
For ECGs, a notable QTc value is defined as an absolute QTc (Fridericia’s) interval of greater than 450 msec for males or greater than 460 msec for females or QTcF increase of ≥60 msec compared to baseline QTcF value – all such ECGs will be flagged by [CONTACT_157126]’s 
cardiologist and require assessment for clinical relevance by [CONTACT_093]. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  115 of 133 
Protocol  No. CLOU064A2302   
16.2 Appendix 2: Liver  event  and laboratory  trigger  definitions  & 
follow -up requirements  
Table 16-1 Liver  event and laboratory trigger  definitions  
 
Definition/ threshold  
Liver  laboratory  triggers  
If ALT,  AST and total bilirubin  normal  at 
baseline:  • ALT or AST > 5 × ULN 
• ALP > 2 × ULN (in the absence of known 
bone pathology)  
• Total  bilirubin  > 3 × ULN (in the absence of 
known Gilbert syndrome)  
• ALT or AST > 3 × ULN and INR > 1.5 
• Potential  Hy’s Law cases  (defined as ALT or 
AST > 3 × ULN and Total  bilirubin  > 2 × ULN 
[mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)  
• Any clinical  event  of jaundice (or equivalent 
term)  
• ALT or AST > 3 × ULN accompanied by 
(general)  malaise,  fatigue,  abdominal  pain, 
nausea, or vomiting, or rash with 
eosinophili a 
• Any adverse event  potentially  indicative  of a 
liver toxicity  
 
ALP:  Alkaline  phosphatase,  ALT:  Alanine aminotransferase,  AST:  Aspartate  aminotransferase,  ULN: 
upper limit of normal  
 
Table 16-[ADDRESS_400544],  and 
TBL 
 
  Action  Taken  
Trigger Liver  Symptoms Monitoring  Follow- up 
Monitoring  Study 
Medication  
ALT 
ALT > [ADDRESS_400545] 
TBL normal, or 
no change for 
participantswith 
Gilbert’s 
syndrome  None Measure ALT, AST,  ALP,  GGT, 
TBL, INR,  
albumin,  CK, and 
GLDH in 48 -72 
hours  Follow  up for 
symptoms  Continue dosing 
ALT > [ADDRESS_400546] 
for more  than two 
weeks  
TBL normal, or no change for 
participants  with 
Gilbert’s 
syndrome  None Measure ALT, 
AST,  ALP,  GGT, 
TBL, INR,  
albumin,  CK, and 
GLDH in 48 -72 
hours  Follow -up for 
symptoms  
Initiate close 
monitoring and 
workup for 
competing 
etiologies  Interrupt  
Study drug can be restarted only 
if another etiology 
is identiﬁed and 
liver enzymes 
return to baseline 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  116 of 133 
Protocol  No. CLOU064A2302   
 
  Action  Taken  
Trigger  Liver  Symptoms  Monitoring  Follow -up 
Monitoring  Study 
Medication  
ALT > [ADDRESS_400547] 
TBL normal, or 
no change for 
participants  with 
Gilbert’s 
syndrome  None Measure ALT, 
AST,  ALP,  GGT, 
TBL, INR,  
albumin,  CK, and 
GLDH in 48 -72 
hours  Follow -up for 
symptoms  
Initiate close 
monitoring and 
workup for 
competing 
etiologies  Interrupt  
Study drug can be restarted only 
if another etiology 
is identiﬁed and 
liver enzymes 
return  to baseline  
ALT > [ADDRESS_400548] 
TBL > [ADDRESS_400549] 
(or INR > 1.5)  
For participants 
with Gilbert’s syndrome: 
Doubling of direct 
bilirubin  None Measure ALT, 
AST,  ALP,  GGT, 
TBL, INR,  
albumin,  CK, and 
GLDH in 48 -72 
hours  Follow -up for 
symptoms  
Initiate close monitoring and 
workup for competing etiologies  Interrupt  
Study drug can be restarted only if another etiology 
is identiﬁed and liver enzymes return to baseline 
ALT > [ADDRESS_400550],  ALP,  GGT, 
TBL, INR,  
albumin,  CK, and 
GLDH in 48 -72 
hours  Follow -up for 
symptoms  
Initiate close 
monitoring and 
workup for competing 
etiologies  Interrupt  
Study drug can be restarted only if another etiolo gy 
is identiﬁed and liver enzymes 
return  to baseline  
Total  Bilirubin  (isolated)  
>1.5 – 3.[ADDRESS_400551]  Repeat  LFTs 
within 48 -72 
hours  Monitor LFTs weekly until resolution
1 to ≤ 
Grade 1 or to 
baseline  Continue dosing 
> 3 - 10 × ULN (in 
the absence of 
known Gilbert 
syndrome)   Repeat  LFT 
within  48-[ADDRESS_400552] the AE 
and contributing factors (e.g., conmeds, med 
hx, lab) in the 
appropriate CRF Monitor LFTs 
weekly until resolution
1 to ≤ 
Grade 1 or to 
baseline (ALT, 
AST, total bilirubin, Alb, 
PT/INR,  ALP and 
GGT)  
Test for 
hemolysis (e.g., reticulocytes, 
haptoglobin, 
unconjugated 
[indirect]  bilirubin)  Interrupt  
> [ADDRESS_400553], total bilirubin, Alb, PT/INR,  ALP and 
GGT until  Discontinue treatment immediately  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400554] the AE 
and contributing factors (e.g., 
conmeds, med 
hx, lab) in the 
appropriate  CRF resolution1 (frequ 
ency at investigator 
discretion)   
General  Clinical  Symptoms  
Any AE potentially  indicative  of a liver 
toxicity including: (General) malaise, 
fatigue, abdominal pain, nausea, or 
vomiting, or rash with eosinophilia  Establish 
causality  
Record the AE and contributing factors(e.g., 
conmeds, med 
hx, lab) in the 
appropriate  CRF Investigator discretion  Consider  study 
treatment interruption or 
discontinuation 
1 Resolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values  at three subsequent  monitoring visits at least  2 weeks  apart,  (3) remain at elevated level after a 
maximum of 6 months, (4) liver transplantation, and (5) death  
Alb: Albumin, ALP: Alkaline phosphatase, ALT: Alanine aminotransferase, AST: Aspartate 
aminotransferase, CK: Creatinine kinase, CRF: Case report form, GGT: Gamma -glutamyl transferase, 
GLDH:  glutamate  dehydrogenase,  INR: International  Normalized Ratio,  LFTs: Liver  function  tests,  Med 
Hx: medical history, PT: Prothrombin time, TBL: Total bilirubin, ULN: upper limit of normal  
 
Table 16-3 Follow  up requirements for liver laboratory triggers - Isolated 
Hyperbilirubinemia  
 
Criteria  Actions  required  Follow -up monitoring  
Total  Bilirubin  (isolated)  
>1.5 – 3.[ADDRESS_400555] - Maintain  treatment - Repeat 
LFTs within 48- 72 hours  Monitor  LFTs  weekly  until 
resolution to ≤ Grade 1 (≤ 1.[ADDRESS_400556])  
or to baseline  
> 3 - 10 × ULN (in the 
absence of  
known  Gilbert  syndrome)  - Interrupt  treatment  
- Repeat  LFT within  48-[ADDRESS_400557]  the AE and 
contributing factors  
(e.g.,  conmeds,  med hx, lab) in 
the appropriate CRF  - Monitor  LFTs  weekly  until 
resolution to ≤ Grade 1 (≤ 1.[ADDRESS_400558]) or to 
baseline (ALT,  AST,  total 
bilirubin,  Alb, PT/INR,  ALP and 
GGT)  
- Test for hemolysis  (e.g., 
reticulocytes,  
haptoglobin,  unconjugated 
[indirect] bilirubin)  
> [ADDRESS_400559],  total bilirubin,  Alb, 
PT/INR, ALP and GGT until 
resolution (frequency at 
investigator discretion)  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  [ADDRESS_400560]  the AE and 
contributing factors  
(e.g.,  conmeds,  med hx, lab)in 
the appropriate CRF   
Any AE potentially  indicative of 
a liver toxicity  - Consider study treatment 
interruption or discontinuation  
- Hospi[INVESTIGATOR_131318]  
- Establish causality - Record 
the AE and contributing factors 
(e.g.,, conmeds,  med hx, lab) in 
the appropriate CRF  Investigator  discretion  
Based on investigator’s discretion investigation(s) for contributing factors for the liver event can include: Serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease. 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  119 of 133 
Protocol  No. CLOU064A2302   
16.3 Appendix 3: Specific  Renal  Alert  Criteria  and Actions  and Event 
Follow -up 
Table 16-4 Specific renal alert criteria and actions  
 
Renal  Event  Actions  
Confirmed serum  creatinine increase 25 – 49% • Consider  causes  and possible interventions  
• Follow  -up within  2-5 days;  increase fluid 
intake before assessment if appropriate  
• Repeat  follow -up (every  2-5 days)  until 
creatinine is <125%  of baseline value  
Serum  creatinine increase 50 % 1 • Consider  causes  and possible interventions 
and initiate renal investigation  
• Repeat  assessment  within  24-48 h if 
possible 
• Interruption of study  drug 
• Close  follow -up (every  24-48 h), consider 
participant  hospi[INVESTIGATOR_157056] <125% of  
baseline value 
New onset  dipstick  proteinuria ≥ 31 
When  urine  proteins  are measured as a follow - 
up of positive urine dipstick measurements:  
Protein -creatinine ratio (PCR) ≥ 1g/g Cr (or 
mg/mmol equivalent as converted by [CONTACT_297235])  • Consider  causes  and possible interventions  
• Assess serum  albumin  & serum  total protein  
• Repeat  assessment  to confirm  
• Consider  drug interruption or discontinuation 
unless other causes are diagnosed and  
corrected 
New onset  hematuria ≥ 31 on urine  dipstick  • Assess and document  
• Repeat  assessment  to confirm  
• Distinguish  hemoglobinuria from hematuria 
• Urine  sediment  microscopy  
• Assess sCr 
• Exclude  infection,  trauma,  bleeding from the 
distal urinary tract/bladder, menstruation  
• Consider  bleeding disorder  
[ADDRESS_400561] initiated or contributed to the event:  
• Blood pressure assessment  (after  5-minute rest, with an appropriate cuff size) 
• Signs and symptoms  like fever,  headache,  shortness  of breath, back  or abdominal pain, 
dysuria or hematuria, dependent or periorbital edema  
• Changes in blood pressure, body weight, fluid intake, voiding pattern, or urine output  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  120 of 133 
Protocol  No. CLOU064A2302   
• Concomitant events or procedures such as trauma,  surgical  procedures, cardiac  or hepatic 
failure, contrast media or other known nephrotoxin administration, or other diseases or 
causes, eg, dehydration due to delirium, tumor lysis 
Table 16-[ADDRESS_400562]  in the CRF:  
• Urine dipstick and sediment microscopy evidence of Drug -Induced Nephrotoxicity (DIN): 
crystals,  red blood cells (dysmorphic/glomerular vs. non-dysmorphic/non- glomerular),  white 
blood cells, tubular epi[INVESTIGATOR_1663]  
• Blood pressure  and body  weight  
• Serum  creatinine,  BUN,  electrolytes  (sodium,  potassium,  phosphate,  calcium),  bicarbonate and 
uric acid  
• Urine  output  
Review  and record  possible contributing  factors  to the renal  event  (co-medications,  other  co-morbid 
conditions) and additional diagnostic procedures (MRI etc.) in the CRF  
Monitor  participant  regularly  (frequency  at investigator's  discretion)  until: 
• Event  resolution:  (sCr within  10% of baseline or PCR  < 1 g/g Cr, or ACR  <300  mg/g  Cr) or 
• Event  stabilization:  sCr level with ±10%  variability  over last 6 months  or protein -creatinine ratio 
stabilization at a new level with ±50%  variability  over last 6 months.  
Analysis  of urine  markers  in samples  collected  over the course  of the DIN event  

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  121 of 133 
Protocol  No. CLOU064A2302   
16.4 Appendix 4: PRO  Tools  
Samples of questionnaires provided here are for illustrative purpose only. The text format and 
wording might slightly vary. 
Patient  Diary:  Urticaria  Patient  Daily  Diary  (UPDD)  
 
 
 
  
 
 
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  122 of 133 
Protocol  No. CLOU064A2302   
 
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  123 of 133 
Protocol  No. CLOU064A2302   
 
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  124 of 133 
Protocol  No. CLOU064A2302   
 
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  125 of 133 
Protocol  No. CLOU064A2302   
Patient  Diary:  Angioedema Activity  Score (AAS)  
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  126 of 133 
Protocol  No. CLOU064A2302   
Dermatology Life Quality  Index (DLQI):  
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  127 of 133 
Protocol  No. CLOU064A2302   

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  128 of 133 
Protocol  No. CLOU064A2302   

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  129 of 133 
Protocol  No. CLOU064A2302   
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  130 of 133 
Protocol  No. CLOU064A2302   
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  131 of 133 
Protocol  No. CLOU064A2302   
 

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  132 of 133 
Protocol  No. CLOU064A2302   

[COMPANY_001]  
Amended  Protocol  Version  No. 01 (Clean)  Confidential  Page  133 of 133 
Protocol  No. CLOU064A2302   
